Date: 8.24.2017 / Article Rating: 5 / Votes: 3162
Oac.essayninja.info #Maccormick v lord advocate

Recent Posts

Home >> Uncategorized >> Maccormick v lord advocate

Essay Writer for All Kinds of Papers - maccormick v lord advocate

Nov/Sat/2017 | Uncategorized



Custom Essay Order -
The Cake of Custom: Parliament is not sovereign

Nov 11, 2017 Maccormick v lord advocate, write my paper for cheap in high quality -

GIBSON v LORD ADVOCATE | Cambridge Law Reports

Board index delphi return-value using thread-function. I have the following problem: I want to call a function in a new thread. To achieve this I create a new thread and in the execute-procedure. I call the function that should be called. The problem is, that the execute-procedure is run directly after I created. But I can't return a value when I create the thread, so that I don't get a. Maccormick. That's why I transformed my call from.

My function in the class looks like this. In the thread's execute-procedure I call the drama portfolio example procedure in the usual manner. and commit the maccormick advocate value given to the constructor of tmythreadclass. That way the function is running in drama portfolio the new thread. So far, so good. At the v lord advocate end of the floating function I save the return-value in a global array, the return-value and the call_number. That way my function wait_for(call_number) waits 'til the value call_number. found in this array and returns the real return-value that is saved in the. I tried this and it works, apart from the fact that the maccormick v lord advocate array isn't. but this can be fixed. I just thought that it can't be the best way to do this. There must be a. Does anybody know how this can be done?

Thanks in advance for your help. Re:return-value using thread-function. In article b6267l$ok. @nets3.rz.RWTH-Aachen.DE, Juergen Schlinker The problem is, that the execute-procedure is run directly after I created. resume it when you have passed the value and want the thread to execute. Hottentot Venus. If you want to pass data to the thread then you can always pass it in the. create call by giving the create call some other name than Create, and. calling inherited Create (with Suspend == true) in the constructor. Then when. you have passed the variable to a property or field of the thread, call Resume. Re:return-value using thread-function. Can you use this: function ResultFromThread : integer; while not myThread.Terminated do; MyResult is a TMyThread property/field that is set in the Execute method.

I have the maccormick v lord following problem: I want to call a function in drama example a new thread. To achieve this I create a new thread and in advocate the execute-procedure. I call the function that should be called. The problem is, that the execute-procedure is run directly after I created. But I can't return a value when I create the thread, so that I don't get a. That's why I transformed my call from. My function in the class looks like this. In the thread's execute-procedure I call the procedure in the usual manner. and commit the value given to the constructor of tmythreadclass. That way the function is floating running in the new thread. So far, so good.

At the end of the function I save the return-value in a global array, the return-value and the call_number. V Lord. That way my function wait_for(call_number) waits 'til the value. found in this array and returns the real return-value that is saved in the. I tried this and it works, apart from the strength model fact that the v lord array isn't. but this can be fixed. Faustus Meaning. I just thought that it can't be the best way to maccormick v lord, do this. There must be a. Does anybody know how this can be done? Thanks in advance for your help. Re:return-value using thread-function. The problem is, that the execute-procedure is run directly after I created. Am I missing something, or why cannot you create the thread suspended, and. then resume it when you have passed the based model value and want the thread to. If you want to pass data to maccormick v lord, the thread then you can always pass it in the. create call by giving the create call some other name than Create, and.

calling inherited Create (with Suspend == true) in the constructor. Model. Then. Maccormick Advocate. when you have passed the variable to a property or field of the thread, re-use it. It's fairly expensive to create and destroy threads but very. cheap to re-use one. Fast automatic table repair at a click of a mouse! Re:return-value using thread-function. Can you use this: function ResultFromThread : integer; while not myThread.Terminated do; MyResult is faustus meaning a TMyThread property/field that is set in the Execute method. Juergen Schlinker juergenschlin. @gmx.de wrote in message. I want to call a function in a new thread. V Lord Advocate. To achieve this I create a new thread and in the execute-procedure.

I call the floating function that should be called. The problem is, that the v lord advocate execute-procedure is run directly after I. But I can't return a value when I create the hottentot venus thread, so that I don't get. That's why I transformed my call from. My function in the class looks like this. At the end of the function I save the return-value in advocate a global array, containing the drama example return-value and the call_number. That way my function wait_for(call_number) waits 'til the value. call_number is found in this array and returns the real return-value. that is saved in maccormick the array. I tried this and hottentot venus, it works, apart from the fact that the array isn't. thread-safe yet, but this can be fixed. I just thought that it can't be the best way to do this. There must be a. message.

If you want to synchronise two threads, there are. a whole bunch of synchronisation objects built-in. It strikes me that the whole thread thing is defeated by. waiting for the computation to finish. Re:return-value using thread-function. function ResultFromThread : integer; while not myThread.Terminated do; MyResult is a TMyThread property/field that is set in the Execute method. Re:return-value using thread-function. The problem isn't to pass parameters to my thread-function, but to retrieve. IF I create the v lord thread and even if I call resume I don't retrieve the. return-value of my function. That's why I use. to wait for my execute-function to terminate. As I see it, there is no easy way of drama portfolio example, retrieving the maccormick v lord advocate return-value since. Floating Signifier. create-call, nor the resume-call returns a value. Re:return-value using thread-function.

In article b63mi1$m9. V Lord. @nets3.rz.RWTH-Aachen.DE, Juergen Schlinker The problem isn't to pass parameters to my thread-function, but to retrieve. IF I create the thread and even if I call resume I don't retrieve the. return-value of my function. That's why I use. to wait for my execute-function to terminate. As I see it, there is no easy way of retrieving the return-value since. create-call, nor the resume-call returns a value. in your main code (via Synchronize) which passes the value back to your. Pass the value (address) of your main code event handler to hottentot venus, the thread in maccormick v lord advocate the. create parameters. You call the thread's inherited with Suspend == true, then. store the event handler value and then Resume your thread. Strength Model. constructor TConvertThread.CreateConversion(SourceFPN, LexFPN : string; inherited Create(true); // create suspended. OnTerminate := OnTerminateThread; // thread's own event handler. FOnProgress := OnProgress; // set thread field to application event handler. if Assigned(FOnProgress) then. FOnProgress(Self, ProgressMax, ProgressPos); // progress passed back to. Maccormick V Lord. Call event handler . Muslims. Re:return-value using thread-function. Sounds really interesting.

Thanks for your help. Maccormick V Lord Advocate. Re:return-value using thread-function. I guess that my solution is related to your solution, but your's if quite. Hottentot Venus. I guess I will do it this way. Thanks a lot for maccormick v lord advocate, helping. Re:return-value using thread-function. I want to call a function in a new thread. To achieve this I create a new thread and in the execute-procedure. I call the floating function that should be called.

The problem is, that the maccormick execute-procedure is faustus meaning run directly after I created. That's why I transformed my call from. It looks like you are instantiating a thread and then immediately. waiting for it to complete. If so, then you have accomplished nothing by. using a thread. V Lord Advocate. If your main thread has nothing to do between the time. it creates a thread and the time it's prepared to get the function. result, then there is no point in having a second thread at who was in the, all.

In the thread's execute-procedure I call the procedure in the usual manner. and commit the value given to the constructor of tmythreadclass. your thread know where to store its result? the return-value and the call_number. That way my function wait_for(call_number) waits 'til the value call_number. found in this array and returns the advocate real return-value that is saved in the. ReturnValue property, which you can access within your subclass. Your. Execute method would look something like this: It should be as simple as that. Then, when your main thread is ready to get the result, it should call. your thread's WaitFor method, which will return the result as soon as. your thread is complete. Here is how I imagine your thread class. You'll of course need to fill. in the specifics for Execute.

The essential part is that you need to. assign a value to hottentot venus, ReturnValue. procedure Execute; override; constructor Create(const AValue: string); constructor TFunctionThread.Create(const AValue: string); // (It is good practive to declare string parameters as const. It is. // more efficient. Maccormick V Lord Advocate. The compiler makes whole copies of non-const. // parameters instead of drama example, just updating the v lord reference count.) // This will create the thread suspended. Call Resume later. // Do whatever it is example you need to do with FValue. In your main thread, you will create instances of this class.

Try. Maccormick V Lord Advocate. storing them in a TObjectList. With the technique I'm about to show, there is no need to targeted holocaust, make the object list thread-safe. ThisThreadIndex will let you keep track of which thread you just. created. Maccormick V Lord Advocate. ThisNewThread is vs sunni a reference to the thread object. How you use. these values is up to maccormick v lord, you. When your main thread needs the result of the function, use code like this: function GetThreadResult(Index: Integer): LongWord; t := FunctionThreadList[Index] as TThread; Don't forget to drama, free the maccormick v lord advocate thread objects eventually. Do not enable their.

FreeOnTerminate behavior; it will cause your program to crash when you. Shiite Muslims. Re:return-value using thread-function. That's why I transformed my call from. I assume you really don't want to create a thread and then wait for it. to finish. As others have pointed out, you don't need to use a separate. thread of execution to do this :-) Assuming you want to push a calculation off into another thread of. Maccormick V Lord. execution and drama portfolio, have that thread asynchronously update say a control in. the main VCL thread when the result is available, then the following. object provides a neat encapsulation of that behaviour. TThreadedWorkers launches a new thread of execution to handle a. Maccormick V Lord. calculation and immediately returns. The result of the calculation, when. ready, is posted asynchronously to the object's window, where a handler. fires an event containing the result of the calculation. This object is pretty much bare-bones, and would need code to in the, handle. things like pre-emptive shut-down of the application, the maccormick v lord advocate possibility of. launching one thread while another is running and so forth.

Also you may. want to faustus meaning, pass back a result more complex than an maccormick, integer. This can be. done by strength model passing back a reference, though mature thought needs to be. given to the stability of such a reference. Classes, Controls, Windows, Messages; UM_WORKDONE = WM_USER + 100; function DoSomeCalculation(iValue: integer): integer; procedure SetValue(const Value: integer); procedure Execute; override; constructor Create(Hdl: HWND); property Value: integer read FValue write SetValue; TCalculation1Event = procedure(iValue: integer) of object; procedure UMWorkDone(var Mess: TMessage); message UM_WORKDONE; procedure SetOnResultOfCalculation1(const Value: procedure DoCalculation1(iValue: integer); property OnResultOfCalculation1: TCalculation1Event read. FOnResultOfCalculation1 write SetOnResultOfCalculation1; constructor TWorkerThread.Create(Hdl: HWND); function TWorkerThread.DoSomeCalculation(iValue: integer): integer; result := iValue * iValue; sleep(1000); // test only. PostMessage(FHdl, UM_WORKDONE, iResult, 0); procedure TThreadedWorkers.DoCalculation1(iValue: integer); procedure TWorkerThread.SetValue(const Value: integer); const Value: TCalculation1Event); procedure TThreadedWorkers.UMWorkDone(var Mess: TMessage); if assigned(FOnResultOfCalculation1) then. Re:return-value using thread-function. to finish. As others have pointed out, you don't need to use a separate. thread of execution to do this :-) If my main-thread that creates the other thread is not doing something. but the user might press buttons, resize the advocate form (and so on) . I can't. run a method that uses. up all the thread-cpu-time.

That's why I create a new thread and use. This way the user can use the form because of the processmessages and the. fine with its own cpu-time. Or didn't you mean this? Re:return-value using thread-function. waiting for it to complete. If so, then you have accomplished nothing by. using a thread. If your main thread has nothing to do between the time. it creates a thread and the time it's prepared to get the function. result, then there is no point in having a second thread at all. If my main-thread that creates the other thread is not doing something. but the user might press buttons, resize the form (and so on) . I can't. run a method that uses up all the thread-cpu-time.

That's why I create a new. This way the user can use the drama form because of the maccormick v lord processmessages and hottentot venus, the. thread runs fine with its own cpu-time. Re:return-value using thread-function. If my main-thread that creates the other thread is not doing something. but the user might press buttons, resize the form (and so on) . I can't. run a method that uses up all the thread-cpu-time.

That's why I create a new. This way the user can use the form because of the processmessages and the. thread runs fine with its own cpu-time. Take advantage of the thread's OnTerminate event instead. Your code. would go something like this: 1. Advocate. Create the thread suspended. 2. Portfolio Example. Assign its OnTerminate event handler. 3. Resume the thread. 4. Allow your main thread to maccormick v lord, continue as usual. In The. The last step means you do nothing. Maccormick Advocate. You do not call ProcessMessages or. enter into floating any other wait loop.

When your threaded function completes. its task, its OnTerminate event will fire. That is the point at which. you should take action. The event is fired in the context of maccormick advocate, your main. As a general rule, if your program needs to call ProcessMessages,

GIBSON v LORD ADVOCATE | Cambridge Law Reports

Maccormick v lord advocate

Write My Essay : 100% Original Content -
The constitutional law in MacCormick v Lord

Nov 11, 2017 Maccormick v lord advocate, buy essays online from successful essay -

The Union and the law: The Journal Online

matt kupchik resume Dr. Mithoefer's MAPS-sponsored. FDA Phase 2 pilot study. We need your support so together we can make a difference. BROWSE MDMA INFORMATION: MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder (PTSD) : Site 1. Principal Investigator: Michael Mithoefer, MD, with co-therapist Ann Mithoefer, BSN. Location: Charleston, SC (USA) MAPS’ flagship Phase 2 pilot study is the first-ever protocol evaluating MDMA’s therapeutic applications in clinical trials conducted under an FDA IND.

Like all of maccormick v lord, MAPS’ psychedelic-assisted psychotherapy studies, the protocol is randomized, double-blind and placebo-controlled. All twenty-one subjects with treatment-resistant PTSD, as a result of sexual abuse, crime, or war, have completed the experimental treatment. The study was completed in hottentot venus September 2008. The data analysis, writing a scientific paper for maccormick advocate publication, and who was in the holocaust, the one-year follow-up remain to be completed. MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder (PTSD) : Site 2. Principal Investigator: Peter Oehen, MD, with co-therapist Verena Widmer, RN. Location: Solothurn (Switzerland) Our Swiss MDMA/PTSD pilot study has full approval from an Ethics Committee (Swiss IRB equivalent) and SwissMedic (FDA equivalent). The protocol has also been submitted to and accepted by FDA under MAPS’ Investigational New Drug (IND) for maccormick v lord advocate MDMA. Based? As a result, the study fits into v lord advocate MAPS’ initiative to develop MDMA.

into a prescription medicine approved by both the FDA and signifier, the European Medicines’ Agency (EMEA). Over half of twelve subjects with treatment-resistant PTSD from v lord advocate, any cause have undergone the experimental treatment. MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder (PTSD) : Site 3. Principal Investigator: Moshe Kotler, MD, with co-therapists Sergio Marchevsky, MD, Rakefet Rodrigez, MD, and floating, Marina Kupchik. Location: Beer Yaakov Mental Health Center (Israel) This study has full approval from the Israeli Ethics Committee and Ministry of maccormick v lord advocate, Health. The experimental treatments are being conducted at Beer Yaakov Mental. Health Center, near Tel Aviv, under the direction of hottentot venus, Principal Investigator Moshe Kotler, M.D., former chief psychiatrist of the v lord advocate Israeli Defense Forces and targeted in the, current Chair, Department of maccormick, Psychiatry, Sackler School of Medicine, Tel Aviv University. The study will evaluate twelve subjects with treatment-resistant PTSD, mostly.

war- or terrorism-related PTSD. The first subject has competed his experimental treatment and the second an third subjects have been enrolled. Like MAPS’ Swiss. MDMA/PTSD study, the protocol has been submitted to and accepted by FDA under MAPS’ IND for MDMA, and is part of MAPS’ initiative to develop MDMA into a prescription medicine approved by both the FDA and the EMEA. MAPS has sponsored three international scientific conferences in floating signifier Israel on MDMA research to facilitate the protocol approval process. MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder (PTSD) : Site 4. Principal Investigator: Ingrid Pacey, MD and maccormick advocate, Andrew Feldmar, PhD. Location: Vancouver, BC (Canada) This study is who was in the holocaust, currently in development.

Enrollment is expected to v lord, begin in Spring 2009. Treatment Manual for MDMA-Assisted Psychotherapy for hottentot venus Treatment of PTSD. Principal Investigators: June M. Ruse, PsyD, Lisa Jerome, PhD, Michael C. Maccormick? Mithoefer, MD, Rick Doblin, PhD, Elizabeth Gibson, MS. This detailed manual, an targeted, early draft of which is already written, provides therapy researchers conducting MAPS-sponsored MDMA/PTSD studies with standardized. methods. It will eventually enable MAPS to train therapists and maccormick v lord advocate, evaluate therapist adherance to the approach described in the manual.

Outcome Study of Psychological Defense Mechanisms During MDMA-Assisted Psychotherapy for Treatment of PTSD. Principal Investigators: Pal-Orjan Johansen, PhD (cand) and shiite vs sunni muslims, Teri Krebs. Norwegian University of Science and maccormick v lord, Technology, Trondheim (Norway) IN PROCESS. This study analyzes audio and video recordings of therapy sessions from the ongoing MDMA-assisted psychotherapy studies in the treatment of subjects with PTSD. The objective of this study is to provide empirical evidence on how MDMA influences defense mechanisms in the context of psychotherapy, to targeted, understand how MDMA might facilitate the therapeutic process, and to inform the development of a standardized treatment manual for MDMA-assisted psychotherapy. The study has cost $15,000, with the remainder fully funded.

MDMA-Assisted Psychotherapy in the Treatment of Anxiety Secondary to Advanced Stage Cancer. Principal Investigator: John Halpenr, MD. Location: McLean Hospital, Harvard Medical School, Belmont, MA (USA) MAPS conducted the design and protocol approval process for this study through a direct gift to McLean Hospital. This study of twelve subjects is v lord advocate, also being conducted under US FDA IND and has received IRB approval and DEA licensure.

Dr. Halpern is the hottentot venus Sponsor/Investigator. In his FDA IND application, he cross-referenced MAPS' IND for MDMA and MAPS will have full access to the data generated from his study. The first subject has completed the experimental treatment. Protocol submitted to FDA on advocate November 26, 2004 (in HTML or PDF format) Protocol approved by McLean Hospital and Lahey Clinic IRBs (in HTML or PDF formats) Informed Consent Form approved by the McLean IRB (HTML or PDF) on November 19, 2004 Prescreening consent (PDF only) approved by the Lahey Clinic IRB on November 10, 2004 Treatment manual submitted for shiite review to McLean IRB July 21, 2004. Other FDA research with MDMA. MAPS' comprehensive review of the scientific literature on MDMA Periodic updated reviews of the literature for maccormick v lord advocate August/September 2001-January 2003, for faustus meaning 2003-March 2004 (HTML and PDF versions), March 2004-January 2005 (HTML and PDF versions), and v lord, a significantly reformatted version covering research up through December 2007 (PDF) Monthly updates of MDMA-related literature MAPS MDMA bibliography with abstracts and PDFs, including a What's New section A review by Alex Gamma, Ph.D. Faustus Meaning? of the major studies exploring the possible link between MDMA and memory.

Rick Doblin has written a paper discussing how the risks of MDMA neurotoxicity have been exaggerated by maccormick v lord advocate, government officials and government-funded scientists in signifier a manner that has been used to advocate, support prohibitionist policies. The scientific and media critiques of Ricaurte's MDMA neurotoxicity research. Ricaurte's July 2003 NIDA Grant Progress Report, obtained 1/26/04 by MAPS through Freedom of Information Act (FOIA) request. Ricaurte explains how he determined he administered methamphetamine instead of MDMA to primates and describes research with genuine MDMA that didn't cause dopamine reductions. The legal record from DEA's 1984-1988 MDMA scheduling hearings Testimony by Rick Doblin, Ph.D. and others before US Sentencing Commission hearing on MDMA, 3/19/01 Why MDMA Should Not Have Been Made Illegal by Marsha Rosenbaum and Rick Doblin Meeting agenda and video archives for MDMA/Ecstasy Research: Advances, Challenges, Future Directions - NIDA-sponsored conference, July 19-20, 2001. February 6, 2009. Who Was Holocaust? MDMA-Assisted Psychotherapy Helps Israeli Subject with PTSD from the 1967 Six-Day War: MAPS President Rick Doblin PhD is delighted to maccormick, share the success of hottentot venus, a recent MDMA-assisted psychotherapy session in v lord advocate Israel.

Rick was told a remarkable story during a check-in with the therapy team that is conducting our Israeli MDMA-assisted psychotherapy for the treatment of Posttraumatic Stress Disorder (PTSD) study. Several weeks ago, the Israeli therapists successfully treated a patient who had suffered from PTSD for over 40 years, since the Six-Day War in 1967. On his second MDMA session, the gentleman became acutely aware of fears he was still harboring within him since the war. He requested to leave the signifier treatment room for a walk outside on the hospital grounds. The therapists escorted him outside as he had a breakthrough catharsis leading to dramatic healing.

Ironically, planes were flying overhead on the way to maccormick v lord, bomb Gaza. With so much new trauma being created, it may seem underwhelming to speak of treating only 12 subjects each in based model our Israeli and proposed Jordanian studies. Yet if successful, these pilot projects will lead to larger-scale studies. Furthermore, as Charles Mackay, author of Extraordinary Popular Delusions and v lord, the Madness of Crowds (published in 1841), observed, “Men, it has been well said, think in herds; it will be seen that they go mad in herds, while they only recover their senses slowly, and one by portfolio example, one.” The MAPS team is honored and humbled to help someone who has suffered for so long. We hope that in the near future MDMA-assisted psychotherapy will be available legally to all who suffer from PTSD. We believe that in the future, our successes in the laboratory will translate into a more peaceful world. Rick shared, “in the midst of war, we are developing the technologies of peace and healing.”

February 3, 2009. Health Canada Approves MDMA/PTSD Protocol Design: On January 16, Health Canada first responded to our Canadian MDMA/PTSD protocol design. They accepted almost all elements of the protocol but had some items they wanted changed. We also asked for a change in the kind of previous treatments for PTSD the subjects will be required to have tried and v lord advocate, failed. On January 20, we submitted our replies, accepting some changes and shiite muslims, making our best argument for maccormick v lord advocate why it was important to floating, include people who were free from substance abuse histories for maccormick advocate the last 6 months rather than for the last 12 months, as Health Canada had suggested. In addition, we asked to be able to hottentot venus, include subjects who failed on other psychotherapy and advocate, either tried and failed, or refused medication. Health Canada had suggested including only subjects who had failed on other psychotherapy, and had tried and failed to obtain relief from medication - excluding subjects who refused to try medication. On February 3, we heard from Health Canada that our responses had been accepted and that our protocol design had been fully approved (Hooray!). This shows yet again that it is possible to negotiate with regulatory agencies that put science first.

On January 12, we heard from based model, Health Canada’s chemistry reviewers. We’ve been gathering our replies ever since, which included obtaining a new analysis of the heavy metals and residue on ignition of the MDMA. In addition, Health Canada had a series of questions about the advocate capsules, the faustus meaning lactose filler, and v lord, the bottles in which the capsules will be stored. On February 2, Professor Rudolph Brenneisen from shiite, Switzerland provided MAPS with documents regarding the maccormick v lord chemical make-up of the MDMA that will be imported to drama portfolio example, Canada from Switzerland. Ironically, the last bit of information we need to gather is the batch number of the lactose! We expect to submit the required chemistry information in the next few days. V Lord? Once the protocol is approved, we can start the process of obtaining the import/export permits for the MDMA from muslims, Switzerland, and can then start the study itself. January 20, 2009. Flagship US MDMA/PTSD Study Final Monitoring Visit: On January 20-22, MAPS’ clinical research monitoring team, Valerie Mojeiko and Josh Sonstroem, went to Charleston, South Carolina to conduct a closeout visit for MAPS’ flagship US MDMA/PTSD study.

The data from this study is now ready to be submitted to FDA. With this ending also comes the beginning of the “long-term follow up” extension to maccormick v lord, this study. Portfolio? During this extension, subjects who were enrolled in the original study will be retested on primary outcome variables one year or more after completion. Maccormick? In the initial study, the last measurement of faustus meaning, PTSD severity was taken two months after the last experimental session. Since this study took over four years to conduct, some of the data from the long-term follow-up will be from subjects who were treated over four years ago.

The value of the long-term follow-up study will be substantially enhanced as a result of the advocate extra length of time since treatment for most of the subjects. MAPS is faustus meaning, pleased to have the help of volunteers Scott Martin MD and Mili Ballard to coordinate this long-term follow-up study. January 2, 2009. MAPS#x2019; International MDMA/PTSD Research Progresses into the New Year. Our Swiss and Israeli MDMA/PTSD studies are continuing to recruit subjects. Our Swiss study has only a few subjects still to recruit while our Israeli study has more than half remaining to be recruited. Sadly, the current war in Israel is creating many more people with PTSD. For our proposed Jordanian MDMA/PTSD study, we#x2019;re in the process of maccormick v lord, having our informed consent form translated into Arabic for review by the Jordanian IRB. Faustus Meaning? We#x2019;re also making progress toward obtaining the necessary insurance to conduct a study in maccormick v lord Jordan.

December 19, 2008. The audio version of faustus meaning, The Economist article about v lord advocate MAPS' Flagship MDMA/PTSD study is now available in MP3 format. December 18, 2008. MDMA/PTSD Documents Submitted to Health Canada. On December 18, all the documents for our Canadian study of MDMA-assisted psychotherapy in the treatment of people with Posttraumatic Stress Disorder (PTSD) were submitted to Health Canada (Canada#x2019;s version of the FDA). We've already obtained approval of our protocol and informed consent from a Canadian Institutional Review Board.

We should receive a reply from Health Canada within 30 days of targeted in the holocaust, our submission. This is going to be a study with 12 subjects, similar in design to the recently completed US MDMA/PTSD study. Our main purpose for this particular study is to see if we can replicate the maccormick results of the US study. Shiite? The budget for maccormick v lord advocate this study is $250,000, all of which remains to be raised. December 10, 2008. MAPS Releases Year-End MDMA Literature Review: As part of hottentot venus, our ongoing clinical research responsibilities, MAPS reviews all of the MDMA- related articles published in scientific peer-reviewed journals to determine whether we need to modify our risk/benefit analysis for our clinical studies. We have now completed our review of the scientific literature published between December 2007 and November 2008 and submitted the review to the Institutional Review Board (IRB) that oversees our US MDMA/PTSD study. Nothing in the review changes our risk/benefit analysis regarding our research in human subjects.

This review--along with all previous reviews--are compiled by MAPS Research Specialist Ilsa Jerome, and are posted on the MAPS website at: www.maps.org/mdma/protocol/litreview.html. December 3, 2008. Maccormick V Lord? Newly Revised MDMA/PTSD Treatment Manual Now Online: MAPS Researchers Michael Mithoefer MD, Annie Mithoefer BSN, and June May Ruse PhD, have created a revised version of MAPS MDMA/PTSD treatment manual. The new version of the manual builds on a previous manual from 2005, and includes lessons learned from our recently completed US MDMA/PTSD pilot study.

The team of researchers reviewed many hours of videotapes of the therapy sessions with the aim of finding clear examples of the key elements of the therapeutic method. In The Holocaust? The manual will be continually revised as we identify best practices and gather data to link methods to v lord, outcomes. The manual, will also be used to develop measurement tools for identifying key elements of the therapeutic method. December 2, 2008. Floating Signifier? A family foundation that wishes to remain anonymous donated $50,000 to MAPS for our US MDMA/PTSD research. V Lord? The foundation had generously supported our US MDMA/PTSD study during the early stages of the research giving substantial donations that played a crucial role in launching this project. November 11, 2008. MDMA/PTSD Study With War Veterans In The Planning Stage: November 7, 2008.

Canadian IRB Gives Conditional Approval To MDMA/PTSD Protocol: October 15, 2008. The fortieth edition Journal of Psychoactive Drugs published an in the, article “MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder” by José Carlos Bouso PhD candidate, Rick Doblin PhD, Magí Farré MD PhD, Miguel Ángel Alcázar PhD, and Gregorio Gómez-Jarabo PhD. Maccormick Advocate? This article reports on faustus meaning the MAPS-sponsored MDMA-assisted psychotherapy study in Spain that was prematurely shut down by the Spanish government. The abstract of the article is as follows: October 10, 2008. From October 6-10, 2008, Michael Mithoefer MD, Annie Mithoefer BSN, and June May Ruse PhD, worked on maccormick v lord advocate the MDMA/PTSD treatment manual. This was their second week working together in person, with a third week anticipated in December or January.

They have reviewed many hours of signifier, videotapes of therapy sessions from Michael and Annie’s recently completed US MDMA/PTSD pilot study, with the aim of finding clear examples of the key elements of the therapeutic method. They intend to develop scales of approximately ten key elements of the therapeutic method. These scales would then be used by raters to evaluate researchers/therapists’ adherence to our specific therapeutic method. October 7, 2008. On October 7, 2008, MAPS sent a draft of a protocol for a MAPS-sponsored MDMA/PSTD pilot study to Royal Jordanian Military psychiatrist Nasser Shuriquie. Dr Shuriquie needs to v lord, show the protocol to other medical officials to gauge whether there is sufficient support to justify submitting a final draft of the protocol to a Jordanian Ethics Committee and the Jordanian Ministry of Health. This version of our protocol differs from other pilot studies in several ways.

It begins with a three-subject open label run-in in which both the targeted holocaust subjects and the therapists know that MDMA is being administered. In this way, the maccormick advocate therapist gets a chance to practice our therapeutic technique and become familiar with the therapeutic process before administering MDMA or placebo to other subjects in the context of a placebo-controlled, randomized, double-blind study. We believe that it is hottentot venus, important for the therapist to get a chance to become comfortable with the procedure prior to starting a controlled study. The remainder of the protocol is a nine-person study, where six subjects receive three sessions of full-dose MDMA, 125 mg followed one-and-a-half to two-and-a-half hours later by 62.5 mg. Three subjects would receive active placebo, in this case 40 mg followed 1.5-2.5 hours later by 20 mg. Our Swiss, Israeli and v lord advocate, Canadian MDMA/PTSD pilot studies are using 25 mg as the active placebo while our US study used an inactive placebo.

September 17, 2008. Who Was Targeted Holocaust? On September 17, 2008, French psychiatrists Olivier Chambon and maccormick v lord advocate, Fred Rosenfeld met with Patrick Lemoine MD in who was in the holocaust Lyon, France to v lord advocate, discuss possibilities of starting a MAPS-sponsored MDMA/PTSD pilot study at a clinic where they work and that Dr. Targeted In The Holocaust? Lemoine directs. MAPS President Rick Doblin PhD and Director of Operations Valerie Mojeiko spoke in Paris in March 2008 at a conference about hallucinations in an attempt to catalyze MDMA/PTSD research [Link to article in current MAPS Bulletin on page 17]. On June, 28 2008, Valerie and Josh Sonstroem, MAPS’ Clinical Research Associates, conducted a site visit at maccormick the clinic where Drs. Example? Chambon and Rosenfeld work. September 16, 2008. The Institutional Review Board that is reviewing our Canadian MDMA/PTSD study sent us a letter dated September 16, 2008, requesting a few changes to the protocol we submitted (PDF) . We were delighted to receive this letter since it is clear now that the study itself will be approved.

The IRB has some issues of concern that need a further exchange of information before being resolved. July 6, 2008. The Sunday Baltimore Sun published an editorial (Tuning In, Not Out) supporting research into the therapeutic potential of psychedelics. Advocate? The editorial mentions the MAPS-supported research into MDMA-assisted psychotherapy in people with PTSD and ends by hottentot venus, stating, Instead of banning drugs that are perceived as bad simply because of their recreational use, scientists should be encouraged to pursue legitimate study - lest we miss out on v lord advocate a valuable medicinal tool. May 4, 2008. Portfolio Example? The Sunday Times (London) recently published Ecstasy is the Key to Treating PTSD, an in-depth piece on MDMA-assisted psychotherapy in maccormick v lord advocate people with PTSD, focusing on Dr. Mithoefer's MAPS-supported study and featuring quotes from MAPS president Rick Doblin and British psychiatrist Ben Sessa. April 3, 2008. The list of shiite vs sunni muslims, articles and information on maccormick advocate potential risks of MDMA now includes a report of estimated risk of MDMA in people with hepatitis C. Strength Model? While there is nothing in the medical literature on maccormick v lord the topic, this report draws on information about MDMA, heptatitis C, and drugs used to treat it.

February 6, 2008. A letter by targeted holocaust, Krebs and Johansen commenting on and questioning the findings of the prospective study of cognitive function in ecstasy users is now published in the Archives of General Psychiatry. The letter addresses issues relating to the nature of the test score differences, the v lord existence of long-term retest effects, participant durg use history and who was holocaust, effects of anxiety arising from stereotype threat. Schilt and colleagues' reply appears alongside the letter. They respond to questions concerning retest learning effects and re-analyze data with respect to drug use history. V Lord? Krebs and Johansen are conducting an examination of psychological defense mechanisms in experimental sessions from who was targeted in the, Mithoefer's randomized, placebo-controlled study of MDMA-assisted psychotherapy in people with PTSD. November 30, 2007. MDMA is not a type of methamphetamine : Despite its title, the recent Science Daily piece Club Drugs Inflict Damage Similar To Traumatic Brain Injury is about studies on the effects of advocate, methamphetamine, not MDMA, and describes findings in rats, not people. Read a brief commentary on this news report. November 29, 2007. Sessa and hottentot venus, Nutt have recently published an editorial in the Journal of Psychopharmacology, MDMA, politics and v lord advocate, medical research: Have we thrown the baby out with the bathwater?, speaking out against the effects of politics and regulation on medical research with MDMA and in favor of more basic and based, medical research.

In their editorial, Sessa and Nutt discuss the costs to the research enterprise imposed by regulation of MDMA, and proposes at least three avenues of further research. The piece is provocative and uneven, but makes for maccormick v lord encouraging reading for supporters of hottentot venus, MDMA psychotherapy research. November 25, 2007. Washington Post magazine published an article featured as the cover story about MAPS' and Dr. Michael Mithoefer's MDMA-PTSD research entitled Peace Drug. This article is overall positive with one minor mistake--the idea of MDMA being prescribed only by specially trained therapists in v lord psychedelic clinics is attributed to Dr. Michael Mithoefer when it should have been attributed to Rick Doblin Ph.D.'s dissertation.

This article is unique as it is the first time that a reporter has been allowed to interview a research participant from this historic study. You can read the comments about this article here. October 12, 2007. MAPS communications director Jag Davies conducted a podcast interview (mp3) with Dr. Michael Mithoefer, in which Dr. Mithoefer discusses the details of his study, his working relationship with wife and co-therapist Annie Mithoefer, and his musings on the psychological mechanisms involved in MDMA-assisted psychotherapy. October 10, 2007. Vs Sunni? Sixteen out of twenty subjects have completed the maccormick v lord double-blind protocol in Dr. Michael Mithoefer's flagship MAPS-sponsored FDA Phase 2 study evaluating MDMA-assisted psychotherapy for subjects with treatment-resistant post-traumatic stress disorder (PTSD). Three new subjects have been enrolled, two of which are close to drama portfolio example, completion of the first stage of the protocol. One of these new subjects is a US military veteran whose trauma occurred during combat in Iraq.

Last month, MAPS and Dr. Mithoefer submitted a protocol amendment to FDA, seeking approval to treat a 21st subject, also a US veteran with PTSD from the Iraq War. We need FDA permission to deviate from maccormick advocate, our inclusion criteria that requires all PTSD subjects to be treatment-failures from both drug and non-drug treatments. The FDA has accepted our request, which we have just submitted to drama example, our institutional review board (IRB) for final review. October 1, 2007. American Medical News published a feature article entitled Altered Perceptions: Good Outcomes from 'Club Drugs'? MAPS President Rick Doblin, PhD, and researchers Michael Mithoefer, MD, John Halpern, MD, and Charles Grob, MD, are quoted.

American Medical News is a weekly newspaper for physicians published by the American Medical Association that is ciculated to over 230,000 physicians and health policy regulators. September 3, 2007. MAPS and maccormick advocate, Dr. Who Was Targeted In The? Mithoefer submitted a protocol amendment to FDA, seeking approval to maccormick v lord, treat a 21st subject, a US veteran with PTSD from the Iraq War. We need FDA permission to deviate from our inclusion criteria that requires all PTSD subjects to be treatment-failures from both drug and non-drug treatments. In The? The request to include a subject who is not a treatment-failure is v lord, due to the sad fact that this veteran, like several others with whom we have spoken, has been diagnosed with PTSD but has never been offered treatment by floating signifier, the military. We expect to hear from FDA in a few weeks. Michael Mithoefer, MD, and maccormick v lord, Annie Mithoefer, BSN, have enrolled 18 out of 20 subjects in their MAPS-sponsored study evaluating MDMA-assisted psychotherapy for subjects with chronic PTSD. Hottentot Venus? Another two potential subjects are currently in the screening process.

The completion of MAPS' flagship FDA Phase 2 clinical research study is now in sight. July 10, 2007. No cause for alarm: Despite claims to maccormick v lord, the contrary, the recently published meta-analysis of studies of memory in ecstasy users does not demonstrate that memory is impaired even after a few doses of ecstasy. Hottentot Venus? Here are our conclusions reached after reviewing the paper and correspondence with one of the study authors. June 27, 2007. Maccormick Advocate? Yesterday, June 26, the 17th subject out of 20 completed the first experimental session in Dr. Targeted? Michael Mithoefer's MAPS-sponsored study evaluating MDMA-assisted psychotherapy for maccormick v lord subjects with treatment-resistant post traumatic stress disorder (PTSD). We are still actively seeking to enroll in the study at least two US veterans with PTSD from the Iraq or Afghanistan wars. This Phase II clinical study is the first-ever FDA-approved human study evaluating MDMA's therapeutic applications. Shiite? Efficacy data is advocate, extremely promising so far, making a strong case for continuing research into FDA Phase III studies.

June 26, 2007. News coverage of a soon-to-be published research report in the journal Human Psychopharmacology vary in depth and accuracy, with some claiming Even Low ecstasy use harms memory, or Taking Ecstasy Once can Damage Memory, while others provide more details suggesting that this is not the case. The research in shiite vs sunni muslims question is maccormick v lord advocate, a meta-analysis of previous research studies. Read initial comments and reflections on the news coverage and hottentot venus, research report. June 19, 2007. On June 3, MAPS-sponsored researchers Michael Mithoefer, MD, Annie Mithoefer, RN, Peter Oehen, MD, and Verena Widmer, RN, presented on MDMA-assisted psychotherapy research at the European Conference on Traumatic Stress in Croatia. Also present at the conference was Swiss researcher Dr. Maccormick V Lord? Franz Vollenweider, who is conducting a physiological study of the subjects in the Swiss MDMA/PTSD study, measuring markers for PTSD before and after treatment. MAPS' MDMA/PTSD research now has preliminary data to hottentot venus, share with PTSD researchers around the world.

June 5, 2007. The Netherlands XTC Toxicity (NeXT) research team has published yet one more prospective report of ecstasy users and non-users. In contrast to their earlier efforts, this report on attention and memory claims to have found differences between the two groups, with non-users performing better on verbal memory tests. However, the report contains problems both with the analysis and interpretation of the data. May 16, 2007. The latest data from one of the first studies to compare people before and after they used ecstasy, part of the Netherlands XTC Toxicity (NeXT) research program, has just appeared in the second of maccormick, two reports. Like the first findings reported from this study, the subsequent report also failed to find any indications that ecstasy in low doses impaired selective attention or working memory, and found no ecstasy-use related changes in brain activation either. May 15, 2007. We have learned that the data being generated from the Swiss and Israeli MAPS-sponsored studies will be accepted by portfolio example, the US FDA.

Although these protocols do not need to be approved by the FDA to be conducted in their home countries (they have already been approved by their home country's regulatory agency equivalent to maccormick, FDA and by local ethics committees), FDA review and example, approval enables us to submit to FDA the data from these two studies as part of MAPS' Investigational New Drug (IND) application for advocate MDMA-assisted psychotherapy in hottentot venus the treatment of PTSD. The data from these studies will be used to help negotiate with FDA regarding the design of larger Phase 3 studies intended to maccormick v lord, gather data to determine whether or not MDMA meets the requirements necessary to be approved as a legal prescription medicine. To learn more about the MAPS-sponsored study in Israel evaluating MDMA-assisted psychotherapy for floating subjects with war- and terrorism-related PTSD, the protocol is posted on the MAPS Web site. To learn more about the MAPS-sponsored MDMA/PTSD study in Switzerland, the protocol is also posted on the MAPS Web site. May 13, 2007. Dr. Maccormick V Lord? Michael and Annie Mithoefer, the strength co-therapists for MAPS' landmark US MDMA/PTSD study, were in Norway recently attending a workshop by Dr. Edna Foa, an internationally-recognized expert in the treatment of PTSD.

The workshop was organized by v lord advocate, Pal-Orjan Johansen, a Ph.D. candidate at the Trondheim Psychotherapy Research Program, Department of Psychology, The Norwegian University of Science and Technology, and Teri Krebs, B.S., Program in Neuroscience, Boston University. While in Norway, Dr. Michael and who was holocaust, Annie Mithoefer were also able to work with Pal and Teri, who are conducting a MAPS-sponsored study reviewing audio and video recordings and transcripts of subjects in the Mithoefer's MDMA/PTSD research, in order to code and compare the psychological defense mechanisms used in both non-drug therapy sessions and in advocate the experimental MDMA-assisted therapy sessions. This study is designed to identify process variables that may help explain how MDMA can be a useful adjunct to psychotherapy. Dr. Who Was Targeted Holocaust? Michael and Annie Mithoefer were also able to discuss with Pal and Teri their MAPS-sponsored project using the internet to search for reports of people with Asperger's (a form of high-functioning autism) who have found MDMA to be helpful in their learning to cope more effectively in social situations. If we do find at least a handful of such reports, this could become another area of advocate, research, if funding becomes available. Drs. Mithoefer, Peter Oehen and Franz Vollenweider, will be presenting their MDMA/PTSD work at the European Conference on Traumatic Stress in Croatia next month.

April 13, 2007. The MAPS-sponsored study in Israel evaluating MDMA-assisted psychotherapy for subjects with war-and terrorism-related posttraumatic stress disorder (PTSD) has full government approval and is now in the subject recruitment stage. Hottentot Venus? The study will be conducted at Beer Yakhov Mental Health Center, near Tel Aviv, under the direction of Principal Investigator Moshe Kotler, M.D., former chief psychiatrist of the Israeli Defense Forces. The therapeutic team has been expanded and will now include Sergio Marchevsky, M.D., in addition to Rakefet Rodrigez, M.D., and Rael Strous, M.D. March 20, 2007. Advocate? Time Magazine's annual What's Next issue ran a brief story entitled Taking a trip for your mental health, highlighting MAPS-sponsored MDMA, psilocybin, and ketamine research. March 17, 2007. An encouraging advancement is that we may be close to enrolling the final five subjects needed to complete Dr. Mithoefer's study.

We've focused more attention on recruitment with ads on who was targeted various psychedelic-related websites and websites for PTSD support groups and currently have more than five subjects going through the screening process. Two of these potential subjects are Iraq War veterans. Advocate? Efficacy data at this stage is promising, so far making a strong case for continuing the research into faustus meaning FDA Phase 3 studies. March 11, 2007. After several years of effort, three rejections, and an appeal, the Institutional Review Board (IRB) for Dr. Michael Mithoefer's flagship MAPS-sponsored US MDMA/PTSD study approved an amendment to the study's protocol. The IRB decided that it will not object to subjects speaking with the media and/or documentary filmmakers following completion of each subject's participation in the study. Maccormick? The IRB originally insisted that patients not speak with the model media even after the entire study is maccormick, complete. After years of careful consideration, the IRB has now determined that it has no jurisdiction to in the, control subjects' decisions about whether or not to speak to the media. Now that the media policy has been resolved, we are ready to move forward with our 12-month follow-up evaluations, which the IRB has previously approved.

March 10, 2007. Dr. Peter Oehen's MAPS-sponsored study evaluating MDMA-assisted psychotherapy for maccormick v lord advocate subjects with chronic posttraumatic stress disorder (PTSD) has been making swift progress. Last Thursday, March 8, the second subject in who was Dr. Oehen's study underwent the second experimental treatment session.

The third subject will undergo the first experimental session later this week, and the fourth and 5th subjects have already been recruited. March 6, 2007. Peter Jennings' special ABC report entitled Ecstasy Rising is available for viewing. This groundbreaking documentary discusses MDMA's cultural history, its use as a therapeutic tool, the government's criminalization and exaggeration of its risks, and MAPS' recent success with MDMA-assisted psychotherapy research. Regarding this clip we would like to give SPECIAL thanks to Nathan for ripping this footage and hosting it onsite ;-) Many gracious THANX. February 28, 2007. MAPS has committed $5,300 to maccormick v lord, Dr. Faustus Meaning? Franz Vollenweider at the Psychiatric University Hospital in Zurich to co-sponsor a secondary study that will gather data for maccormick advocate physiological assessments of subjects in Dr. Oehen's MDMA/PTSD study.

The additional study will use several different measures to assess the psychophysiology of PTSD by using EEG/ERP and other biological measures such as heart rate variability (HRV) and shiite, pre-pulse inhibition (PPI). These parameters will be measured before and after the MDMA-assisted psychotherapy to allow researchers to v lord, evaluate changes in various areas of the faustus meaning brain and body. We expect that this additional neurophysiological and biological data will document the efficacy of MDMA-assisted psychotherapy. The amendment to Dr. Maccormick V Lord? Oehen's protocol to include Dr. Vollenweider's research was previously approved by Dr. Oehen's Ethics Committee (IRB) in September 2006. For more on shiite this study, see Dr. Oehen's article in the Fall 2006 MAPS Bulletin . February 26, 2007. Maccormick Advocate? The UK's Sky News published a short article describing Dr. Peter Oehen's MAPS -sponsored pilot study evaluating MDMA-assisted psychotherapy for subjects with treatment-resistant post-traumatic stress disorder (PTSD).

February 14, 2007. Swiss Radio International's Swissinfo published a brief original article describing Dr. Peter Oehen's ongoing MAPS-sponsored pilot study evaluating MDMA-assisted psychotherapy for subjects with treatment-resistant post-traumatic stress disorder. February 9, 2007. The Data Safety Review Board (DSMB) for Dr. Hottentot Venus? Michael Mithoefer's MAPS-sponsored FDA Phase 2 pilot study evaluating MDMA-assisted psychotherapy for subjects with posttraumatic stress disorder (PTSD) met in late January for its final review, now that 15 out of 20 subjects have completed the experimental treatment. The DSMB recommended that the study continue without modification.

Ironically, the DSMB's only safety concern was that those subjects who received the placebo might see a substantial increase in PTSD symptoms after tapering off of psychiatric medications. Maccormick? The DSMB is comprised of an M.D., a Psy.D. and hottentot venus, a Pharm.D. not otherwise involved in maccormick advocate the study. Efficacy data at this stage is promising, so far making a strong case for continuing the research into FDA Phase 3 studies. Drama Example? We're already looking beyond the next five subjects and the completion of this initial study, to future research protocols. January 23, 2007. Slate published a positive description of MAPS' MDMA drug development efforts in a front page article entitled What a Long, Strange Trip It's Been: Ecstasy, the New Prescription Drug? January 12, 2007. MAPS has donated $3000 to Pal-Orjan Johansen and Terri Krebs for a project that will seek to use the internet to search for reports of maccormick v lord advocate, people with Asperger's (a form of high-functioning autism) who have found MDMA to floating signifier, be helpful in their learning to cope more effectively in social situations. If we do find at least a handful of such reports, this could become another area of research, if funding becomes available.

MAPS also awarded another grant of $6000 to advocate, Pal-Orjan Johansen and Terri Krebs to expand their work reviewing transcripts of subjects in MAPS-sponsored MDMA/PTSD research, in order to code and compare the psychological defense mechanisms used in both non-drug therapy sessions and in the experimental MDMA-assisted therapy sessions. This study is designed to identify process variables that may help explain how MDMA can be a useful adjunct to psychotherapy. January 6, 2007. From January 3-6, 2007, MAPS' clinical research team (Amy Emerson, Valerie Mojeiko, and Josh Sonstroem) was in Charleston, SC, conducting a monitoring inspection of Dr. Michael Mithoefer's MAPS-sponsored IRB-, DEA-, and US FDA-approved MDMA/PTSD study. On January 5, the 15th subject participated in her third and final experimental MDMA-assisted psychotherapy session.

On January 6, MAPS President Rick Doblin visited Charleston to meet with Dr. Michael and Annie Mithoefer and MAPS' clinical research team to review the shiite muslims data, which looks very promising. An additional $125,000 will be required to maccormick v lord advocate, complete this study. December 14, 2006. In response to the sensationalistic and inaccurate recent news coverage of prospective Ecstasy user studies by faustus meaning, Dutch researcher Dr. Maccormick V Lord? Maartje M. de Win, MAPS President Rick Doblin, Ph.D. wrote this open letter to floating signifier, Dr. de Win voicing his concerns, and MAPS Clinical Research Associate Ilsa Jerome, Ph.D., wrote a special report evaluating the media's claims and how they relate (or not) to the actual data. December 8, 2006. While in Thailand to testify in maccormick a medical MDMA trial, MAPS President Rick Doblin took the opportunity to do an interview with The Nation , Thailand's largest English-language daily newspaper. In the interview, Doblin speculates on the possibility of floating, conducting MDMA/PTSD research with tsunami victims and maccormick v lord, discusses MAPS' international psychedelic research agenda. November 24, 2006.

Dr. Peter Oehen conducted the second experimental MDMA-assisted psychotherapy session with the faustus meaning second subject in his ongoing MAPS-sponsored MDMA-assisted therapy pilot study for subjects with treatment-resistant post-traumatic stress disorder (PTSD). According to Dr. Oehen, the subject delved into some challenging content, but the long-term results appear to be quite positive. She was confronted very hard with anxiety, negative emotions related to the sexual abuse and especially her isolation and avoidance of closeness, said Dr. Oehen. It was hard work for maccormick v lord advocate her in the following days but since then she has made substantial progress.

Therapist reports confirm that the subject confronted very hard with anxiety and with negative emotions related to their tramua - especially isolation and avoidance of closeness. This was followed by hard work for the subject during the following days but since then they have made substantial progress. October 23, 2006. The MDMA arrived on-site today at Harvard's McLean Hospital for Dr. Floating? John Halpern's MAPS-initiated study evaluating MDMA-assisted psychotherapy for v lord advocate subjects with advanced-stage cancer suffering from end-of-life anxiety disorders. Floating Signifier? MAPS has withdrawn from direct sponsorship of this study, but will still have access to the data generated by Dr. V Lord? Halpern, as will any other organization that requests it. October 22, 2006. The MAPS clinical research monitoring team arrives in Israel today for the Site Initiation visit for the MAPS-sponsored MDMA/PTSD pilot study at signifier Beer Yakhov Mental Health Center in v lord advocate Tel Aviv, Israel, under the direction of Principal Investigator Moshe Kotler, former chief psychiatrist of the Israeli Defense Forces.

The study will focus on drama portfolio individuals suffering from war-related PTSD. The MAPS clincial monitoring team consists of MAPS President Rick Doblin, Ph.D., Clinical Research Associate Valerie Mojeiko, and advocate, volunteer clinical research expert Amy Emerson. Their job is to strength based, help the researchers prepare the study to fit the strict guidelines necessary for the data generated to be eligible for consideration by the FDA and v lord advocate, the European Medicines Agency. On October 25, Doblin and Lester Grinspoon, M.D., will join Israeli and faustus meaning, Palestinian drug policy experts in maccormick advocate Jerusalem to talk at the first Arab-Israeli Joint Conference on vs sunni Peace and Drug Policy, sponsored by maccormick advocate, the Ale-Yarok (Green-Leaf) Party. The conference will focus on who was holocaust issues related to the cultural impacts of maccormick advocate, marijuana, its regulation, and its medical uses and research. While in Israel, MAPS staffers Rick Doblin and Valerie Mojeiko will also be conducting a Psychedelic Emergency Services training seminar for a team of volunteers organizing a rave near the hottentot venus Dead Sea. October 19, 2006. Principal Investigator Peter Oehen, M.D., officially initiated the Swiss MAPS-sponsored pilot study evaluating MDMA-assisted psychotherapy for subjects with treatment-resistant posttraumatic stress disorder (PTSD). Today, Dr.

Oehen conducted the first experimental MDMA session with the first subject. Maccormick V Lord Advocate? Congratulations, Dr. Oehen! September 13, 2006. Dr.

Michael Mithoefer treated the signifier 13th subject with a third MDMA-assisted psychotherapy session today in his MAPS-sponsored FDA Phase II pilot study of MDMA-assisted psychotherapy for individuals with treatment-resistant post-traumatic stress disorder (PTSD). The 16th patient out of 20 was also just screened and admitted to the study earlier this week. September 12, 2006. Dr. Peter Oehen's MAPS-sponsored MDMA/PTSD protocol has full government approval and the first subject began the screening process last week. V Lord Advocate? The Ethics Committee (the Swiss IRB equivalent, which previously approved Dr. Oehen's MDMA/PTSD protocol) met on September 7 to review an addendum to the protocol, and we just learned today, September 12, that the IRB has granted approval, meaning that the study can now officially be initiated!

The addendum is for an associated study by Dr. Franz Vollenweider, University of Zurich, that will examine subjects before and after treatment with MDMA-assisted psychotherapy. Dr. Hottentot Venus? Vollenweider is going to maccormick v lord, measure several physiological factors that have been associated with PTSD (startle response, heart rate reactivity) as well as various EEG parameters to see if the MDMA-assisted psychotherapy results in any changes in these measures. The first applicant for the study will be administered baseline CAPS and PDS tomorrow, and, now that we have full approval, we hope to report shortly that the first subject has been treated with MDMA-assisted psychotherapy. August 21, 2006.

The Norwegian Research Council website recently posted Ecstasy: Historien Starter (article in PDF format) (English translation Ecstasy; The History Begins), an article by who was, Pål-Ørjan Johansen that discusses the scheduling history, the research controversies, and new research into maccormick v lord advocate the therapeutic potential of MDMA. August 20, 2006. VG, one of the drama largest Norwegian newspapers, published a very positive piece on MDMA psychotherapy research that includes interviews with Charles Grob, M.D., and Pål-Ørjan Johansen, Ph.D. (View PDF of article). August 15, 2006. In their Newsdesk section, the journal Lancet Neurology published Hallucinogen Research Inspires Neurotheology, a report on developments in research with psychedelic compounds, such as ketamine or psilocybin. The piece contains comments from Roland Griffiths, John Halpern and Deborah Mash. August 5, 2006. The Israeli Import Permit and maccormick v lord, the Swiss Export Permit have now been approved. On Thursday, August 3rd, in faustus meaning the midst of war, about 5 grams of MDMA arrived in Israel for MAPS' MDMA/PTSD study, imported into v lord advocate Israel from Switzerland. This study has full government approval and will be initiated in portfolio example Fall 2006.

July 21, 2006. V Lord Advocate? Dr. Michael and Annie Mithoefer treated the 13th subject with the second experimental MDMA/placebo session in their MAPS-sponsored MDMA/PTSD trial today. Signifier? Dr. V Lord Advocate? Mithoefer described it as impressive. June 17, 2006. Switzerland's DEA equivalent, the BAG, has officially approved Dr.

Peter Oehen's MAPS-sponsored study evaluating MDMA-assisted psychotherapy as a treatment for subjects suffering from treatment-resistant Posttraumatic Stress Disorder (PTSD). Permission from BAG was the final regulatory hurdle, since Dr. Strength? Oehen has already received approval from the Ethics Committee (Switzerland's IRB equivalent) and SwissMedic (Switzerland's FDA equivalent). June 16, 2006. Dr. Michael Mithoefer initiated the first experimental MDMA-assisted psychotherapy session with the 13th subject out of 20 in his MAPS-sponsored FDA Phase II pilot study. This subject was the first to v lord advocate, receive supplemental dosing of who was targeted in the holocaust, half the initial amount of MDMA administered 2 to 2.5 hours after the v lord initial dose in order to hottentot venus, prolong the plateau of MDMA's therapeutic effectiveness, a change recently approved by advocate, Dr.

Mithoefer's Istitutional Review Board (IRB), the Food and Drug Administration (FDA), and the Data Safety Monitoring Board (DSMB). The supplemental dose did not seem to intensify the already strongly therapeutic experience but it did prolong the period of maximum therapeutic effect for at least 90 minutes. This appeared to be very useful. We were also happy to see that, as expected, there was no problem with vital signs. June 7, 2006. Switzerland's FDA equivalent, SwissMedic, has now fully approved Dr. Peter Oehen's MAPS-sponsored MDMA/PTSD study. The protocol design had already been approved, and faustus meaning, earlier this week we received approval for the source of the MDMA itself, which MAPS is maccormick advocate, purchasing from a Swiss manufacturer. Faustus Meaning? Now that Dr.

Oehen has received permission from SwissMedic and an Ethics Committee (the Swiss IRB equivalent), the v lord advocate only regulatory hurdle remaining is licensing from BAG, the Swiss DEA equivalent, which is portfolio, expected within a month. Initiation of advocate, Dr. Oehen's study will take place shortly thereafter. Approval from SwissMedic of the source of the MDMA for the Swiss MDMA/PTSD study will now enable MAPS to move forward with the export of MDMA from Switzerland to Israel. The import/export of the MDMA is the last regulatory step in the initiation of Dr. Moshe Kotler's MAPS-sponsored MDMA/PTSD research at Beer Yaakov Mental Health Center in Tel Aviv, in subjects with war and terrorism-related PTSD. June 4, 2006.

Dr. Hottentot Venus? Michael Mithoefer has received Institutional Review Board (IRB) approval for several key changes that FDA had recently approved to v lord advocate, his MAPS-sponsored study evaluating MDMA-assisted psychotherapy as a treatment for PTSD. The changes include (1) adding a third experimental session to the two that are currently included in the protocol to test whether a third session adds significantly to the therapeutic process, (2) providing supplemental dosing of faustus meaning, half the initial amount of MDMA administered 2 to 2.5 hours after the v lord initial dose in strength based model order to prolong the plateau of MDMA's therapeutic effectiveness, and (3) doing without an ER doctor on standby in the next room since Dr. Mithoefer has become a board-certified ER doctor as well as a board-certified psychiatrist. Now that the Data Safety Monitoring Board (DSMB), FDA, and IRB have all approved these changes to our protocol, they will be implemented for the study's remaining eight subjects. May 15, 2006. Maccormick? The Boston Globe published A Good Death, an article that discussess the resurgence of interest in studying MDMA and hottentot venus, psychedelic drugs to help people with cancer deal with anxiety and pain. The piece describes research MAPS helped design and maccormick v lord advocate, locate funding for hottentot venus that will look at the potential therapeutic benefits of MDMA in people who are anxious as a result of advanced stage cancer. The latest MAPS Bulletin contains an article about the advocate woman described in this article who used MDMA to hottentot venus, treat cancer-related pain and anxiety.

A PDF of the this piece is now available.. April 14, 2006. A recently published editorial in the Lancet supports research into the potential therapeutic benefits of psychedelic drugs and v lord advocate, calls for portfolio a new legal structure that makes this research easier and less burdensome to conduct. The Lancet editorial was likely inspired by maccormick v lord advocate, a commentary published in strength based the British Journal of Psychiatry. V Lord Advocate? This editorial was then covered by the British newspaper, the Guardian. April 5, 2006. Strength? In some fantastic news, philanthropist Peter Lewis has agreed to maccormick, donate $250,000 directly to Harvard Medical School-affiliated McLean Hospital to portfolio example, fund the costs of Dr. John Halpern's study of maccormick, MDMA-assisted psychotherapy in hottentot venus subjects with anxiety associated with advanced-stage cancer. Dr.

Halpern's MDMA/cancer anxiety study is already fully approved by the FDA, DEA, two Institutional Review Boards (IRB's, at Lahey Clinic and McLean Hospital) and the Massachusetts Dept. of Public Health. Maccormick V Lord Advocate? Now that the study is fully funded, Dr. Halpern is faustus meaning, preparing to initiate the study and hopes to maccormick, enroll the first subject within the next several months. As we reported in the last email update, MAPS has withdrawn from direct sponsorship of this study. The McLean Hospital administration felt that MAPS long-term advocacy for MDMA psychotherapy research and general opposition to Prohibition would cause the results of the study to be challenged as biased if MAPS were to sponsor the study and they did not want McLean Hospital to hottentot venus, be involved in a study funded by MAPS. Maccormick V Lord? Therefore, we decided that it would be best for MAPS to offer to withdraw from further direct financial sponsorship of Dr.

Halperns research so that the study, which many people labored so long to start, could proceed. Sacrifices sometimes need to be made. In this case, we decided that the benefits of the example study moving forward substantially outweigh MAPS' withdrawal from v lord, direct sponsorship. Who Was Targeted In The? MAPS will still have access to the data generated by Dr. V Lord Advocate? Halpern, as will any other organization that requests it. March 7, 2006. The DEA has, after over one year, issued a license for Dr. John Halpern's study of MDMA-assisted psychotherapy in subjects with anxiety associated with advanced-stage cancer. The final regulatory approval has thus been obtained. Additional approvals have already been received from two Institutional Review Boards (IRB-McLean and Lahey Hospitals) as well as the Food and Drug Administration (FDA) and the Massachusetts Department of Public Health. MAPS has donated over $94,000 to McLean Hospital over the last five years in an effort to initiate the evaluation of MDMA-assisted psychotherapy.

One fruit of this support has been Dr. Halpern's $1.8 million grant from the National Institute on Drug Abuse (NIDA) for faustus meaning a methodologically state-of-the art study started with MAPS funding of the neurocognitive consequences of the use of Ecstasy. Now that the MDMA/cancer anxiety study is fully approved, MAPS is withdrawing from any further financial sponsorship. MAPS, independent of McLean and Dr. Halpern, still hopes to assist with seeking donors interested in now donating directly to McLean Hospital. We believe that this financial distance from MAPS, and more so the rigor of the methodological design of the study itself, will enable the results of the study to be viewed by skeptics as more objective.

If the results of the pilot study are promising, MAPS will again explore options for the support of research at advocate McLean Hospital. February 6, 2006. Strength Based Model? MAPS' Data Safety Monitoring Board (DSMB) met to review records for the six new subjects who have enrolled since their last meeting in Dr. Michael Mithoefer's study evaluating MDMA-assisted psychotherapy as a treatment for PTSD. With data from a total of eleven subjects before them, the advocate DSMB reported that they did not have any concerns about the safety of the study, and recommended that it continue without modification. Strength Based? The DSMB is comprised of an M.D., a Psy.D., and a Pharm.D. not otherwise involved in the study. Dr. Mithoefer has successfully treated 11 out of an v lord advocate, eventual 20 subjects, and is currently treating the twelfth. The DSMB also reviewed and approved three protocol changes that Dr. Mithoefer and MAPS will initially submit to FDA and then, if approved, to muslims, our Institutional Review Board (IRB).

Dr. Mithoefer is seeking permission to: 1) Increase the number of MDMA experimental sessions from two to three, to advocate, evaluate whether this extra session will enable subjects to make more therapeutic progress. 2) Administer supplemental doses of faustus meaning, 1/2 the initial dose of MDMA 2 to 2 1/2 hours after the initial dose, in maccormick v lord order to prolong the relatively short plateau of MDMA's full therapeutic effectiveness. 3) Since Dr. Strength Model? Mithoefer has recently renewed his Board certification in ER medicine, we have asked to maccormick v lord advocate, do without the targeted holocaust additional Board-certified ER doctor sitting in the next room. In comparison, Dr.

Peter Oehen's study in Switzerland has been designed and approved for three MDMA experimental sessions and the use of maccormick v lord advocate, supplemental doses. Dr. Kotler's study in Israel has been designed and approved with supplemental dosing but just two MDMA experimental sessions. January 25, 2006. An article in hottentot venus the New Zealand Herald about posttraumatic stress disorder (PTSD) in veterans mentions the use of MDMA for PTSD but makes some incorrect claims. A letter to the editor from Rick Doblin corrects the mistakes. This article demonstrates that there is a widely perceived need for more effective treatments for PTSD and that the MDMA research is increasingly accepted as a necessary and not very controversial effort. December 27, 2005. An article in the Washington Post, A Political Debate On Stress Disorde, by v lord advocate, Shankar Vedantam, reports that in 2004 the US Veterans Affairs Department spent $4.3 billion on PTSD benefit payments to a total of 215,871 veterans.

If the results of the model second half of our MDMA/PTSD study are as promising as the results of the first half, we will have data suggesting that it would be financially wise for maccormick v lord the VA to fund the entire $5 million cost of MAPS' Phase III studies to evaluate whether MDMA-assisted psychotherapy for holocaust PTSD should become approved by the FDA as a legally-available treatment for PTSD. MAPS received word from Dr. Peter Oehen, Principal Investigator of the Swiss MDMA/PTSD pilot study cosponsored by v lord, MAPS and the Swiss Association for Psycholytic Therapy, that the final written approval from the signifier ethic committee arrived today. Dr. Oehen will now submit the protocol and the other documents to maccormick advocate, Swissmedic, for a review process that we expect will take a month or two. December 20, 2005. Dr. Michael Mithoefer, Principal Investigator of the MAPS-sponsored MDMA/PTSD psychotherapy study in Charleston, South Carolina, filed an Annual Status Report with his Institutional Review Board (IRB).

There have been no drug-related Serious Adverse Events (SAEs) and the results on treatment efficacy are promising. November 15, 2005. An excellent roundtable discussion about psychedelics and vs sunni, Judaism was published in Jewish Currents, published by the Association for Promotion of Jewish Secularism, Inc. The article is entitled, Just Say Maybe- Psychedelic Drugs, Healing and Politics: An Interview with Four Jewish Researchers (Rick Doblin, Charlie Grob, Julie Holland, Howard Lotsof). November 11, 2005. The Good Drugs Guide Radio show, out of England, broadcast a show entitled,The State of Ecstasy. The show is described as follows, It's ten years since the death of Leah Betts, a teenager who died after taking a single tablet of ecstasy, also known as MDMA. Maccormick Advocate? Her tragic death triggered a huge backlash against the drug here in the UK. Who Was Targeted Holocaust? Even so, 700,000 people still take E every week in this country.

So what have we learnt about maccormick v lord ecstasy in the last decade? Do the stories of terrible comedowns, brains like swiss cheese, and instant death have any credibility? Could MDMA really become a prescription drug? And has the faustus meaning music got any better? We find out. V Lord? Guests include Dr Julie Holland, author of Ecstasy The Complete Guide, Rick Doblin, president of shiite muslims, MAPS.org, and Mike Linnell of drug charity Lifeline. The show also uses clips from the v lord advocate excellent ABC documentary, Ecstasy Rising. MAPS received word that the Israeli Ministry of Health has approved our MDMA/PTSD pilot study!! One condition was that the Israeli Anti-Drug Authority write a letter formally indicating support for example the protocol, which the Israeli Anti-Drug Authority has done. Now we need to bring the Israeli therapeutic team to maccormick v lord advocate, the US to observe an MDMA/PTSD session conducted by Dr. Michael and Annie Mithoefer and we need to bring MAPS Clinical Research Monitoring Team to Israel, to set up the holocaust Case Report Forms and the Standard Operating Procedures (SOPs).

Plus we need to arrange to export MDMA to advocate, Israel for the study. Once these steps have all been accomplished, the who was targeted study itself can begin enrolling subjects. We're anticipating that the study can begin in March 2006. November 8, 2005. Maccormick? Dr. Faustus Meaning? Michael Mithoefer received the disappointing news that the advocate National Institute of floating signifier, Mental Health (NIMH) has rejected our grant application seeking $125,000 over two years for the development of a treatment manual for the use of MDMA-assisted psychotherapy in the treatment of maccormick v lord, posttraumatic stress disorder (PTSD).

MAPS' grant application was not scored (it was considered in the bottom half of all applications). This rejection isn't really surprising since the last time NIMH gave a grant for anything to do with psychedelic psychotherapy was over 30 years ago, with all NIMH intramural psychedelic psychotherapy research stopping in 1967. MAPS invested $2,768 in the NIMH grant application, but the money is not wasted. We have gained a better understanding of what it will take to in the, complete the treatment manual that we have already begun to develop and maccormick v lord, we now can say that we have indeed tried to model, obtain funding from NIMH. Maccormick? Maybe once we complete the initial pilot study, we can submit the strength results to advocate, NIMH and try again to obtain support. It has been reported that in 2004, the Veterans Affairs Department (VA) spent $4.3 billion on PTSD disability payments! In 2006, the VA requested $2.2 billion for mental health services. Once we have completed our initial pilot study, we may have a better chance of obtaining some federal funding for vs sunni MDMA/PTSD research. November 7, 2005. Advocate? The Daily Texan, the newspaper of the University of model, Texas at Austin, published a letter about, The harms of MDMA that presented misleading information about MAPS' MDMA research projects. The letter critiqued a previous column entitled, Debunking drug folklore, MAPS President Rick Doblin replied to correct the record.

While taking time to write to a student newspaper may not at first glance represent a wise use of MAPS staff time, in the age of Google, even student letters can be read by maccormick, a large number of people, especially when the topic is discussed repeatedly in the student newspaper. Indeed, the Daily Texan also published a more reasonable letter, The harm of Ecstacy, II. While MAPS concentrates on scientific research, our educational mission is also of major importance. October 21, 2005. An article in shiite the UCLA Daily Bruin discusses animal rights protesters objecting to a proposed study in primates, Making Connections: MDMA Research on the Mechanisms of Affiliation and Trust. The article mentions that this research was submitted for maccormick funding to MAPS, by Anthropology Professor Alan Page Fiske, who is quoted as saying, The biggest problems we have in the world are people not trusting each other and not feeling a solidarity (and) feeling distant, Fiske said. If we could understand the basis of compassion and caring, that's about the most important thing human and biological sciences could do.

A MAPS Bulletin article about Prof. Fiske's research can be found here. At present, there is no funding for the study. Briefly stated, MAPS has not funded animal research for about ten years but is not categorically opposed to hottentot venus, doing so if the maccormick research is of sufficient importance. MAPS considers Prof. Fiske's proposed research to strength, be sufficiently important to maccormick v lord advocate, be worthy of strength based model, being conducted but the information it would generate isn't essential for maccormick advocate MAPS' program of research intended to develop MDMA into an FDA-approved prescription medication. MAPS' top priority is strength based model, our human studies into the therapeutic use of MDMA. These studies require substantial resources so our intention is to conduct further research in v lord animals only when required by FDA.

October 14, 2005. A DEA Field Investigator came to McLean Hospital to test the alarms on the safes at the Pharmacy, where the roughly 4 grams of faustus meaning, MDMA will be stored for the MAPS-sponsored MDMA/cancer anxiety study. Everything seemed to be in advocate order and floating, the DEA investigator stated that his report should get processed within one month. We're cautiously optimistic we'll have the final approvals before the end of maccormick v lord, 2005. October 8, 2005. Dr.med. Peter Oehen submits an MDMA/PTSD protocol for review to a Swiss ethics committee, for who was targeted in the a pilot study co-sponsored by MAPS and the Swiss Association for Psycholytic Therapy (SAePT). Advocate? This study will involve three experimental sessions instead of two and will use supplemental dosing 2 1/2 hours after the initial dose. August 2, 2005. Ironically, after NIDA-funded researchers Drs.

McCann and Ricaurte claimed that MDMA damaged dopamine neurons and could cause Parkinson's disease, a claim that they later had to retract, new research conducted at faustus meaning Duke University Medical Center has shown that MDMA is the most effective of 60 drugs tested in reversing the symptoms of maccormick v lord advocate, Parkinson's disease! This research was discussed in portfolio an article in v lord News-Medical.Net; note also a brief commentary on this and other related research into MDMA as an anti-Parkinson's disease treatment. July 22, 2005. The 10th subject had her 2nd experimental session, which went well. Once she completes her final follow-up evaluation in about two months, we will have completed half of based, Stage 1 of the study. We'll then conduct a preliminary data analysis and submit it to MAPS' Data Safety Monitoring Board (DSMB) for review. There have been no Serious Adverse Events (SAEs) during the first half of our study and the outcome data looks promising. Stage 2 is for maccormick v lord those subjects who received placebo and wish to reenroll in targeted in the holocaust the study to receive MDMA open-label. The second subject in Stage 2 is scheduled to receive her second MDMA session on v lord Monday, August 1. This session will also be used as a training session for Drs.

Halpern and Naidoo from Harvard Medical School. They have the subject's permission to observe in signifier order to help them prepare to conduct their MAPS-sponsored study of MDMA in subjects with anxiety associated with advanced-stage cancer. We'll still waiting on DEA to issue a Schedule I license before this study can begin. July 19, 2005. Australia's Herald Sun publishes Pill poison, an article about the proliferation of of ecstasy dealing, consumption, and adulteration in the nation's most populated region.

The link also includes and editorial from the Herald Sun demanding that the community take responsibility for the nation's drug problems. July 18, 2005. V Lord? Austrailia's United Press runs Dealers lacing ecstasy with other drugs, reporting on the widespread adulteration of ecstasy tablets throughout the country. July 7, 2005. The IRB approved the requested changes, conditional to accepting changes in hottentot venus the consent documents. Dr. Mithoefer accepted all changes the IRB recommended.

Now the investigators can continue to plan and carry out treatment manual development. July 1, 2005. A letter from the National Institute of Mental Health (NIMH) arrived at v lord advocate MAPS today, saying that our grant application, Treatment Manual Development for MDMA-Assisted Therapy, has been received and assigned to a Scientific Review Group (SRG). The initial peer review should be completed by the end of November 2005, with funding decisions made in drama portfolio example January 2006 after the meeting of the appropriate National Advisory Group. MAPS' grant application can be found at: http://www.maps.org/mdma/ptsd_study/grant0605/ June 23, 2005. Michael Mithoefer submitted proposed changes to the MDMA/PTSD, including provisions for videotaping all psychotherapy sessions, a step needed for maccormick v lord advocate developing a treatment manual for MDMA-assisted psychotherapy in people with PTSD, as needed to carry out the work proposed in the grant application submitted to NIMH. June 17, 2005. UK News site Guardian Unlimited ran this story about Alexander Shulgin, his history as a pharmacologist, and strength, the repercussions of his 1965 synthesis of v lord advocate, MDMA. June 6, 2005. The study protocol for the MDMA/PTSD study to who was targeted in the, take place in maccormick v lord advocate Israel was reviewed and vs sunni muslims, approved by the Beer Yaakov Medical Center ethics committee (IRB).

The study has now been sent to the Israeli national ethics committee. If it is approved by the national ethics committe, it will then be reviewed by the Ministry of maccormick, Health. May 31, 2005. Michael Mithoefer MD submitted a grant application to NIMH for developing a treatment manual of MDMA-assisted therapy for PTSD. May 23, 2005. Online Publication Nursing Spectrum puts forth an article discussing the Harvard study of MDMA psychotherapy for treatment of anxiety associated with terminal cancer. Author Lisette Hilton quotes Dr. John Halpern that the benefits of this therapy would have greater application for nurses who tend to dying patients on faustus meaning a daily basis than for the physicians who prescribe the therapy. The CQ (Congressional Quarterly) Weekly published an excellent cover story by Tim Starks, entitled New Prescriptions for War Trauma.

The article interviews Dr. Michael Mithoefer and discusses the maccormick advocate MAPS-sponsored study of MDMA-assisted psychotherapy in the treatment of PTSD. May 19, 2005. Psychology Today offers two articles about strength psychedelic research constraints in the United States, one from 2005 and the other from 1994. Compare what 11 years can do!

May 18, 2005. Join Together, a drug abuse prevention organization, ran a news summary regarding the maccormick v lord advocate recent St. Petersburg Times article on shiite muslims the MDMA research MAPS sponsors. May 16, 2005. Canadian newspaper Northern Life ran an article in the online police beat section by Jason Thompson in maccormick v lord advocate which Dr. Stephen Kish of the Northern Ontario School of faustus meaning, Medicine, among others, discuss problems and potential of MDMA use. May 12, 2005. Rick Doblin appeared on Joe Scarborough's MSNBC segment yesterday. Here is maccormick, a transcript as well as a video of the interview. May 11, 2005.

Dr. Meg Jordan, Global Medicine Hunter, puts out a podcast about MAPS' research into the use of MDMA in the treatment of postraumatic stress disorder (PTSD) in Iraq War vets, and about her work with the therapeutic use of MDMA in the late 1970s! May 9, 2005. The International edition of Newsweek published A Psychedelic Cure, a piece similar to the a piece published last week in the domestic edition, but with greater discussion of proposed studies of based model, MDMA-assisted psychotherapy in Spain and Israel.. The St. Petersburg Times ran a front page article,Party pill gets tryout in maccormick advocate therapy written by Janet Zink, offering reporting on vs sunni muslims MAPS' mission of decriminizaling the use of MDMA for therapeutic purposes.

May 2, 2005. Newsweek Magazine runs a story on MDMA research by Eve Conant, Ecstasy: A Possible New Role for A Banned Club Drug. The changing economics of Ecstasy is leading a rising number of youths to turn to cheaper, more available drugs. Among them: addictive prescription painkillers such as OxyContin and Vicodin, inhalants such as paint thinner, and methamphetamines. Two recent surveys said OxyContin and Vicodin had passed Ecstasy in popularity among teens. And this is considered progress! comments Rick Doblin, MAPS President. April 11, 2005. The LA Times published, Ecstasy's Good Side, reporting on MDMA/cancer anxiety study to be conducted by v lord advocate, John Halpern MD, and portfolio, discussed related studies (such as the study of psilocybin in people wiht cancer-related anxiety conducted by Charles Grob MD, and the ongoing study of MDMA in people with PTSD. Note that the article erroneously reports on the location of the last study, which is at the offices of Michael Mithoefer MD, and not at the Medical University of South Carolina. March 25, 2005. The largest Israeli newspaper, Yediot Ahronot, published a favorable article about MAPS' Israeli conference, which took place the day before, and advocate, the use of MDMA-assisted psychotherapy in treating posttraumatic stress disorder (PTSD).

The article was accompanied by an incredible graphic of a drowning man holding on to a life preserver that was actually an Ecstasy pill with a smiling face. March 24, 2005. MAPS sponsored a very successful conference in Israel on research with MDMA, ibogaine and marijuana for the Israeli Ministry of Health, the Israeli Society of drama, Addiction Medicine, and representatives from the Israeli Anti-Drug Authority. The conference was intended to educate Israeli regulators and researchers about maccormick MAPS' proposed MDMA/PTSD pilot study that we're trying to sponsor in Israel, under the direction of Dr. Moshe Kotler, Chair, Department of Psychiatry, Tel Aviv University, Sackler School of Medicine. After the conference, Dr.

Kotler said that he was ready to submit our draft protocol to the ethics committee for review. March 10, 2005. Today the based Drug Enforcement Administration will visit Dr. John Halpern of Harvard Medical School's McLean Hospital as a routine procedure before issuing his Schedule I license. Once Dr.

Halpern has received his license, the MAPS-funded study of MDMA-assisted psychotherapy for v lord advocate anxiety in advanced cancer patients can begin. March 8, 2005. The NPR show, To the Point, hosted by Warren Olney, discussed Dr. Michael Mithoefer's MAPS-sponsored MDMA/PTSD study and FDA's newly approved expansion of the drama study to include subjects with war-related PTSD. Guests include Dr. Andrew Pomeranz (PTSD therapist), Dr. Michael Mithoefer, Rick Doblin, Ph.D. and Robert Dupont, Ph.D. Advocate? (first Director of the National Institute on Drug Abuse). The story runs from faustus meaning, 23:35-50:52.

The Scientist published Renewed Faith in Ecstasy, a brief article on the recent history and progress of MDMA research, and featuring quotes from Rick Doblin. March 4, 2005. Maccormick V Lord Advocate? BBC On-Line published an article describing recently published findings that ecstasy use was associated with increased self-reported symptoms of depression, but only in people who have a certain form of the serotonin transporter gene. You can also read a commentary on targeted the paper. February 26, 2005. New Scientist published a lengthy and maccormick v lord, extensive overview of current and floating signifier, planned research into the medical or psychiatric benefits of psychedelic substances, including MDMA, psilocybin, LSD, ketamine and ibogaine, and covernig a wide array of MAPS-supported and Heffter Institute supported studies.. Maccormick V Lord? The article contains a history of medical research with psychedelics. February 23, 2005. Drama Example? The Boston Globe published a lengthy piece on the MDMA/cancer anxiety study that will take place at Harvard University's McLean Hospital. The piece features quotes from Halpern and from Rick Doblin. National Public Radio (NPR)'s All Things Considered aired an interview of John Halpern, who spoke about the advocate MDMA/cancer anxiety study.

You can hear a recording of the interview on faustus meaning the NPR website or you can read the maccormick advocate transcripts of the interview. ABC World News Tonight briefly reported on the MDMA/cancer anxiety study to be conducted by John Halpern MD. February 17, 2005. The Guardian published an extensive discussion of vs sunni, current and planned research into the therapeutic uses of MDMA and psychedelic drugs. The article quotes John Halpern, Rick Doblin and Michael Mithoefer, and covers a surprising breadth of current and planned research in this area. The Guardian published another report specifically noting the recent expansion of the MDMA/PTSD study to now accept people with combat-related PTSD. The report features quotes from Michael Mithoefer, the prinicpal investigator. V Lord Advocate? This is not a new study specifically looking at combat stress.

Rather, the ongoing study is now no longer restricted to people with crime-related PTSD. The German newspaper Der Spiegel published a report on the recent expansion of the MDMA/PTSD study to include people with combat-related PTPSD that is even more muddled than the report from the Guardian, above. Not only does this report suggest that a new investigation is underway, but that the US military is drama portfolio, involved in this study. V Lord Advocate? As already noted, there is no new study specifically studying MDMA-assisted therapy in people with combat-related PTSD, and the military has not been involved in any step of this research so far. February 16, 2005. The January issue of the Brazilian science magazine Galileu published Da Balada Para o Diva,, an hottentot venus, article in Portugese by Juliana Tiraboschi about maccormick research into the potentially therapeutic uses of MDMA.. The paper discusses the MDMA/PTSD study and quotes MAPS president Rick Doblin. You can also read a PDF version of the article. Dr. Michael Mithoefer and Annie Mithoefer were guests on Kathleen Brooks' radio show on World Talk Radio, Darkness to Light: Breaking the Conspiracy of Silence, for an hour-long discussion of their MAPS-sponsored MDMA/PTSD study.

February 4, 2005. Faustus Meaning? The UCLA newspaper the maccormick Daily Bruin featured a report on Charles Grob's research on psilocybin in people with cancer experiencing anxiety relating to their illness. The piece quoted Grob and Dr. John Halpern, the principal investigator of the MAPS-sponsored study of MDMA in people with cancer-related anxiety. Today Michael and Ann Mithoefer performed the first experimental (MDMA or placebo) session for the sixth participant enrolled in the study of MDMA-assisted psychotherapy in people with PTSD. If all goes well, the next experimental session will occur in three to five weeks. January 30, 2005. January 30, 2005. The New York Times Sunday Magazine published a profile of psychedelic chemist, Sasha Shulgin, that highlighted the approval of who was holocaust, MDMA research at advocate Harvard sponsored by MAPS (though MAPS was not mentioned). Faustus Meaning? The article includes a quote from Dr.

Steve Hyman, Harvard Provost and ex-Director of the National Institute of Mental Health, saying that he is skeptical whether MDMA-assisted psychotherapy in subjects with anxiety associated with advanced-stage cancer will actually prove beneficial but that he thinks the v lord research should go forward. The ghost of floating signifier, Timothy Leary has now definitely be laid to rest at Harvard. Now it's up to maccormick advocate, us to prove what we have been saying for decades, that MDMA and other psychedelics have remarkable healing potentials. As the saying goes, Beware what you wish for. The challenge of proving the safety and faustus meaning, efficacy of v lord advocate, psychedelic psychotherapy is model, formidable, but definitely a goal worth the decades of prior and future work. January 21, 2005. Psychiatry News (a publication of the American Psychiatric Association) reported on maccormick v lord the proposed MDMA/cancer anxiety study, with quotes from signifier, principal investigator John Halpern MD.. January 16, 2005. The Boston Globe published an v lord advocate, article contrasting FDA approval of MAPS' study of who was, MDMA-assisted psychotherapy in subjects with anxiety associated with advanced-stage cancer with DEA rejection of Prof.

Lyle Craker's MAPS-sponsored application for a license to establish a facility to produce marijuana for federally-approved research. The Week in Review section of the advocate Sunday New York Times had a thoughtful but rather snide and shiite muslims, inaccurate article on the research into the use of MDMA and psilocybin in the treatment of anxiety associated with advanced cancer. Prof. Mark Kleiman criticizes a NYTimes article on v lord the use of faustus meaning, psychedelics in treating anxiety in subjects with advanced-stage cancer. He notes the flawed central assumption of the article which is that all drugs are alike, and that drugs have the property of maccormick advocate, dulling perception and faustus meaning, cognition, making people less present to what is happening to them. January 14, 2005. Dr.

John Halpern submitted his application today to DEA for a Schedule I license, the final regulatory approval required before we can begin the MDMA/cancer anxiety study. Dr. Halpern has already received his State Schedule I license. January 8, 2005. Dr. John Halpern is the guest on C-SPAN's Washington Journal for a live, half-hour national call-in show focused on Dr. Halpern's MAPS-sponsored study of v lord, MDMA-assisted psychotherapy in subjects with anxiety associated with advanced-stage cancer. January 7, 2005. The Boston Herald published a short piece describing the MDMA /cancer anxiety study, quoting primary investigator John Halpern and shiite, MAPS President Rick Doblin. January 6, 2005. MAPS donated $26,616 to McLean Hospital, Harvard University, for Dr.

John Halpern's MAPS-sponsored study of the use of MDMA-assisted psychotherapy in subjects with anxiety associated with advanced-stage cancer. This represents the first payment in what we expect will total $250,000 for this study. The approval of this study by maccormick v lord, McLean Hospital (where the floating signifier MDMA-assisted psychotherapy will take place), the Lahey Clinic (where the patients receive primary care for advocate their cancer), and the FDA, represents a triumph of hope over fear, hope for the too-long obstructed promise of MDMA-assisted psychotherapy v. Faustus Meaning? fear of the risks of MDMA exaggerated by anti-drug crusaders and scientists for their own ends. At a time when the US government has placed all its eggs in the fear basket (war, terrorism, drugs, financial ruin of Social Security, gay marriage, etc., etc.), the remarkably widespread media reporting of maccormick, FDA's approval of psychedelic research again at Harvard after 40 years shows that people are eager for balance, for hopeful news. Drama Portfolio? It's now clear that the American public would welcome whatever help can be provided in facing directly life's final challenge, to die gracefully and in peace, even if such help comes from v lord, a previously demonized and criminalized substance also used by young people seeking pleasure. January 5, 2005. The Harvard Crimson reported on the MDMA/cancer anxiety study that will be taking place at faustus meaning McLean Hospital. V Lord Advocate? Principal Investigator John Halpern MD is quoted, as well as MAPS President Rick Doblin PhD. The on-line version of this article has a link to a letter written by Timothy Leary and hottentot venus, Richard Alpert (Ram Dass) and published in the Crimson in maccormick 1962. December 31, 2004.

An amazing editorial, Examining Ecstasy, about FDA approval of MAPS' MDMA/cancer anxiety study, was published today in the Ottawa Citizen. MAPS' Harvard study is considered restrained and Charles Grob is chastised for speaking of potential spiritual benefits! December 30, 2004. An article in The Australian reports on floating signifier the FDA approval of MAPS' MDMA/cancer anxiety study and quotes Australian Medical Association Queensland public health committee chairwoman Jeanette Tait as saying, The medical community would look askance at this type of trial, except that it is being conducted by advocate, such a respected body, she said. As it is such a fairly substantial body doing the trial, especially with FDA approval, I think the results will be very interesting.

There's so much to be wary about illicit drugs and their use. Dr. Tait's comments reaffirm the value of MAPS' efforts to faustus meaning, conduct MDMA psychotherapy research at Harvard, since the research is being taken more seriously as a result of where it is being conducted. December 29, 2004. Some of the most important Spanish newspapers and journals broke the news about the MDMA/cancer anxiety study, echoing the news report from the Washington Post. These reports are apparently very favorable. These include EE UU ensaya el uso de éxtasis en enfermos de cancer terminal (El País, December 28, PDF), Cientficos de EE UU investigarn el uso del 'éxtasis' en enfermos terminales (El Correo Digital, December 29, PDF) and EEUU aprueba un estudio sobre el uso psiquitrico del 'éxtasis' (El Mundo, December 28, PDF). December 27, 2004. Excellent Washington Post article by Rick Weiss about FDA approval of MDMA/cancer anxiety research and general renewal of research into the therapeutic potential of MDMA and psychedelic compounds. [ Also see scans of the article. ] The AP Wire Service published a report on the recent FDA approval of the MDMA/cancer anxiety study, with quotes from principal investigator John Halpern MD. December 17, 2004. The FDA approved John Halpern's MDMA/cancer anxiety study today.

November 19, 2004. A fateful step has been taken. Today, MAPS submitted Dr. Maccormick V Lord? John Halpern's MDMA/cancer anxiety protocol and associated documents to the FDA. FDA should receive the faustus meaning protocol Monday, November 22 and maccormick advocate, will then have 30 days from that point to signifier, review it. FDA will either approve the protocol or place it on clinical hold pending resolution of maccormick v lord advocate, any issues FDA felt it appropriate to raise. If approved by FDA, the last remaining major hurdle before the faustus meaning study can start will be Dr.

Halpern's need to obtain a DEA Schedule 1 license to v lord advocate, dispense the MDMA to be used in the study. After FDA approval has taken place, we feel that DEA will most likely issue the license sooner rather than later, probably voluntarily. DEA cooperation will be due to the compelling nature of this study, the amount of existing interest and support, the very low risk of diversion since there are no take-home doses, and, most importantly, the regulatory limits on the factors that DEA can use to evaluate applications for Schedule I licenses to conduct FDA-approved research. If fully approved, this study will become the first psychedelic research to shiite muslims, take place at Harvard since 1965. A new era will then have begun in earnest 21st Century psychedelic research! November 15, 2004. At the request of our Institutional Review Board (IRB), MAPS has established a Data Safety Monitoring Board (DSMB) that works for MAPS reviewing the data from Dr. Mithoefer's MDMA/PTSD study on an ongoing basis. V Lord Advocate? The DSMB met today to review the hottentot venus charts from the first five subjects who have completed their final follow-up evaluation. which takes place two months after the second experimental session. The DSMB concluded that We did not see any significant adverse events that caused us any concerns about the safety of maccormick, this study. They recommended that the study continue without modification.

The next scheduled meeting of the DSMB will take place after the next five subjects (the 6th-10th) have completed their final follow-up evaluations. The DSMB will also meet if there is a serious adverse event. November 10, 2004. The Lahey Clinic Institutional Review Board (IRB) met this evening to review the hottentot venus MAPS-sponsored pilot study designed to explore the use of MDMA-assisted psychotherapy in subjects with anxiety associated with advanced cancer, to be directed by v lord advocate, co-investigators Dr. Drama Example? John Halpern, Dr. Todd Shuster, Dr. Umadevi Naidoo, and Dr. Arthur Siegel.

This protocol has to be reviewed and approved by both the IRB at McLean, where the psychotherapy and experimental sessions will take place, and by the IRB at Lahey Clinic, where Dr. Maccormick? Shuster works and from where the subjects will be recruited. After the protocol was introduced by Dr. Strength Based? Shuster, Rick Doblin, Ph.D. and Dr. Halpern responded for maccormick about 30 minutes to a series of thoughtful and important questions from members of the IRB. The protocol and second, short informed consent form (covering just the initial screening process at Lahey) were then. approved! We've already gotten approval from the McLean Hospital IRB at Harvard Medical School (see Oct. 27, 2004 entry), so now it's on to the FDA. We expect to submit the documents to FDA within the based next week to ten days. FDA must, by v lord advocate, regulation, respond in some manner within 30 days.

The McLean IRB approved the signifier shortened informed consent form for the MAPS-sponsored pilot study designed to explore the use of maccormick v lord advocate, MDMA-assisted psychotherapy in subjects with anxiety associated with advanced cancer. October 26, 2004. Harvard Medical School's McLean Hospital Institutional Review Board (IRB) met to review the MAPS-sponsored pilot study designed to explore the use of MDMA-assisted psychotherapy in portfolio example subjects with anxiety associated with advanced cancer, to be directed by co-investigators Dr. John Halpern, Dr. Advocate? Todd Shuster, Dr. Umadevi Naidoo, and Dr. Arthur Siegel. The protocol was. approved! The only conditions were that that the approval was subject to FDA and DEA approval, and we were requested to shorten (!) the informed consent form. October 12, 2004.

As a result of a FOIA request made earlier this year, MAPS now has information on National Institute on Drug Abuse (NIDA) funding awarded to Dr. George Ricaurte and Dr. Una McCann in 2003 for the study of MDMA (Ecstasy) neurotoxicity and functional consequnces of Ecstasy use. The pair of Johns Hopkins researchers were awarded over hottentot venus, $1.8 million dollars during 2003. Maccormick V Lord Advocate? This brings their total government funding to more than $16.4 million since 1989.

October 8, 2004. The October 8-14 Boston Phoenix features an interview with MAPS' president Rick Doblin Ph.D. that discusses, among other things, ongoing research into the therapeutic effects of MDMA, psilocybin, and marijuana. September 30, 2004. The Salt Lake City Weekly published a piece on who was targeted holocaust Ecstasy Therapy. The piece includes interviews with two therapists practicing underground MDMA-assisted therapy, and an interview with Rick Doblin Ph.D., president of MAPS. September 27, 2004. Wired published a piece charting the progress of research into the therapeutic uses of psychedelic drugs, including the ongoing studies of maccormick, MDMA-assisted psychotherapy in people with PTSD, psilocybin in floating people with OCD, and psilocybin in cancer patient with anxiety, as well as planned studies into MDMA-assisted therapy in people with anxiety associated with advanced stage cancer, and maccormick, psilocybin and hottentot venus, LSD in people with cluster headaches. September 14, 2004. Maccormick V Lord? The journal Movement Disorders has recently published two letters in response to in the holocaust, a report of parkinsonism in a former ecstasy user, and maccormick v lord advocate, include a reply from the authors of the vs sunni case report. The two letters include a letter authored by MAPS' Lisa Jerome and Rick Doblin and maccormick v lord, MDMA/PTSD study principal investigator Michael Mithoefer, and a report of a transient dystonia appearing after Ecstasy use.

In their reply to both letters, the authors acknowledge the shiite vs sunni muslims likely rarity of movement disorders associated with Ecstasy use, but fail to discuss the maccormick lack of evidence for who was targeted holocaust a relationship between Ecstasy use and movement disorders. August 20, 2004. The second experimental session for the 4th subject in the MDMA/PTSD study took place today. The session went very well. The next Data Safety Monitoring Board (DSMB) meeting will take place after the 5th subject has completed the final follow-up testing, two months after that subject's 2nd experimental session.

August 16, 2004. Dr. John Halpern submitted a lengthy response to the questions that we were asked to address by the IRB reviewing the maccormick v lord advocate MDMA/cancer anxiety study. Now we wait until the IRB meeting at faustus meaning the end of August to see if there are more questions. We're feeling hopeful about an eventual resolution of all the issues. August 15, 2004. Medicine Hope for Psychedelic Drugs, an advocate, article from BBC News (UK Web), by Arran Frood, discussed psychedelic psychotherapy research supported by Heffter Research Institute and MAPS. This article is mostly based on an interview with Dr. Charles Grob and leaves the strength model impression that it's about time that research into the therapeutic uses of psychedelics has resumed. August 10, 2004.

MAPS' Data Safety Monitoring Board (DSMB) for the MDMA/PTSD study met today to maccormick v lord, review the data on the first five subjects who participated in at least one experimental session. The DSMB was comfortable with the who was data, and maccormick, has recommended that the study continue as designed, without any modification. August 6, 2004. . The third subject in the MDMA/PTSD study participated in the second (and final) experimental session. The experimental sessions have all been scheduled on Fridays, which is working out to be a convenient time and gives subjects the model weekend to rest and reflect. August 4, 2004. Maccormick? The Charleston, South Carolina Post and Courier published an article about the MDMA/PTSD study. While the article overemphasizes the supposed dangers of MDMA, it does at least give the impression that MDMA may indeed have therapeutic potential. Dr. Mithoefer has written a letter to the editor clarifying some misleading statements made in the Post and Courier article. The Post and who was holocaust, Courier also published another article on the history of psychedelic research. On August 8, the Post and Courier printed the v lord following correction: A story on Page 1A of Wednesday's editions of The Post and Courier incorrectly stated that Dr.

Michael C. Mithoefer was administering Ecstasy to patients. The story should have made it clear that the drug was being given to research subjects. The federally approved research program is unrelated to Mithoefer's private practice and who was holocaust, patients. Dr. Mithoefer also notes that the story would have more appropriately drawn a distinction between dangerous recreational use of Ecstasy and controlled clinical studies if it had noted other studies, including three US studies approved by the FDA, that found no serious adverse events and no evidence of neurotoxicity in tests administered under medical supervision.

July 28, 2004. The McLean IRB meet on Wednesday to review the MDMA/cancer anxiety study. They have some concerns that we need to address but it seems like they are rather straightforward issues so it's possible that we will get approval at next month's meeting. If so, then we will start seeking the rest of the approvals (from an IRB at the Lahey clinic where the oncologist works and where the maccormick v lord subjects will come from, FDA and DEA). July 25, 2004. A front page article in hottentot venus the Sunday Baltimore Sun discussed MAPS' MDMA psychotherapy research in a favorable light, illustrated with a photo of advocate, Rick Doblin. Of special note is the conclusion, in which Dr. George Ricaurte says that MDMA may one day find a place as an floating, accepted medication. On July 29, the Sun published a clarification to the article. July 21, 2004. Dr.

John Halpern has integrated preliminary comments from the maccormick McLean IRB and submitted revised versions of a protocol, informed consent, treatment manual, and based, the most recent update of the MDMA literature review (January 2003-March 2004) for maccormick v lord his MAPS-sponsored proposed study of MDMA-assisted psychotherapy in subjects with anxiety related to advanced-stage cancer. July 9, 2004. The third subject participated in his first experimental session in Dr. Mithoefers' MAPS-sponsored MDMA/PTSD study, without any adverse side effects. Several additional subjects are also scheduled to participate in their first experimental sessions during this month. July 6, 2004. MAPS' effort to start research at Harvard into the use of MDMA-assisted psychotherapy in subjects with anxiety associated with advanced cancer began a new phase today, as Dr. John Halpern submitted a draft of the protocol to targeted, the McLean Hospital Institutional Review Board (IRB) for preliminary review. We anticipate several months of review and discussion before we will be able to determine if the protocol will be accepted. Maccormick Advocate? If so, the study then moves to the Lahey Clinic IRB for further review (Dr. Todd Shuster, oncologist co-investigator, works at Lahey Clinic and will refer subjects to participate in the study), and then on to the drama portfolio FDA.

We're hoping that this study will be the vehicle to restart psychedelic research at v lord advocate Harvard again, for muslims the first time since 1965! June 28, 2004. Dr. John Halpern of Harvard Medical School's McLean Hospital submitted a protocol for review to the McLean Institutional Review Board (IRB) for a MAPS-sponsored study of MDMA in the treatment of anxiety in advanced stage cancer patients. Maccormick V Lord Advocate? After years of laying the groundwork for this study, and months of protocol development, we have now formally begun the effort to open a new area of research for floating MDMA and to restart psychedelic research at Harvard for the first time since 1965. If the McLean IRB approves the v lord study, the who was targeted protocol will then go to the IRB at maccormick Lahey Clinic, where oncologist and co-investigator Dr. Muslims? Todd Shuster works and from where the subjects will be referred into the study, and then on to FDA. Maccormick V Lord? We anticipate that this study will take three to six months to become fully approved and hope to signifier, start treating the first subjects in late 2004 or early 2005. Before MDMA was criminalized in 1985, several psychiatrists and maccormick v lord, therapists worked with cancer patients with MDMA with positive results in terms of reduced anxiety and pain. Strength Model? In the 1960s and early 1970s, LSD was also used successfully in maccormick the psychotherapeutic treatment of cancer patients.

MAPS work to resume this line of research at Harvard represents an in the holocaust, extremely important effort to v lord, start a new era of psychedelic research, at a culturally symbolic place where many people think psychedelic research went off the track, evidenced by Timothy Leary and Richard Alpert (Ram Dass) being kicked out of Harvard in strength model 1963. V Lord? After almost 40 years in the proverbial wilderness, its time for psychedelic research to faustus meaning, return to Harvard! May 14, 2004. The second experimental session took place today for the second subject. (Due to scheduling complications, the first subject's second session is scheduled for next week.) The session, which went very well, is the last experimental session for this subject. She will receive some additional non-drug psychotherapy and a final follow-up evaluation two months from now. May 13, 2004. Nature publishes a lengthy article and editorial about MDMA psychotherapy research. The articles, about which Rick Doblin has written a lengthy commentary, are supportive of MAPS' research efforts. Maccormick V Lord Advocate? Alex Gamma wrote a letter to the editor responding to claims of insufficient knowledge of extent of risks in strength human trials made in the piece and providing greater detail on a human trial of advocate, MDMA described in the article. May 3, 2004.

Rick Doblin met in Jerusalem with Dr. Miki Reiter, Israeli Ministry of Health, about MAPS' proposed Israeli MDMA/PTSD pilot study in subjects with war and terrorism-related PTSD. Dr. Portfolio Example? Reiter is supportive of the maccormick advocate project and welcomed MAPS offer to donate $75,000 to fund the pilot study. May 2, 2004. An Israeli dentist who survived a suicide bombing in a Jerusalem cafe in March 2002 that killed about 11 people met in person with Rick Doblin in Jerusalem. Floating? The dentist contacted MAPS last week after searching the internet for pages about MDMA and PTSD. The dentist, who has permanent hearing loss but wasn't otherwise seriously wounded, developed PTSD after the maccormick v lord advocate bombing.

After treatment with psychotherapy and SSRIs that was only moderately helpful, he discovered on his own that MDMA was of major benefit to him. Faustus Meaning? He contacted MAPS since he felt it was a shame that MDMA had been available to him only maccormick v lord illicitly and at risk to his professional license. Floating Signifier? After a long discussion, he surprised Rick by mentioning that the place he had chosen for their meeting was the same cafe in which the bombing had taken place. He has written a report, which is maccormick, followed by additional comments from Rick. April 30, 2004. Rick Doblin met in New York City with Israeli psychiatrist Dr.

Moshe Kotler, the Principal Investigator of MAPS' proposed Israeli MDMA/PTSD pilot study in subjects with war and terrorism- related PTSD. Now that the US study is fully approved, Dr. Kotler feels the time is right to move forward with the protocol design and approval process for the Israeli pilot study. Dr. Kotler used to be the faustus meaning chief psychiatrist for the Israeli Defense Forces (IDF). April 23, 2004. The second subject participated in her first experimental session (MDMA or placebo). Maccormick V Lord Advocate? Each subject will receive two experimental sessions, two to three weeks apart, in additional to about 8 non-drug psychotherapy sessions. This study is now well underway and is moving forward steadily.

April 19, 2004. This is the strength 61st anniversary of the world's first planned LSD experience. On Monday, April 19, 1943, at v lord advocate 4:20 PM, Albert Hofmann ingested 250 micrograms of LSD and neither he nor the world was ever the same again. Albert was trying to determine if an signifier, odd experience he had on v lord Friday, April 16, 1943, was related to the LSD that he was synthesizing. Turns out, it was! April 16, 2004. Historic Days! The first experimental session in MAPS' MDMA/PTSD study took place today. Both the subject and the experimental team guessed that the substance that was administered was MDMA instead of the muslims placebo. In any case, the session was remarkably therapeutic and seemed to represent a breakthrough for the subject.

Sixty-one years ago, on April 16, 1943, the world's first LSD experience took place due Dr. Albert Hofmann's accidental ingestion of some of the chemical that he was synthesizing. V Lord Advocate? The date of the first experimental session in the MDMA/PTSD study was set several weeks ago. The coincidence of that date being the 61st anniversary of the world's first LSD experience was unintentional, but fortuitous. September 24, 2002. John Mendelson, M.D., Associate Professor at University California San Francisco, commented on hottentot venus Michael Mithoefer, M.D.s proposed MDMA study. Mendelson states that the risk of heart valve changes after two MDMA exposures, as suggested in the study protocol, are very low. April 9, 2004. MAPS issues a report based on documents obtained through Freedom of Information Act (FOIA) requests showing that from 1989-2002, Drs.

Ricaurte and McCann received federal grants totaling over $14.6 million dollars for MDMA and MDMA-related research. (A FOIA request for 2003 data has been submitted.) This is a rather amazing amount of money and suggests that Drs. Ricaurte and McCann had some powerful incentives to exaggerate the risks of MDMA. This also speaks volumes about our society's warped priorities in that not a single penny of maccormick, federal money has been awarded to explore any of the strength model therapeutic uses of MDMA. This is an imbalance that MAPS hopes to rectify over v lord advocate, the coming years. April 6, 2004. In an article in Talon News (bringing the hottentot venus conservative message to America), the fundamentalist drug warrior, Rep, Mark Souder, Chairman of the House Government Reform Subcommittee on Criminal Justice, Drug Policy, and Human Resources and author of the infamous law that denies educational loans to students with a prior drug conviction, has strongly criticized Peter Jennings's Ecstasy Rising documentary. V Lord? Rep. Souder's criticisms of targeted in the, Peter Jennings' lack of a moral compass demonstrate yet again that the Drug War is a holy, moral crusade where facts are subjugated to ideology. The first psychotherapy session with the maccormick first subject took place today! In addition, a second subject passed the screening process and has qualified for the study.

This study is definitely underway, full speed ahead. April 5, 2004. Video archives of the Peter Jennings special, Ecstasy Rising, are now available. April 1, 2004. Ecstasy Rising. Federal Campaign to Curb Club Drug Use Hasn't Dimmed Its Popularity, ABCNEWS.

March 30, 2004. A new study of MDMA self-administration in monkeys found MDMA to be far less toxic than assumed from previous studies. Study findings suggest that when monkeys take doses of faustus meaning, MDMA similar to v lord advocate, those used by Ecstasy-using humans, there are no signs of hottentot venus, harm to serotonin or dopamine cells. Study findings also suggest that monkeys, like humans, may slowly lose interest in taking MDMA over time, and v lord, that this change of heart is not a sign of brain toxicity. March 24, 2004. A DEA-licensed pharmacist, a Randomization Monitor, and Dr. Mithoefer are creating the MDMA and placebo capsules today for use in who was targeted in the the MDMA/PTSD study.

The process is being filmed by maccormick advocate, a camera crew from ABC for use in a feature story about the MDMA/PTSD study to be aired on World News Tonight at 6:30PM EST on April 1. Later that evening Peter Jennings' Ecstasy Rising documentary will be broadcast at floating 10PM est/pst, 9PM cst/mst. March 16, 2004. Maccormick V Lord? IRB approval was extended another six months, to September 15, 2004, or until the shiite vs sunni first Data Safety Monitoring Board (DSMB) report is available. Approval is maccormick, conditional upon review of the data on an ongoing basis by who was holocaust, the DSMB. The first DSMB report will take place after the first subject has participated in the first experimental session and before any subject has had their second experimental session. This first DSMB meeting will most likely take place in late April or early May. The second DSMB report will take place after the first five subjects have undergone the first experimental session. The third DSMB report will take place after the first five subjects have completed their final follow-ups, the fourth after the 6th-10th subjects have completed their final follow-ups and the fifth and final scheduled meeting will take place after the 11th -15th subjects have completed their final follow-ups. Unscheduled meetings will take place if ever there is a Serious Adverse Event (SAE). March 12, 2004. Advocate? MDMA arrives!

Today the tiny amount of MDMA required for the MDMA/PTSD study (4 grams) arrived, shipped with all the appropriate DEA forms and procedures. Patients are being scheduled for screening to see if they meet the inclusion and exclusion criteria. This study is example, now fully underway. The tentative date for the first experimental session is April 16, completely coincidentally the same date that, in 1943, Albert Hofmann first accidentally discovered the psychedelic properties of LSD. March 10, 2004. The Ecstasy Factor - Bad Science Slandered a Generation's Favorite Drug. Now a New Study Aims to Undo the Damage, by Carla Spartos, Village Voice. This is maccormick advocate, a strong, hard-hiting article.

March 4, 2004. Jose Carlos Bouso has been invited to participate in a Spanish TV program on March 12, 2004, along with the following other guests: - The Director of the Spanish Antidrug Agency (Plan Nacional sobre Drogas). - The Director of the Madrid Antidrug Agency. - The President of the Help Against Drug Addiction Foundation (FAD, Fundacion de Ayuda Contra la Drogadiccion), the most important private organization against drugs in Spain. - One famous Spanish sociologist expert in drug abuse.

Jose Carlos has an excellent opportunity to raise the issue of the willingness of supporters of the Drug War to suppress science and floating, ignore the welfare of PTSD patients in order to support Drug War propaganda. The Drug Policy Alliance reports on v lord DEA approval of the MAPS' sponsored MDMA/PTSD study. DEA Accedes to Ecstasy Test by Kristen Philipkoski, Wired News. This article contains a remarkable quote from George Ricaurte giving qualified support for the MDMA/PTSD study. March 1, 2004. The Israeli newspaper, Maariv, published an article about the approval of the MDMA/PTSD study, entitled United States Approves Ecstasy to Treat Trauma: The FDA says the strength model party drug will be used to treat people who have been sexually assaulted by Alex Doron. February 26, 2004. V Lord Advocate? One of most important national Spanish newspapers (El Mundo) published an article regarding the final approval of the floating US MDMA/PTSD study in its Science section. The article is maccormick v lord, quite favorable and also tells that the MAPS-sponsored Spanish MDMA/PTSD study was shutdown for political reasons. We will continue to struggle to faustus meaning, reopen the Spanish MDMA/PTSD study.

CNN Show: American Morning, 7 AM. Dr. Drew Pinsky thinking too reductionistically_ about the use of MDMA for the treatment of PTSD, . it's quite legitimate. I think the idea that it creates a psychological effect may be somewhat naive, the idea that somehow people are more open to looking at the narrative around their trauma because of the sort of subjective effects of the drug, that, to me, is kind of naive because it's so biologically powerful. It's almost like looking at electric shock therapy again.

February 25, 2004. Advocate? Rick Doblin was the guest in targeted holocaust a live email chat on the Chronicle for Higher Education website. To read the exchanges, see the transcript. Corrections and comments on the CNN announcement by Ilsa Jerome, Ph.D and Rick Doblin, Ph.D. Watch the CNN announcement (RealPlayer is required) February 24, 2004. The DEA issued Dr.

Mithoefer a Schedule 1 license. The first MDMA-assisted psychotherapy research project since MDMA was criminalized in 1985 now has the v lord advocate necessary regulatory approval from the FDA, the IRB and the DEA and can proceed. February 23, 2004. MAPS donated $11,000 to McLean Hospital, Harvard Medical School, for Dr. Drama Example? Halpern's work on the protocol design and approval process for maccormick advocate a study of MDMA-assisted psychotherapy in subjects with anxiety as a result of end-stage cancer, with outcome measures to evaluate anxiety, pain and quality of life. MAPS has previously donated $15,000 to McLean for this study on June 2003.

We plan to submit the based model protocol to the McLean IRB before the end of Summer 2004. Ecstasy Agonistes A retracted study on a controversial substance raises questions about the reliability of government-sponsored research on drugs, By Thomas Bartlett, Chronicle of Higher Education. The Chronicle of Higher Education's February 25, 2004 colloquy live email chat with Rick Doblin is available in advocate the Chronicle archive. February 18, 2004. Inching closer! Dr.

Mithoefer spoke with Dr. Belinda Hayes at DEA headquarters. She indicated that DEA has received a fax of the document they need from FDA but not the hard copy which they need to issue the license. She says the person at FDA claimed to faustus meaning, have mailed it 2 weeks ago. She said it should only be a matter of days once they get the document before they get it entered into the system and then issue the license. January 27, 2004. Dr.

Mithoefer received a call from DEA indicating they have not received the official reply from FDA yet in response to their request for a consultation. However, they know that FDA recommended that he be given a Schedule I license and as soon as DEA receives the official reply, they will be issuing his Schedule I license. This is the maccormick v lord first time we have heard from the DEA that Dr. Mithoefer will receive his license and the study will be able to move forward. January 26, 2004. NIDA responds to portfolio, MAPS' FOIA request for documents about maccormick v lord Dr. Targeted In The? Ricaurte's MDMA research. January 16, 2004. Rick Doblin has written a paper discussing how the risks of MDMA neurotoxicity have been exaggerated by government officials and government-funded scientists in a manner that has been used to support prohibitionist policies. Read a critique of a recently published study of self-reported memory problems in Ecstasy users, along with additional comments. You can also view the full text of the report in PDF format.

January 15, 2004. MAPS received a call from FDA reporting that DEA's request for a consultation about maccormick Dr. Portfolio Example? Mithoefer's qualifications to conduct research has finally arrived at advocate FDA. Furthermore, FDA's recommendation has already been sent back to DEA. We are inching ever closer. According to the Code of Federal Regulations [section 304(a) of the Act (21 U.S.C. 824(a))], DEA must issue Schedule I licenses to researchers with FDA-approved protocols within 10 days of DEA receiving a recommendation from FDA that an applicant is qualified to do the research, unless the strength based applicant can be denied on any of the grounds specified in v lord advocate section 304 (a) and has either 1) lied on the application, 2) been convicted of a drug felony, or 3) no longer has State registration to faustus meaning, administer controlled substances. Since none of these criteria apply, we may be quite close to being able to start this study.

However, there could be some delays caused by the uncertain amount of maccormick v lord advocate, time between when FDA sends its recommendation to floating, DEA and when DEA acknowledges receiving it, with interagency mail notoriously slow. Maccormick V Lord Advocate? MAPS will now work to drama, expedite this process however we are able. January 14, 2004. Dr. Michael Mithoefer has been flown to New York City and is being interviewed today for the upcoming prime-time Ecstasy documentary being created by Peter Jennings' documentary team. We're encouraged that a large national audience will learn of our efforts to conduct MDMA psychotherapy research. The documentary will probably be aired in late February or March. January 13, 2004. We're still waiting on DEA to v lord advocate, issue Dr. Mithoefer his Schedule I license.

DEA claims it is waiting to hear from signifier, FDA regarding a requested consultation about Dr. Mithoefer's qualifications to conduct research. We've inquired at FDA to determine whether DEA's request for consultation has actually arrived yet and, if so, when FDA will reply. We expect to v lord advocate, hear back from FDA shortly. According to the Code of Federal Regulations, DEA must issue a Schedule I license for FDA-approved research within 10 days of receiving favorable recommendation from FDA unless the applicant has lied on his application, has had a drug-related felony conviction, or no longer licensed by the State. Since Dr. Mithoefer cannot be refused his license on any of these grounds, we're cautiously optimistic we will be able to start the study shortly after FDA responds to DEA's request for consultation. January 6, 2004. MAPS submits a Freedom of Information Act (FOIA) request to FDA seeking copies of all correspondence between FDA and either the DEA, the Office of National Drug Control Policy, or the Partnership for a Drug-Free America, regarding the MDMA/PTSD protocol.

We'd like to see what, if anything, these organizations have been communicating to FDA regarding this study. December 17, 2003. Dr. Mithoefer learned today that on December 11, 2003, the South Carolina DEA office submitted its recommendation to DEA headquarters that it give Dr. Mithoefer his Schedule I license for the MDMA/PTSD study. Floating Signifier? DEA headquarters told Dr. Mithoefer last week that it is still waiting to receive a recommendation from FDA's Controlled Substances Staff but we have no information as to maccormick v lord advocate, whether the FDA has actually received DEA's request for a consultation. Step by step we move closer to starting.

December 7, 2003. A recent media report appeared, making some unduly alarming claims about MDMA and DNA mutations. However, the claims turn out to be false. Read a commentary on the research and what it actually meant. Targeted Holocaust? You can also read the full text (PDF) of the original research report. Science Gets Recruited in the Drug War, by Ronald Bailey. Reason Magazine Online. Rick Doblin, President of MAPS, published these comments on the NYT article. The Drug Policy Alliance have issued this related press release today. November 28, 2003. The politics of maccormick v lord advocate, rEsearch by faustus meaning, Harry Shapiro, is advocate, published in the Nov/Dec issue of the British magazine, Druglink.

This article reports that Ricaurte's mislabeling error came to faustus meaning, light when a student attempted to replicate the v lord advocate study and then made an official complaint when permission to publish the hottentot venus new findings was denied. In order to verify if this was accurate, Rick Doblin called the Johns Hopkins press office and was informed that Dr. Advocate? Ricaurte says that there is no substance whatsoever to shiite, this allegation. November 26, 2003. MAPS sent a letter today to NIDA Director Nora Volkow, Ph.D., responding to a November 18, 2003 letter from Dr. Volkow to Rick Doblin. This exchange of letters was part of maccormick advocate, a package of material that MAPS sent today to hottentot venus, members of NIDA's National Advisory Council on Drug Abuse (NACDA) requesting that NACDA recommend to NIDA that it release information about the MDMA research of Dr.

Ricaurte. Dr. Volkow indicated in her thoughtful but careful letter that she didn't think it was necessary for NIDA to proactively release the information about the MDMA research of Dr. Ricaurte that MAPS requested and noted that MAPS will obtain some information as a result of its Freedom of maccormick v lord advocate, Information Act (FOIA) request. In reply, Rick Doblin noted that, NIDA should be forthcoming with the information requested. To do otherwise leaves the hottentot venus impression that NIDA is maccormick v lord advocate, not actively and aggressively trying to clear up this disturbing episode that has damaged the credibility of NIDA's educational efforts regarding the risks of MDMA and other illegal drugs.

November 24, 2003. The British newspaper The Guardian published a positive article today about MAPS' progress towards final approval of our MDMA/PTSD study. Later today, BBC Scotland will interview me about the MDMA/PTSD study during its drive-time rush hour show. BBC World News just called about doing an interview that it will send out tonight to stations all over the place, and floating signifier, BBC London called for its Five Live national show. Also, the youth station in Dublin, Ireland (Spin1038) will conduct an interview. Just the struggle to obtain permission for the study is presenting us with some good opportunities to do public education about MDMA.

The BBC published this news article today on its highly regarded website. November 21, 2003. Editorial published in Movement Disorders by Stephen Kish, Ph.D., What is the Evidence that Ecstasy (MDMA) Can Cause Parkinson's Disease? This strong editorial examines the maccormick v lord advocate evidence that ecstasy can cause Parkinson's and suggests that the evidence is very weak. It also critiques the flawed McCann/Ricaurte PET evidence that MDMA causes substantial reductions in serotonin transporter. November 15-17, 2003.

MAPS' MDMA/PTSD research team met in Charleston, South Carolina to faustus meaning, review the forms and procedures that will be used to conduct the maccormick study. The meeting went extremely well. Amy and floating, Todd, the clinical research monitors who are volunteering to maccormick v lord advocate, help us implement pharmaceutical-level monitoring and checks and balances, were impressively professional. This study will be conducted with a level of formality and oversight that MAPS is hottentot venus, implementing for the first time but that will become standard on all our MDMA research projects. November 12, 2003.

Dr. Advocate? Mithoefer receives his Schedule I research registration (R1) from South Carolina's Department of strength model, Health and Environmental Control (DHEC). Dr. Mithoefer is maccormick advocate, still waiting on his DEA Schedule I license, which is vs sunni, all we need to maccormick v lord advocate, get started with the study. November 10, 2003.

RTI denies it made mistake that torpedoed results of a $1.3M study. Triangle Business Journal, by faustus meaning, Leo John. October 28, 2003. DEA Inspection goes very well. Several DEA agents inspected Dr. Maccormick? Mithoefer's facility today as part of DEA's review of his application for a Schedule I license to handle the signifier 3.5 grams of MDMA needed for v lord advocate the entire study. Who Was Holocaust? The inspectors focused on issues of diversion control and checked out the safe, the v lord alarm system and portfolio, the forms and advocate, procedures that will be used to track all of the MDMA and placebo capsules. The DEA agents were interested in drama portfolio helping Dr. Mithoefer understand and follow their rules and were quite reasonable. Dr. Mithoefer was told he will probably receive his license in maccormick advocate several weeks to vs sunni muslims, several months.

October 23, 2003. Maccormick? Protocol Improvements Recommended by IRBs. Though MAPS' long series of interactions with multiple IRBs was often frustrating, several improvements have been incorporated into the protocol design as a result of recommendations/requirements made by various of the IRBs. MAPS has prepared a document listing these improvements, with the primary ones consisting of having patients remain overnight in the treatment facility which will be staffed by an RN, having data periodically reviewed by an independent Data Safety Monitoring Board (DSMB), requiring subjects to take a quiz after reading the informed consent form to make sure the primary risks were understood, and requiring a minimum score on the questionnaire assessing the floating severity of PTSD that reflects a moderate severity. October 20, 2003 MAPS sends a letter to all members of the maccormick v lord National Institute on floating signifier Drug Abuse's National Advisory Council on Drug Abuse, requesting that it recommend that NIDA release all the information about maccormick v lord Dr.

Ricaurte's research that MAPS has requested in its Freedom of Information Act (FOIA) request. (also in Word format) October 17, 2003. Promising news from DEA. Floating Signifier? DEA has now scheduled an inspection of Dr. Mithoefer's facility on October 28, by agents from both the regional DEA office and the South Carolina Bureau of Drug Control. This is a routine step in the processing of a Schedule I license. It's encouraging to see that DEA is finally moving forward with its responsibilities, now that IRB approval for the protocol has been obtained.

October 14, 2003. An article by Kelly Morris, entitled Concern over advocate, research reawakens ecstasy neurotoxicity debate is floating, published in the journal Lancet: Neurology Vol 2, November 2003. October 9, 2003. Nature publishes a short news story (PDF and HTML) on the MAPS sponsored MDMA/PTSD study. Nature 425, 552 (09 October 2003) MAPS has a few comments on the article. October 8, 2003. Could MDMA help people with Parkinson's disease ? A recently published study in marmosets suggests that MDMA can reduce side effects of some medicatios used in the treatment of PD. October 2, 2003.

MAPS responds to v lord advocate, Ricaurte et al.'s retraction letter. MAPS addresses the evidence that Ricaurte et al. cite in their retraction letter in which they fail to give up the ghost and make a feeble attempt to floating, claim that MDMA could, after all, actually cause dopaminergic neurotoxicity and maccormick v lord, Parkinson's Disease. October 1, 2003. Strength Based Model? MAPS Submits FOIA Request to NIDA. MAPS receives a confirmation letter from maccormick v lord advocate, NIDA's Freedom of Information Act (FOIA) staff that it has received our request for specific information about the studies that Drs. Ricaurte et al. conducted with genuine MDMA that failed to find dopaminergic neurotoxicity, and about the studies that were conducted with the hottentot venus mislabeled bottles of MDMA and v lord, methamphetamine. The letter seems to indicate that there is a good chance that NIDA will release most or all of the information we requested, but that remains to be seen. September 23, 2003. Triumph. The Institutional Review Board (IRB) reviewing Dr. Mithoefer's MDMA/PTSD protocol made its final decision -- and approved the study!

This is a historic moment for MAPS and for MDMA research. The approval marks the end of faustus meaning, a three-month process with this IRB, and a 22-month IRB process overall. Dr. Mithoefer and MAPS have been struggling to obtain IRB approval since November 2001, when the FDA approved the maccormick study. This is the faustus meaning eighth IRB to which we've tried to submit the protocol.

Five refused to maccormick, accept it for review (after varying periods of consideration), one approved it then revoked that approval for political reasons, and another finally tabled the review, after spending months formally reviewing the targeted holocaust study before making it clear, through unreasonable demands, that the maccormick advocate committee did not want to approve it. Along the way, we also established a MAPS IRB, but fortunately, we didn't need to use it. The last remaining step before we can begin the shiite vs sunni muslims study is for Dr. V Lord Advocate? Mithoefer to faustus meaning, obtain a DEA Schedule I license. DEA received Dr. Mithoefer's application more than 15 months ago. We hope to maccormick advocate, receive a license somewhat quickly now that IRB approval has been obtained, but you can never tell with DEA. After Dr. Mithoefer does obtain a Schedule I license, we can finally begin the study of MDMA-assisted psychotherapy in subjects with chronic Posttraumatic Stress Disorder (PTSD).

September 18, 2003. MAPS sends a letter to NIDA Director Nora Volkow noting the many unanswered questions in the Ricaurte et al. retraction and requesting the release of additional information. MAPS states that the credibility of NIDA is at hottentot venus stake. These sentiments are also expressed in a powerful editorial just released by the scientific journal, Nature. September 6, 2003. Amazing Retraction! Dr. V Lord Advocate? George Ricaurte retracted his paper published in faustus meaning Science on Sept. 27, 2002. He originally claimed that MDMA caused severe dopaminergic neurotoxicity in primates injected with a common recreational dose regimen of MDMA, and maccormick, suggested that Ecstasy users could develop Parkinson's.

Dr. Ricaurte now reports that his research team administered methamphetamine instead of faustus meaning, MDMA to maccormick v lord advocate, his monkeys, a mistake which came to light after he failed to replicate his findings after the oral administration of MDMA of hottentot venus, even higher doses of MDMA to additional monkeys. Dr. Ricaurte's claims were challenged by MAPS in an exchange of letters in Science in June 6, 2003. Those letters, and a series of media articles about today's retraction can be found here. September 5, 2003. George Ricaurte, Ph.D.'s retraction of his paper Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of methylenedioxymethamphetamine (MDMA) is published in Science. August 25, 2003. For the last several months, another independent Institutional Review Board (IRB) has been reviewing Dr. Michael Mithoefer's MAPS -sponsored MDMA/PTSD protocol. Today, we submitted our response to advocate, another series of questions and a revised protocol and informed consent form.

We anticipate hearing from the IRB in several weeks. MAPS had considered forming its own IRB and had written a set of required standard operating procedures and obtained commitments from a group of illustrious people to who was in the holocaust, serve on the MAPS IRB. However, before launching the v lord advocate MAPS IRB, we decided to try one more time with an Independent IRB. Floating? So far, this IRB has restored our faith in the IRB review process since the maccormick advocate review is being based on shiite the scientific merits of the design. If MAPS does obtain IRB approval, the advocate final step in the approval process will be for Dr. Mithoefer, the Principal Investigator, to based model, obtain a DEA Schedule I license to handle a total of 3 grams of MDMA for administration to all the subjects in the study (12 subjects will each receive a dose of 125 mgs on two occasions, three to five weeks apart, with another 8 subjects will receive placebo on maccormick advocate two occasions, also three to five weeks apart). Floating? While DEA has held up Dr. Maccormick? Mithoefer's application for a Schedule I license for MDMA for over a year, and has previously indicated that it might refuse to drama example, approve Dr.

Mithoefer's license on the grounds that it considered the study not to be in the public interest, we have more recently gotten the maccormick advocate impression that DEA will indeed approve the hottentot venus license once IRB approval for the protocol has been obtained. A legal analysis submitted to maccormick advocate, DEA by faustus meaning, MAPS President Rick Doblin has been helpful in maccormick v lord advocate that it showed that the Controlled Substances Act (CSA) was written by a Congress that was suspicious the drama portfolio DEA would seek to block medical research into Schedule I drugs, which has indeed turned out to be the case. Fortunately, the CSA does not permit the DEA to maccormick, take the shiite vs sunni muslims vague category of advocate, public interest into account when it reviews applications for vs sunni muslims Schedule I licenses for FDA-approved research but is v lord, restricted to using a much more limited set of criteria relating exclusively to in the holocaust, whether the physician can be trusted to administer the drugs to the research subjects and not divert any to non-medical uses. While nothing can be predicted with certainty, it seems that MAPS' 17-year struggle to start MDMA psychotherapy research (MAPS was founded in 1986) may finally be successful within the next several months. Maccormick V Lord Advocate? Time will tell. June 19, 2003. Drs. Mithoefer, Jerome and Doblin have written a reply to the Ricaurte et al. Portfolio Example? letter published in Science on June 6, 2003. We have submitted our reply to Drs. Ricaurte and McCann and indicated that we would be happy to v lord advocate, post their response to the MAPS website if they want to continue this debate. Read more.

June 9, 2003. MAPS donated $15,046.25 to McLean Hospital, affiliated with Harvard Medical School. The donation is to enable Dr. John Halpern to develop a protocol for the use of MDMA-assisted psychotherapy in the treatment of anxiety and depression in end-stage cancer patients, and for work related to obtaining approval for the study from the signifier McLean Institutional Review Board (IRB) and the FDA. Maccormick Advocate? The donation will support a portion of model, Dr. Halpern's time from now until the end of v lord advocate, December 2003. If this project is approved, it will represent the first psychedelic research at Harvard since 1965 and will signal the beginning of the post-Leary era. June 6, 2003.

Letters in Science. An exchange of drama portfolio example, letters about MDMA dopaminergic neurotoxicity between the MAPS MDMA/PTSD team and maccormick v lord, the NIDA-funded research team of Ricaurte et al. appeared in the journal Science, June 6, 2003, Vol. 300, p. 1503-4. MAPS has already submitted to Science a request for a correction to a misleading statement in the Ricaurte et al. letter, in which only one of the primates was claimed to have died from the doses of MDMA administered, as compared to two primates reported to have died in the initial paper. Shiite Vs Sunni? For details, see MAPS' discussion of the maccormick advocate Ricaurte et al. study.

MAPS is in the process of signifier, preparing a response to v lord advocate, the Ricaurte et al. letter for the MAPS website and targeted in the, Forum. In brief, Ricaurte et al. V Lord? state that dopaminergic deficits will only targeted in the be found in binge users, but then discount all the studies in heavy MDMA users that found no dopaminergic changes by saying that they contained no or only a few binge users. V Lord Advocate? This raises the obvious question of just how common is hottentot venus, this binge use pattern, since they allege in the title of their paper that the doses they administered to the primates represented a common recreational dose regimen. Ricaurte conclude their letter by saying that we remain of the opinion that there are not sufficient data to conclude that clinical MDMA research can be conducted without running the risk of monoaminergic brain neural injury. First, it's impossible to maccormick advocate, ever prove that there is no risk. Nevertheless, by Ricaurte et al.'s own admission that binge use isn't even the signifier same as heavy use, it is possible to maccormick v lord, conclude that there is no evidence that the clinical use of MDMA will in any way cause dopaminergic neurotoxicity or lead to Parkinson's. Note also that Ricaurte et al. conclude with a general statement about both serotonergic and dopaminergic risk, and dismiss as being unpublished evidence from Dr. Franz Vollenweider's PET scan study that showed no evidence of drama, serotonin changes in MDMA-naive subjects administered doses of advocate, MDMA in the therapeutic range. April 11, 2003.

Yet Another Dead End. The new IRB informed MAPS today that it has decided not to accept the protocol for review. MAPS was clearly told in writing a month ago that this IRB would accept the protocol for review. Now, after we spent all the staff time to prepare and submit the necessary documents and yet another month has gone by, that decision is reversed. Hottentot Venus? We were told that the IRB believes that the local IRB has to take responsibility. However, there is no local IRB, since the v lord project is based, not affiliated with any local institution. A fear of advocate, liability was also mentioned. This is also rather puzzling since MAPS has been able to arrange for an insurance policy for several million dollars that would indemnify the IRB from example, lawsuits, in the extremely unlikely event that a subject in the study would choose to sue the IRB.

Proposing to research a potentially beneficial use of maccormick advocate, one of the most demonized drugs in America, and around the world, could be considered a fool's mission. But it's not, it's just extraordinarily difficult and who was targeted, extraordinarily important. After all, MDMA-assisted psychotherapy really can promote healing in a unique manner unlike any other prescription medicine. A moment of despair is now in order, after which MAPS will select a new strategy for moving forward with this project. March 7, 2003. Yet Another New Start. A new IRB has reviewed the v lord documents from the first two IRBs that led to dead-ends and agreed to based, review the protocol. Documents were submitted, with feedback expected in a month or so. March 6, 2003.

A Decision to Let the Review Stay Tabled. Maccormick? Two weeks have passed without MAPS receiving an estimate for the costs of consultants from the IRC-IRB. In any case, MAPS has decided to let the review remain tabled, not to pay for faustus meaning consultants, and v lord advocate, start over with another IRB. We didn't immediately inform the IRC-IRB since we expected to hear any day about the costs of the drama portfolio example consultants, at which time we planned to explain our decision. The proverbial straw that broke the maccormick v lord camels back was that the IRB indicated that even though a majority of its members agreed that MAPS has offered persuasive arguments against the use of a CRO and the multi-site design, the panel will not withdraw those suggestions unless and until an unanimous decision is reached after a report from consultants on seemingly unrelated matters.

After waiting until March 25 without being informed of the costs of the consultants, over a month after MAPS requested in writing that these costs be provided, MAPS sent a letter to the IRC-IRB saying that we were withdrawing the application. MAPS then learned that the staff person at the IRC-IRB with whom MAPS has primarily interacted has left the based model IRC-IRB for reasons unrelated to our protocol. March 3, 2003. No Decision Unless Unanimous, and After Consultation. The IRC-IRB sends a letter indicating that it needs to v lord, receive the advice of consultants before making a decision on the issues of the CRO and floating signifier, the multi-site study. Maccormick? While the IRC-IRB does indicate that a majority of the members of the panel find MAPS' arguments that a CRO is not needed to be compelling and that a majority are willing to consider abandoning the request for shiite a multi-site study, we are told that no decision will be made unless it is unanimous, which MAPS is claimed to v lord, have previously agreed to though this was never mentioned before and is not standard practice.

February 25, 2003. A Request for A Decision. Faustus Meaning? MAPS phones the IRC-IRB and maccormick, requests that the portfolio example panel make a definite decision on whether it would require MAPS to hire a CRO and/or move to maccormick v lord advocate, a multi-site design, neither of which MAPS is willing to strength model, do, before MAPS decides whether to pay for consultants which the letter from the IRC-IRB seems to indicate would be focused on issues unrelated to maccormick advocate, the need for a CRO and a multi-site study. February 21, 2003. IRB Review Tabled. The IRB informed MAPS that it cannot proceed with its review until it obtains the advice of based model, two qualified, objective psychiatric consultants, with fees for the consultants required to be paid by advocate, MAPS.

An estimate of costs will be submitted to MAPS for approval prior to the IRB's engaging the services of strength based, these consultants. February 14, 2003. More Documents. MAPS submitted a document detailing our standardized procedures for maccormick v lord responding to agitated subjects, or those with suicidal ideation associated with study procedures. We also submitted a document discussing the $175,000 bid that we received from floating, a Contract Research Organization (CRO) for monitoring the study, along with information about the volunteer who would monitor the study for MAPS who had the exact same credentials as the person who would be assigned by the CRO. February 10, 2003. An Exhaustive and Exhausting Reply. MAPS submitted a twelve page basic reply (which included in a bit of comic relief a required menu of the snack foods and drinks that we would offer to v lord, subjects on the MDMA therapy days and our plans for handling the issue of food-related allergies), and assorted other documents including a letter from the researcher conducting the screening and holocaust, outcome measures explaining that he had never met Dr. Mithoefer in person and had no particular interest in MDMA an eight page informed consent form for the friend/partner who would pick up the subject after the MDMA session a release form for sharing of subject's personal medical information a wallet card for subjects showing there had participated in a legal MDMA research project in case they were drug tested for any reason in the several days after the experimental sessions during which time they might test positive for MDMA or amphetamines, and a confidentiality agreement for any physicians or therapists who referred subjects to the study. February 6, 2003. Advocate? A Rapid Response.

MAPS submitted a six page response focusing just on the issues of the Contract Research Organization and the multi-site study requirements, to be following up within a week or so with a more detailed discussion of these and other issues raised by the IRC-IRB. February 4, 2003. An Astonishingly Depressing Response. After the extensive discussions and good feelings of the January 28, 2003 in-person meeting, at which we seemingly discussed all the outstanding issues, the totally surprising reply sent by the IRC-IRB came with several scientifically misguided new demands. One of who was targeted holocaust, these (hiring a Contract Research Organization to maccormick v lord, take over the conduct of the study to avoid unconscious bias) was unusual, exorbitantly expensive and hottentot venus, unnecessary since the maccormick advocate study was already a placebo-controlled, double-blind pilot study, with blinded, independent raters. Another (redesigning the study into a multi-site study with two different therapeutic teams) would probably not even be approved by the FDA since single-site studies to hottentot venus, standardize the intervention precede multi-site studies. The IRC-IRB response, which included quite a few other requirements, indicated a profound misunderstanding by the IRC-IRB of the generally-accepted scientific research process and communicated that the IRC-IRB was deeply fearful of approving this protocol. Though I (Rick Doblin) am by nature happy and optimistic (which some friends of mine have teasingly referred to as evidence of MDMA brain damage), the IRC-IRB response resulted in two days of a dark depressive funk, the likes of which I haven't felt for almost 30 years, back when I was working through early difficult LSD experiences. Maccormick Advocate? The resolution of the depression came with the decision to throw myself into strength responding in detail to the IRC-IRB letter, in the hopes that a clearer presentation on our part of the qualifications of our research team members, the logic behind our protocol design choices, and a willingness to v lord advocate, give the signifier IRC-IRB whatever information it asked for, would result in a return to generally-accepted scientific research principles.

January 31, 2003. V Lord? A Productive Dialogue. The January 28 meeting with the new IRB, at which Dr. Michael Mithoefer and Rick Doblin, Ph.D. appeared in floating person, involved a series of thoughtful questions about protocol design, risk assessment, confidentiality procedures and maccormick advocate, the nature of PTSD and currently available treatments. Hottentot Venus? The meeting was characterized by mutual respect.

We expect to receive a written report outlining the IRB's decisions within the next several weeks. January 21, 2003. A Substantive Reply to IRB. MAPS submitted a series of documents today to the IRC-IRB, in maccormick v lord response to their initial comments about the protocol which MAPS received on January 6. These documents represent a very substantial amount of staff time on MAPS' part and include a twenty page primary response letter, a five page protocol summary, a two page plan for faustus meaning external evaluation, a two page phone script for the initial screening calls from v lord advocate, potential volunteers, and a sixty page updated review of the MDMA literature published since our initial review was completed. Dr.

Michael Mithoefer and faustus meaning, Rick Doblin will meet in person with the IRB review panel on January 28 to discuss the issues under consideration. January 21, 2003. Advocate? History Lesson for the DEA. MAPS submitted a letter to DEA from Rick Doblin concerning Dr. Michael Mithoefer's July 2002 application for a Schedule I license to possess the MDMA that will be used in faustus meaning the MDMA/PTSD study. DEA has indicated that it has safety concerns that need to v lord advocate, be addressed before it will issue the portfolio license. V Lord Advocate? However, DEA is only legally charged with diversion control (preventing drugs approved for medical use to be diverted to shiite vs sunni muslims, non-medical uses) and has no legal mandate to review safety concerns, which are the responsibility of the FDA. V Lord? In 1994, DEA tried to use similar arguments to justify its delay in issuing a Schedule I license to Dr. Signifier? Donald Abrams for maccormick v lord advocate his FDA-approved marijuana/AIDS wasting study. Fortunately, FDA Commissioner Dr. David Kessler protested to Dr.

Lee Brown, Director, Office of National Drug Control Policy (the Drug Czar), who wrote a letter to DEA Administrator Tom Constantine reminding him that DEA has no authority to review scientific matters. Dr. Brown told DEA that established lines of responsibility and authority should be respected and that national policy was to signifier, permit research with Schedule I drugs. MAPS' letter reminds DEA of this history and urges it to respect the national interest in facilitating, and not obstructing, important research into v lord advocate new treatments for PTSD. January 6, 2003. Renewed hope. Today, MAPS received the initial set of shiite muslims, comments of the IRC-IRB. My initial impression is that we will eventually be able to get some protocol approved, but that we might need to limit enrollment to maccormick v lord, more severe PTSD patients who have failed on psychotherapeutic treatments as well as an SSRI, and are 21 or older. We have been requested by the new IRB to provide a substantial amount of additional information.

We hope to submit our response within several weeks for the next review, which Dr. Michael Mithoefer and I will probably attend on either January 28 or February 4. Despite the additional work that is ahead of shiite muslims, us, it's a profound relief that the maccormick v lord new IRB is willing to approach this issue based on the science. December 17, 2002. A New Start. MAPS submitted the MDMA/PTSD protocol for review to the Independent Review Consulting Institutional Review Board (IRC-IRB), with the protocol to be discussed by the review board on January 2, 2003. Drama Example? Officials at the IRC-IRB have read the entire correspondence between MAPS and the Western IRB and have indicated that they will carefully review the protocol on its merits without bias due to the controversial nature of MDMA-assisted psychotherapy research. Maccormick V Lord Advocate? This IRB has a reputation for being rigorous but fair, a set of characteristics that inspires confidence. December 10, 2002.

A Shameful Conclusion. Hottentot Venus? On November 20, after the Western IRB decided not to review MAPS' MDMA/PTSD protocol, Rick Doblin spoke to James Baldwin, Ph.D., Executive Director of the Western IRB. Dr. Baldwin informed Rick that he was not authorized to speak about what motivated the Western IRB to decide not to engage in a dialogue about the rationale for WIRB's decision to revoke approval, to refuse to continue to review the maccormick v lord protocol, and to refund MAPS' fee. Instead, Dr. Baldwin suggested that for faustus meaning more information, Rick should contact Mr. Ron Warren, Senior Vice President of the Western IRB.

After Rick Doblin made repeated attempts over several weeks to speak with Mr. Warren, his secretary finally informed Rick Doblin on December 10 that he was unwilling to speak and had nothing to add to the letter. So it ends, with a shameful silence. November 27, 2002. MDMA/PTSD Research in Israel. Maccormick Advocate? MAPS sent a draft of the targeted in the holocaust MDMA/PTSD pilot study that MAPS is seeking to sponsor in Israel to Dr. Moshe Kotler and Dr.

Jorge Gleser, Israeli Ministry of Health, for maccormick their review. MAPS' conference on MDMA/PTSD research, held at Beer Yakov Mental Health Center near Tel Aviv on November 14 for members of the Israeli Ministry of Health, the Israeli Society of Addiction Medicine, and the Israeli Anti-Drug Authority, was very well received. The conference and the proposed pilot study were discussed in based a positive article mentioned on the front page of Maariv, Israel's second largest newspaper. The protocol design meeting, held at Beer Yakov on Nov. 17, was also productive, with the draft protocol submitted today reflecting design choices made at that meeting. November 20, 2002. Pathetic News.

Ron Warren, Senior Vice President of the Western IRB, wrote a letter to Dr. Michael Mithoefer, reporting the v lord advocate outcome of the November 19 meeting of the WIRB's Executive Policy Committee. The WIRB letter was two short sentences, The Western Institutional Review Board, Inc. (WIRB) has made the decision not to provide institutional review board services for the Multidisciplinary Association for Psychedelic Studies (MAPS). Please find enclosed a refund of your previously paid fees, along with the material you submitted for IRB review. The WIRB retreated from its supposed scientific rationale for in the revoking approval for MAPS' MDMA/PTSD study, as described in its September 6, 2002 letter and critiqued in MAPS' October 10 letter, and fell back on no rationale whatsoever. The WIRB has shown itself to be scientifically out of its depth and lacking of v lord advocate, sufficient integrity to acknowledge its mistakes and shiite vs sunni, refocus on a rational, data-based, risk/benefit analysis of MAPS' MDMA/PTSD protocol. Most importantly, MAPS will very soon start the process of maccormick, submitting the protocol to portfolio, another IRB for review.

November 18, 2002. MAPS submitted a short letter to the Western IRB's Executive Policy Committee, in advance of its November 19 meeting at which it will discuss its review of MAPS' MDMA/PTSD protocol. The letter discussed MAPS' Israeli MDMA/PTSD project, briefly reviewed US government and advocate, international treaty policies regarding research with Schedule I drugs, and reported that MAPS had submitted unpublished data to FDA about MDMA and heart valve tissue, data which the WIRB cited as partial justification for revoking approval which neither MAPS nor FDA had seen. October 17, 2002. A Surprising New Issue. After reviewing MAPS' letter, Dr. James Baldwin of the WIRB informed RIck Doblin that the October 30 meeting was canceled, but not for faustus meaning the reasons MAPS had hoped. Dr. James Baldwin said that the meeting was premature because the WIRB now needed to convene its Executive Policy Committee (EPC) to discuss whether the WIRB should be involved with research with Schedule I drugs. Advocate? The next EPC meeting is scheduled for November 19.

The WIRB is no longer reviewing the protocol based on example the science but on non-scientific, internal policy issues, not a very encouraging development. October 11, 2002. A Comprehensive, Strong Response. Advocate? MAPS submitted a lengthy written response to the WIRB letter, along with 14 letters of information and support from hottentot venus, MDMA scientists around the world. Maccormick V Lord? MAPS' letter addressed every point raised in the WIRB letter and floating signifier, was so solid that we thought perhaps the WIRB would conclude that the October 30 meeting was not necessary. October 3, 2002. A Glimmer of v lord advocate, Hope. Rick Doblin speaks with James Baldwin, Ph.D., Executive Director of the WIRB. Dr. Drama Example? Baldwin apologized for the tone of the WIRB letter and maccormick advocate, seemed to view favorably MAPS' arguments.

He was informed that the one scientist whom the WIRB letter claimed was against the study was actually in favor of the study (subject to two conditions that MAPS could easily agree with), that the second scientist cited in the WIRB letter was strongly in faustus meaning favor of the study, and that the third scientist was probably not fully informed about the details of the protocol and was neither opposed to maccormick advocate, or in favor of the study. Dr. Baldwin tentatively scheduled a meeting between Rick Doblin and Michael Mithoefer and the WIRB for October 30, in Olympia, Washington. September 27, 2002. Outrageous News. Dr. George Ricaurte publishes an drama, article in Science reporting on primate data that he claims suggests that even one night's recreational use of Ecstasy can lead to Parkinson's. This government-funded research, which ignored the high mortality rate of the test animals and advocate, directly contradictory human data, is a classic example of risk amplification and the demonization of illegal drugs. Based? MAPS obtained a copy of this article before publication and responded by maccormick v lord advocate, sending out our first press release ever. MAPS' critique was favorably reported in articles in the New York Times and Washington Post and elsewhere.

MAPS has also written a letter to the editor of Science. September 6, 2002. Strength Model? Terrible News. The Western IRB, which approved the MDMA/PTSD protocol on July 10, informed us by letter that approval was withdrawn. The revocation was based on secondhand reports of conversations (not on data!) that a WIRB staff person had with three MDMA researchers. V Lord Advocate? The WIRB letter was written in a surprisingly insulting manner and contained numerous mistakes. MAPS was not informed that the protocol was being reevaluated and did not have an opportunity to respond to the reports by signifier, the WIRB staff person, who didn't like the fact that the maccormick advocate WIRB had approved the protocol. July 17, 2002. Tremendous news. On July 10, we received word that the Institutional Review Board (IRB) had approved MAPS' MDMA/PTSD study! We can now definitely say that the US study will take place.

Dr. Michael Mithoefer still needs to obtain his DEA Schedule 1 license, which should take about 4-6 weeks, but this is just a matter of time. There is now an excellent chance that the Israeli Ministry of Health will approve an Israeli MDMA/PTSD study. Floating Signifier? Michael and I are tentatively planning to go there in late Sept. or early Oct. for a one-day seminar organized by the Ministry to maccormick, discuss the strength based model latest findings in v lord advocate MDMA research, and protocol design options for the Israeli study. Here are the financial implications: We still need to raise an additional $60,000 for the US MDMA/PTSD study and another $60,000 for the Israeli study. MAPS is also seeking $10,000 for our National Institute of Mental Health (NIMH) grant application for support for shiite vs sunni muslims the development of v lord, a treatment manual that describes in detail hw MDMA-assisted psychotherapy for PTSD should be conducted and provides specific ways to evaluate whether the therapy technique itself is being delivered appropriately. We are also seeking $20,000 for our ongoing MDMA literature review.

Any help or suggestions would be greatly appreciated. June 19, 2002. MDMA/PTSD protocol submitted to the Western Institutional Review Board (WIRB). Review expected to take 3-5 weeks. June 14, 2002. FDA gives final approval to conduct the treatment sessions in Dr.

Michael Mithoefer's office, with a crash cart and an Emergency Room doctor and who was in the, nurse in the next room in maccormick v lord case they are needed. May 14, 2002. Conference call with Dr. Mithoefer, Rick Doblin and FDA o fficials, in hottentot venus which we come to maccormick advocate, tentative agreement to conduct the study in Dr. Mithoefer's office, as long as we hire both an ER doctor and nurse to sit in hottentot venus the room. May 10, 2002.

FDA rejects our request, primarily saying that they would like a larger emergency response team. March 14, 2002. Request submitted to FDA to v lord, change the location of the treatment sessions from the based model Medical University of maccormick, South Carolina (MUSC) to hottentot venus, Dr. Mithoefer's office. Maccormick V Lord? We propose renting a crash cart and faustus meaning, hiring an emergency room nurse to be on site in the room next to the treatment room for the first five hours of each session, in case Dr. Michael Mithoefer and Annie Mithoefer, R.N. V Lord? need help responding to an adverse event. November 28, 2001. Based Model? The fourth patient in the Spain MDMA/PTSD dose-response study was treated on November 28, 2001. We have now completed the 50 mgs dose group (3 patients received 50 mgs and 1 received a placebo). The next dose level is 75 mgs (5 patients will receive 75 mgs and maccormick advocate, 2 will receive a placebo). November 2, 2001.

It's my pleasure to shiite, report some excellent news. Maccormick V Lord? About 10 AM, Friday, November 2, FDA contacted me to say that MAPS' MDMA/PTSD protocol was approved. This approval marks the culmination of based model, 16 years of maccormick, efforts to obtain permission from FDA for hottentot venus MDMA-assisted psychotherapy research, since MDMA was criminalized in 1985. Maccormick V Lord Advocate? This approval also marks the beginning of what I hope will be a $5 million, 5-year project to develop MDMA into muslims a prescription medicine. On Wednesday, Dr. Maccormick? Michael Mithoefer, the principal investigator, and I had a conference call with FDA during which we discussed various design issues. The conference call was calm, serious and respectful. We agreed to make several design changes, mainly closer monitoring of blood pressure and omitting the opportunity for placebo subjects who still met inclusion criteria for drama portfolio PTSD at the final evaluation to enroll in an open label extension study during which they would receive MDMA. We argued against several other possible changes, mainly the idea that patients should be required to have had prior experience with MDMA.

On Thursday, I faxed an addendum specifying the changes we had agreed upon and the places where the protocol needed to be changed. Last night, I saw on CNN that anthrax was discovered in the FDA mailroom at Rockville, where the advocate FDA officials reviewing the protocol work. Today, FDA officials were still at work and informed me that the protocol was approved without the need for any additional changes. Of course, we still need to obtain Institutional Review Board approval from the Medical University of South Carolina. This should take several additional months. I've already let the Israeli Ministry of Health know that the FDA approved the vs sunni muslims study. According to Dr. Moshe Kotler, the principal investigator of the proposed Israeli MDMA/PTSD protocol, FDA approval was need for an MDMA/PTSD study before he would feel comfortable submitting a protocol to advocate, the Ministry.

The subjects in the ongoing Spain MDMA/PTSD study are women survivors of sexual assault with chronic PTSD. The subjects in vs sunni muslims the FDA-approved study are women and men survivors of criminal assault with chronic PTSD. The Israeli study will hopefully include subjects whose PTSD was the result of war and terrorism. The formal approval letter from v lord advocate, FDA will arrive next week. -- Rick Doblin, Ph.D. October 1, 2001. MAPS submitted to the FDA today the protocol for Dr.

Michael Mithoefer and Dr. Who Was In The Holocaust? Mark Wagner's MAPS-supported pilot study into the use of MDMA-assisted psychotherapy in the treatment of patients who have experienced criminal victimization and as a result have suffered from chronic, treatment-resistance posttraumatic stress disorder (PTSD). The submission of this protocol to FDA marks a major milestone in the history of MAPS, and hopefully in the history of MDMA research. FDA has 30 days to maccormick v lord advocate, respond to the protocol. We fully expect FDA eventually to approve the study in some form. (Faster download - without individual case reports from Phase 1 study; longer version - with individual case reports from Phase 1 study) July 18, 2001.

As part of its submission to FDA of a protocol designed to study the use of who was targeted in the, MDMA in the treatment of PTSD, MAPS' commissioned an advocate, extensive review of the scientific literature on MDMA. Hottentot Venus? This literature review was developed under the direction of Matt Baggott with Ilsa Jerome, Ph.D., and is now being made available to regulatory agencies, other researchers and the public. The literature review will be updated on a regular basis as new research is published. July 16, 2001. V Lord Advocate? A draft of the MDMA/PTSD protocol that MAPS has been working for 2 years to develop, with Dr. Strength Based Model? Michael Mithoefer and Mark Wagner, Ph.D., at the Medical University of South Carolina, has now been posted to the web. The protocol will submitted to FDA shortly after NIDA's scientific meeting on MDMA, held at the National Institutes of Health campus in Bethesda, MD, on July 19-20.

If and when it becomes approved in some form, this protocol will be the first FDA-approved study of the maccormick therapeutic use of MDMA since MDMA was placed in Schedule 1 in faustus meaning 1985. March 19, 2001. Maccormick Advocate? The US Sentencing Commission held an open hearing concerning its proposal to increase penalties on signifier MDMA. V Lord? Testimony about MDMA opposing the increase was presented by faustus meaning, Rick Doblin, Ph.D., David Nichols, Ph.D., Charles Grob, M.D., Julie Holland, M.D. and Richard Glen Boire, Esq. Testimony about legal issues by opponents of the v lord increase was presented by Ed Mallet, Executive Director of the in the National Association of Criminal Defense Lawyers (NACDL), Julie Stewart, Executive Director of Families Against Mandatory Minimums (FAMM), and Bill McColl, Legislative Director of The Lindesmith Center/ Drug Policy Foundation (TLC/DPF). The testimony had little effect and the Sentencing Commission recommended substantial increases in penalties.

MDMA is now, dose for dose, punished more heavily than heroin. Judge Diane Murphy, Chair of the U.S. Sentencing Commission, explained the rationale behind the Commission's recommendation during a hearing of the Senate Caucus on International Drug Control on March 21, 2001. (See also visual presentation) February 3, 2001. MAPS convened a protocol design meeting in San Francisco to discuss the details of a protocol evaluating the maccormick v lord use of MDMA-assisted psychotherapy in the treatment of Post-Traumatic Stress Disorder (PTSD). The meeting included. among others, the principle investigator and therapists of the South Carolina team (Dr. Michael Mithoefer and Annie Mithoefer, RN), the MAPS team that has for the last year and a half been reviewing the MDMA literature for submission to FDA (Matt Baggott, Ilsa Jerome), the team that has been creating the faustus meaning MDMA bibliography of all scientific papers on maccormick v lord MDMA published in peer-reviewed journals (from erowid.org), and scientific consultants including Dr. Charles Grob, Dr.

George Greer, and Dr. Dave Nichols. Muslims? The meeting was quite productive, with the protocol expected to advocate, be submitted to FDA in April 2001. February 2, 2001. Rick Doblin outlines MAPS' strategy for the development of the therapeutic use of MDMA into an FDA-approved prescription medicine, at the State of shiite vs sunni, Ecstasy conference in San Francisco, sponsored by the Lindesmith Center- Drug Policy Foundation. Additional transcripts of other speakers have been helpfully archived by maccormick v lord advocate, an anti-drug group. November 9, 2000. The first patient was treated in the MAPS-supported MDMA/PTSD study being conducted in Madrid, Spain, under the director of hottentot venus, Jose Carlos Bouso, Ph.D. candidate.

Jose Carlos and Marcela Ot'alora were the v lord co-therapists. The four hour session went very well and the patient seemed to have gotten to a deeper, more therapeutic level. Of course, we won't know for some time whether the patient received a dose of 50 mgs or a placebo! What we do know is that study is off to targeted, a great start. Read more about this study, including the protocol and informed consent form. November 1, 2000. A Journal of the Amreican Medical Association (JAMA) letter reports on the DanceSafe/MAPS pill testing program (the letter says people paid for maccormick advocate their own testing but that was a mistake. MAPS paid for most of the hottentot venus testing of these pills). August 15, 2000. V Lord Advocate? A discussion about Raves, Ecstasy and Youth was held at based model the Shadow Convention 2000 in Los Angeles.

A celebrity panel of MDMA researchers, experts and psychonauts was assembled by the Lindesmith Center/Drug Policy Foundation; video and maccormick v lord advocate, audio coverage of hottentot venus, this unique event can be found at the Shadow Conventions 2000 website. May 5-6, 2000. The California Association of maccormick advocate, Toxicologists held a conference in North Hollywood, California, the vs sunni muslims first day of which was devoted to drugs that are commonly found at raves. Read summary and comments by v lord, Earth and Richard G. Boire. March 2000 - New York Lindesmith Center.

Hear in RealAudio MDMA ('Ecstasy') Research: When Science and Politics Collide . Sound quality is strength based model, excellent except for maccormick v lord advocate the first few minutes, so be patient. Example? Speakers: Julie Holland, MD, attending psychiatrist, Bellevue Hospital Psychiatric Emergency Room and faculty, NYU School of Medicine; John P. Maccormick Advocate? Morgan, MD, professor of pharmacology, City College of vs sunni muslims, New York; and Rick Doblin, president, MAPS) and Ph.D. candidate, Kennedy School of Government, Harvard University, assessed scientific and political efforts to conduct MDMA research in v lord the US and abroad. See also the transcript of Holland's talk. February 2000 - Spain. A pilot study of targeted, MDMA therapy in the treatment of PTSD has been approved and will be the v lord first formal therapy study with MDMA ever conducted. (Read current update. MAPS has pledged $54,000 for this study; we have raised $23,000 and are seeking additional contributions. Autumn 1999 - MAPS Israel MDMA Conference. MAPS organized an international symposium on the medical utility of hottentot venus, MDMA.

Talks from this event, held August 31 to September 1, 1999, are posted on this site (talks by George Greer, Juraj and Sonja Styk and Mark Kleiman). See also video clips of some of the talks. July 24, 1999 In a teleconference with the FDA concerning MDMA psychotherapy research to treat anxiety, depression and pain in cancer patients, the FDA indicates a willingness to approve a proof of principle study. MDMA was synthesized in 1912 and patented in Germany by Merck in 1914 but was not the subject of human research at maccormick that time. In the 1950s it was briefly researched by the U.S. Government as part of the CIA's and faustus meaning, the Army's chemical warfare investigations.

It was forgotten until the middle 1970s when it was rediscovered by v lord, the psychedelic therapy community and began to be used as an adjunct to drama example, psychotherapy by psychiatrists and v lord advocate, therapists who were familiar with the field of psychedelic psychotherapy. MAPS published a book, The Secret Chief, about the leader of this therapy community. In the early 1980s, the drug began to strength based model, be used non-medically, particularly in v lord Texas, under the in the holocaust name Ecstasy. Both the non-medical and therapeutic use of MDMA were made illegal in 1985 despite the maccormick v lord advocate Drug Enforcement Administration Administrative Law Judge Francis Young's recommendation that physicians be permitted to continue to administer it to their patients. Hottentot Venus? Rick Doblin, Alise Agar and Debby Harlow helped coordinate the pro-MDMA contingent in the DEA lawsuit. For an excellent history of the early use of MDMA, see Pursuit of Ecstasy by Beck and Rosenbaum. In 1986, with the goal of developing MDMA's therapeutic potential through FDA-approved protocols, Rick Doblin founded MAPS as a non-profit research and educational organization with the mission to act as a psychedelic and medical marijuana pharmaceutical company. MAPS immediately opened a Drug Master File for MDMA with data gathered from the v lord advocate standard preclinical animal toxicity studies required by FDA . Subsequently, five different applications for permission to drama, conduct human research with MDMA were submitted to FDA between 1986 to 1988, to the Neuropharmacologic Drug Products Division directed by Dr. Paul Leber.

All five applications were rejected. Maccormick V Lord Advocate? Three protocols for double-blind controlled trials were from researchers at, respectively, Harvard Medical School, UC San Francisco Medical School, and U. of New Mexico Medical School, and were all rejected. Two applications submitted by individual physicians were for single case studies, one for a terminal cancer patient who had been successfully treated for targeted in the holocaust pain with MDMA-assisted psychotherapy prior to the criminalization of MDMA and the other for a unipolar depression patient for whom all available treatments had been attempted without success. Maccormick V Lord? Both of faustus meaning, these single-patient INDs were also rejected. The FDA based its rationale for rejecting all protocols and maccormick advocate, single case studies on the hypothetical risk of functional consequences of potential neurotoxicity from MDMA. Shiite Vs Sunni? MDMA research claimed that the rejection of all efforts to conduct FDA-approved MDMA research was based not on rational risk/benefit assessments but on maccormick v lord an underlying cultural prejudice against medical research with drugs that were criminalized and on one or more FDA officials' personal opposition to human research with psychedelics. Since FDA Review Divisions are sometimes described as operating like fiefdoms under the control of their Directors, proponents felt profoundly stymied. Proponents claimed that concerns about drama MDMA neurotoxicity, which numerous studies had failed to link with functional or behavioral consequence and which in any case had not been clearly demonstrated to occur at all at therapeutic does levels, were reminiscent of scientific research in the 1960s that claimed to prove that LSD damaged chromosomes.

These reports were effective in generating public disapproval of v lord advocate, LSD and in hindering research but were later determined to have no clinically significant effect. MAPS continued to fund animal toxicity studies at floating Stanford (1986-1988) and human safety studies at Stanford and v lord, Johns Hopkins (1988-1991). In 1992, FDA reviewed a MAPS-supported protocol submitted by Dr. Charles Grob, then at UC Irvine, for a study of the use of MDMA in the treatment of pain, anxiety and depression in who was targeted in the holocaust cancer patients. FDA's Drug Abuse Advisory Committee recommended that the cancer patient study be postponed and maccormick advocate, that a Phase 1 dose-response safety study be conducted first. Vs Sunni? The protocol was redesigned, with FDA giving final approval for maccormick advocate the Phase 1 safety study on November 5, 1992. The safety study was completed in 1995. Data from the safety study revealed no unusual risks and indicated that MDMA could be safely administered within a clinical research context.

Dr. Grob submitted the first draft of the protocol for the study of cancer patients in 1997. Who Was? Negotiations with FDA moved very slowly, due to v lord advocate, initial FDA decisions to put MDMA psychotherapy research on a slow track to who was targeted holocaust, nowhere. However, FDA opposition eventually lessened as MAPS and Dr. Grob persisted in our efforts to maccormick, obtain permission for signifier research into the use of MDMA-assisted psychotherapy in cancer patients.

A July 24, 1999 teleconference with the v lord advocate FDA concerning MDMA psychotherapy research to muslims, treat anxiety, depression and pain in cancer patients went very well, with the FDA indicating a willingness to approve proof of principle study. Unfortunately, Dr. Grob's other work-related responsibilities made it difficult for him to find the time to work on the approval process for this research project. On March 18, 2000, Rick Doblin and Michael Mithoefer met at an ayahuasca conference in maccormick San Francisco, sponsored by Ralph Metzner, and model, begin talking about maccormick conducting MDMA psychotherapy research in the US. This marks the drama portfolio example beginning of their effort to study subjects with chronic posttraumatic stress disorder. On November 9, 2000, the first subject is treated in Jose Carlos Bouso's MAPS-sponsored MDMA/PTSD study in Madrid, Spain. On May 13, 2002, the Spain MDMA/PTSD study gets shut down due to political pressure, after six subjects have been enrolled in the study without any persisting adverse effects. Dr. Grob subsequently decided to focus on the use of psilocybin, instead of maccormick v lord advocate, MDMA, in cancer patients, on the accurate theory that psilocybin research would be less controversial than MDMA research. In June 2003, MAPS starts formally working with Dr. John Halpern, McLean Hospital, Harvard Medical School, on the design of a study administering MDMA-assisted psychotherapy to who was in the, end-stage cancer patients.

Late in 2003, Dr. Grob managed to obtain approval for his psilocybin/cancer patient study. Merck's official history of MDMA: Journal article and media report Historical Articles about MDMA 1984-1993 MAPS in the Media Archive: 2000-current. Parkinson's Disease MDMA reduces symptoms of Parkinson's. Dr.

David Nichols of v lord advocate, Purdue University says The story results from lack of knowledge about what Ecstasy does in floating the brain, Self Development/General Therapeutic Through the Gateway of the Heart -- a collection of over 50 personal accounts of the therapeutic/spiritual/personal growth uses of MDMA, first published in 1985. MDMA in a severely disturbed man with psychosis, administered by v lord, his brother MDMA helped after therapy, pills and ECT didn't MDMA: a catalyst for healing my fears and floating signifier, depression MDMA in a woman with Ovarian Cysts Potentials for MDMA in neuromuscular therapy Alleviation of emotional and physical pain in an elderly man MDMA as adjunct to advocate, therapeutic bodywork. Confessions of a middle-aged Ecstasy eater (son introduces father) A series of floating, letters on MDMA and cancer (daughter introduces father) A Family's Perspective on the Use of MDMA (parents introduce daughter)

Write My Paper -
MacCormick v Lord Advocate - Wikipedia

Nov 11, 2017 Maccormick v lord advocate, buy essay online help and buy professionals essays -

MacCormick v Lord Advocate - Wikipedia

1984 essay contest With an unbeatable lineup of over maccormick v lord advocate 300 of the greatest literary works the world has ever known, Signet Classics is the publisher that students, education professionals and the public turn to more than any other. Now, we are proud to host our twenty-second annual Signet Classics Student Scholarship Essay Contest, in drama portfolio example which five high school juniors or seniors can each win a $1,000 scholarship award to be used toward their higher education plus a Signet Classics library for their school! Essays must be submitted by v lord advocate, a high school English teacher on behalf of students who write an essay on one of strength based five topics for this years competition book, Incidents in the Life of a Slave Girl . Select one of the following five topics: How is Incidents in the Life of maccormick advocate a Slave Girl still relevant more than two hundred years after slavery has been abolished? Be specific about how the treatment of oppressed people today reflects the treatment of slaves in the book and what can be learned from Harriet Jacobs story. Harriet Jacobs experiences suggest that slavery negatively impacts not only the slave, but also the model slaveholder.

In what ways are the v lord masters and mistresses in the book corrupted by slavery? Why does this occur? Incidents in the Life of a Slave Girl is a story of survival and even success in an almost impossible situation. Faustus Meaning? What about Harriet Jacobs character accounts for her ability to overcome? What special circumstances did slaves face in motherhood?

How do these women cope with or adapt to their situation? In what ways do they protect and preserve the next generation? What are the differences between the Christianity practiced by slaves and the Christianity practiced by slave owners? Is religion depicted more convincingly as a force for progressive change or as a way to preserve the advocate status quo? Official Rules for 22nd Annual Signet Classics Student Scholarship Essay Contest. No purchase necessary. Strength Based? A purchase will not enhance your opportunity to win. Open to 11th and 12th grade full-time matriculated students who are attending high schools located in the fifty United States and the District of Columbia, or home-schooled students between the maccormick ages of 16-18 who are residents of the fifty United States and the District of Columbia. Matriculated students: Four (4) copies of the essay should be mailed by an English teacher on behalf of the student (each English teacher may submit only one junior and one senior essay). Each of the four (4) copies of the essay should include a cover letter on school letterhead and includes the following details: Date Student#8217;s full name, grade, address, e-mail and home telephone number Name of high school Name, email and daytime telephone number of English teacher submitting essay (please include summer contact information if different from school year contact information) Name, e-mail and daytime telephone number of the school#8217;s administration officer Topic selected (#1, #2, #3, #4 or #5) Certification by teacher that the holocaust essay is the student#8217;s original work.

Essays submitted without a cover letter on school letterhead or cover letters that do not include the advocate above details will be disqualified. Home-schooled students : Four (4) copies of the essay must be mailed by a parent or legal guardian on behalf of the student. Each of the drama portfolio four (4) copies of the essay should include a cover letter on the parent/legal guardians letterhead that certifies that the student is maccormick advocate, home-schooled and includes the following details: Date Student#8217;s full name, address, e-mail and home telephone number Student#8217;s equivalent grade Name and hottentot venus, daytime telephone number and e-mail of the sponsoring parent/legal guardian Topic selected (#1, #2, #3, #4 or #5) Certification by sponsoring parent/legal guardian of home-schooled student that the maccormick advocate essay is the student#8217;s original work. Essays submitted without a cover letter on parent/legal guardian#8217;s letterhead or cover letters that do not include the floating signifier above details will be disqualified. Essays must be at least two and no more than three double-spaced pages, computer or typewritten (please do not staple submissions). Please include four (4) copies (including four (4) cover letters) of v lord each essay submitted. Entries must be mailed to Penguin Publishing Group, Academic Marketing Department, Signet Classics Student Scholarship Essay Contest #22, 375 Hudson Street, New York, NY 10014. To be eligible, all entries must be postmarked by based, April 14, 2018 and received on or by April 21, 2018. Maccormick? Submissions by fax, email or any other electronic means will not be considered. Entries will not be returned. By entering the strength model Contest, contestants agree to abide by these rules, and represent and maccormick v lord advocate, warrant that the shiite vs sunni entries are their own and original creations, and do not violate or infringe the rights, including, without limitation, copyrights, trademark rights or rights of v lord publicity/privacy, of any third party.

Entries are void if they are in whole or in faustus meaning part illegible, incomplete, damaged or handwritten. No responsibility is assumed for late, lost, damaged, incomplete, illegible, postage due or misdirected mail entries. V Lord? All eligible entries received will be judged by a qualified panel of judges chosen by Penguin Publishing Group and winners will be selected on shiite vs sunni muslims, or about June 15, 2018. Winning essays must demonstrate a comprehensive understanding of the themes and issues presented in Incidents in maccormick the Life of a Slave Girl . Submissions will be judged on style, content, grammar, and drama, originality. Judges will look for clear, concise writing that is maccormick advocate, original, articulate, logically organized, and well supported. Winners will be notified by June 24th, 2018 via email, and will be announced online on or about July 1st, 2018. Holocaust? There are five (5) prizes available to be won. Each prize includes a check in the amount of one thousand dollars ($1,000.00) to be used toward winner#8217;s tuition and/or expenses related to their higher education. Maccormick? Each prize also includes a Signet Classics Library for the winner#8217;s school library, or public library in the case of a home-schooled winner (Approximate Retail Value (#8220;ARV#8221;) = $1,600.00). Total ARV per prize = $2,600.00.

In the event that there is an insufficient number of qualified entries or if the judges determine in shiite vs sunni their absolute discretion that no or too few entries meet the v lord quality standards established to award the prizes, Sponsor reserves the who was targeted in the right not to award the maccormick prizes. Based? Open to 11th and 12th grade full-time matriculated students who are attending high schools located in advocate the fifty United States and the District of Columbia, or home-schooled students between the ages of 16-18 who are residents of the fifty United States and based, the District of Columbia. Void where prohibited by law. All state and local restrictions apply. Employees of Sponsor and its parent company, subsidiaries, affiliates or other parties in any way involved in the development, production or distribution of this Contest, as well as the immediate family (spouse, parents, siblings, children) and household members of each such employee are not eligible to participate in v lord advocate this Contest. No cash substitution, transfer or assignment of prizes allowed. In the event of the unavailability of a prize or prizes, Sponsor may substitute a prize or prizes of equal or greater value. Strength Based Model? All expenses, including taxes (if any), on advocate, receipt and use of prizes are the sole responsibility of the winners. Winners may be required to execute an Affidavit of drama example Eligibility and Release. The affidavit must be returned within fourteen (14) days of advocate notification or another winner will be selected. If a winner is under 18 years of age, their parent/legal guardian will also be required to sign the based Affidavit.

Because the ARV exceeds $600.00, winners shall be required to provide a Social Security Number or an Individual Taxpayer Identification Number to Sponsor for issuance of a 1099 Form. The winner#8217;s school library or public library in v lord the case of a home-schooled winner that will receive a Signet Classics Library shall also be required to provide a Federal Tax Identification Number to vs sunni Sponsor for issuance of a 1099 form, in connection with its receipt of this portion of the prize. By accepting a prize, the winners and their parents and/or legal guardians grant to Sponsor the right to maccormick v lord edit, publish, copy, display and drama portfolio example, otherwise use their entries in connection with this Contest, and to further use their names, likenesses, and maccormick v lord advocate, biographical information in advertising and promotional materials, without further compensation or permission, except where prohibited by law. LIMITATION OF LIABILITY. By competing in this Contest and/or accepting a prize, entrants release Sponsor, its parent, subsidiary or affiliated companies, or the agencies of any of them and the authors and/or editors of drama portfolio any books promoted hereby from any and all liability for any loss harm, injuries, damages, cost or expenses arising out of or relating to maccormick advocate participation in this Contest or the floating acceptance, use or misuse of the prize(s). UNDER NO CIRCUMSTANCES SHALL THE RELEASED PARTIES BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR EXEMPLARY DAMAGES, ATTORNEYS#8217; FEES, OR ANY OTHER DAMAGES. Any dispute arising from the contest will be determined according to the laws of the state of new york, without reference to its conflict of law principles, and by entering, the maccormick entrants consent to the personal jurisdiction of the state and federal courts located in New York County and agree that such courts have exclusive jurisdiction over all such disputes. For a copy of the winners list, send a self-addressed, stamped envelope by December 15, 2018 to faustus meaning Penguin Publishing Group, Academic Marketing Department, 375 Hudson Street, New York, NY 10014, Attention : Signet Classics Student Scholarship Essay Contest #22, or check online after July 1 st , 2018. Maccormick V Lord Advocate? Penguin Publishing Group. Academic Marketing Department. 375 Hudson Street, New York, NY 10014.

The title for the 23rd Annual Signet Classics Essay Contest will be Adventures of Huckleberry Finn by Mark Twain. Essay topics will be posted on our website after July 2018. When two missing teenage girls are found, a fathers nightmare has only begun Learn more about hottentot venus David Bell's next. 2 months ago. Start reading the advocate tale about Peter Pan and floating, the friend who became his nemesis, a nemesis who may not be the blackhearted. 3 months ago. Shared from our friends at Penguin Random House! 3 months ago. Maccormick? Congratulations to #KazuoIshiguro, author of The Remains of the drama portfolio example Day, on v lord, receiving the @NobelPrize for Literature!. Drama? 1 hour ago.

RT @PutnamBooks: Only one more day to enter our sweeps with @theskimm, @WhitneyCummings, @OutdoorVoices, and @SanJoseHotel. 1 day ago. Advocate? RT @BerkleyPub: Recipe for the perfect #autumn day: . + ?? + . Get your fall #TBR on lock w/ our October suspense. 1 day ago. Enter for a chance to win five Hardcover Classics beautifully illustrated by Anna Bond of drama + RIFLE PAPER Co. ! #1 + The New York Times bestselling author Jan Karon returnswith the story readers have been waiting for!

Buy Essay Online Cheap -
MacCormick v Lord Advocate - Wikipedia

Nov 11, 2017 Maccormick v lord advocate, order paper writing help 24/7 -

MacCormick v Lord Advocate - Wikisource, the free online

You Can Prevent Colorectal Cancer. Get the maccormick advocate facts about screening. Learn More. What to Expect During a Colonscopy. Follow a patient's first-hand experience in this. educational video Watch Video. Promote Colorectal Cancer Awareness. Download, print, and hottentot venus post graphics on maccormick v lord advocate social media to raise colorectal cancer awareness. Download Now.

Removal of a pre-cancerous polyp Watch Video. Know the latest facts about the faustus meaning number 2 cancer killer in maccormick v lord advocate the United States. Assess your risks. Know your screening options. Floating Signifier. Learn why training and maccormick v lord experience of the endoscopist are vital to a thorough colonoscopy. Watch a video. Listen to signifier, a Podcast. Get the answers to your most pressing colonoscopy questions. ACG Colorectal Cancer Awareness Graphics. This infographic illustrates in a powerful, easy to understand way, the risks of colorectal cancer and v lord advocate the impact of getting screened.

Don't take a gamble on your health. This infographic is based on an important statistic from the American Cancer Society: Of the 50,830 people expected to die of colon cancer in 2013, screening (or use of early detection tests) could have saved more than half of them. View infographic. Shared Goal: Reaching 80% Screened for Colorectal Cancer by 2018. ACG supports the National Colorectal Cancer Roundtables (NCCRT) new initiative 80% by 2018. With the American Cancer Society and NCCRT, we are working toward the shared goal of reaching 80% of eligible adults screened for colorectal cancer by hottentot venus 2018. Find a doctor. Compared with other ethnic groups, African-Americans are diagnosed with colorectal cancer at a younger age and those with colorectal cancer have decreased survival. ACG recommends African Americans begin screening at age 45. Learn more.

Audio Podcasts: ACG Experts Answer Your Most Common Questions. Colorectal Cancer Screening: Navigating the maccormick Options. Not sure what screening test is floating, right for you? Dr. Mark B. Pochapin offers insights on colorectal cancer prevention and detection tests and describes ACG guidelines and recommendations to help patients make sense of their options. Family History, Lynch Syndrome and Other Colorectal Cancer Risk Factors. Dr. Carol A. Maccormick Advocate. Burke and faustus meaning her patient Anita, who has Lynch Syndrome, share their insight on CRC risk factors, like family history, and the life-saving importance of screening-whether or not you have symptoms. Maccormick Advocate. Listen Now.

Colorectal Cancer and African Americans: Don't be Afraid to Live. Dr. Fritz Francois explains the special concerns for African Americans and why screening should begain at age 45. His patient, Vincent, shares his experience with colonoscopy and offers advice to those who are apprehensive about this potentially life-saving test. Listen Now. Colorectal (large bowel) cancer is a disease in drama portfolio which malignant (cancer) cells form in the inner lining of the colon or rectum. Together, the colon and rectum make up the large bowel or large intestine.

The large intestine is the maccormick v lord advocate last segment of the digestive system (the esophagus, stomach, and small intestine are the first three sections). Floating Signifier. The large bowel's main job is to reabsorb water from the contents of the intestine so that solid waste can be expelled into the toilet. The first several feet of the large intestine is the colon and v lord the last 6 inches is the rectum. Most colon and rectal cancers originate from benign wart-like growths on the inner lining of the colon or rectum called polyps. Not all polyps have the potential to vs sunni, transform into cancer. Those that do have the potential are called adenomas.

It takes more than 10 years in v lord advocate most cases for an adenoma to develop into cancer. This is why some colon cancer prevention tests are effective even if done at 10-year intervals. This 10-year interval is too long, in some cases, such as in floating signifier persons with ulcerative colitis or Crohn's colitis, and in persons with a strong family history of v lord colorectal cancer or adenomas. Colorectal cancer is the in the holocaust third leading cause of maccormick v lord cancer-related deaths in the United States when men and strength based women are considered separately, and the second leading cause when both sexes are combined. It is expected to cause about 50,310 deaths during 2014. Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. The American Cancer Society's estimates for v lord advocate the number of colorectal cancer cases in shiite the United States for 2014 are: 96,830 new cases of colon cancer 40,000 new cases of rectal cancer. Source: American Cancer Society, Cancer Facts Figures 2014.

What are the Colorectal Cancer screening options? Talk to your doctor about what colorectal screening tests are right for you. Guidelines from the maccormick American College of Gastroenterology distinguish between colorectal cancer prevention tests and colorectal cancer detection tests. According to based, ACG, prevention tests are preferred over maccormick v lord advocate detection tests. Preferred Colorectal Cancer Prevention Test: Colonoscopy. Colonoscopy every 10 years is the preferred colorectal cancer prevention test.

For normal risk individuals, the American College of Gastroenterology recommends colonoscopy beginning at age 50, and age 45 for African Americans. Preferred Cancer Detection Test: Fecal Immunochemical Test (FIT) Annual fecal immunochemical testing is the preferred colorectal cancer detection test. FIT is a relatively new test that detects hidden blood in the stool. If results are positive, a colonoscopy is performed. CT Colonography every 5 years. CT Colonography is an holocaust X-ray designed to look for colon polyps and cancers. V Lord Advocate. CTC every 5 years is an alternative to who was targeted in the, colonoscopy for v lord advocate patients who decline colonoscopy. If polyps are detected, a regular colonoscopy is required to remove these pre-cancerous growths. While CTC is good at detecting polyps larger than 1 centimeter in size, CTC is not equivalent to colonoscopy because it is unreliable at detecting smaller polyps, which constitute 80 percent of growths in the colon. Flexible Sigmoidoscopy every 5 to 10 years.

Annual Hemoccult Sensa Fecal DNA Testing every 3 Years. Most early colorectal cancers produce no symptoms. Vs Sunni Muslims. This is v lord advocate, why screening for colorectal cancer is so important. Symptoms of colorectal cancer vary depending on the location of the cancer within the colon or rectum, though there may be no symptoms at all. The prognosis tends to be worse in symptomatic as compared to asymptomatic individuals. The most common presenting symptom of colorectal cancer is faustus meaning, rectal bleeding. Cancers arising from the left side of the colon generally cause bleeding, or in their late stages may cause constipation, abdominal pain, and obstructive symptoms. On the other hand, right-sided colon lesions may produce vague abdominal aching, but are unlikely to maccormick, present with obstruction or altered bowel habit.

Other symptoms such as weakness, weight loss, or anemia resulting from drama portfolio, chronic blood loss may accompany cancer of the right side of the colon. You should promptly see your doctor when you experience any of these symptoms. Remember to v lord advocate, promptly see your doctor if you experience any of these symptoms: New onset of abdominal pain Blood in or on the stool A change in stool caliber or shape A change in vs sunni typical bowel habits, constipation, diarrhea. Adenomas can grow for years and maccormick v lord transform into cancer without producing any symptoms. By the time symptoms develop, it is drama, often too late to cure the cancer, because it may have spread. Screening identifies cancers earlier and maccormick advocate actually results in cancer prevention when it leads to removal of adenomas (pre-cancerous polyps). The cause of colorectal cancer in most cases is unclear. However, most colorectal cancers develop from polyps, which are abnormal growths in strength based model the colon. If polyps grow unnoticed and are not removed, they may become cancerous.

Screening tests can find precancerous polyps so they can be removed before they turn into v lord advocate, cancer. The development of more than 75-90 percent of colorectal cancer can be avoided through early detection and removal of pre-cancerous polyps. Everyone age 50 and older . The average age to develop colorectal cancer is hottentot venus, 70 years, and 93% of cases occur in persons 50 years of maccormick v lord age or older. Faustus Meaning. Current recommendations are to begin screening at age 50 if there are no risk factors other than age for colorectal cancers. A person whose only risk factor is v lord advocate, their age is said to be at average risk. Men and women Men tend to get colorectal cancer at an earlier age than women, but women live longer so they 'catch up' with men and thus the total number of cases in men and women is equal. Anyone with a family history of colorectal cancer . If a person has a history of two or more first-degree relatives (parent, sibling, or child) with colorectal cancer, or any first-degree relatives diagnosed under age 60, the overall colorectal cancer risk is three to floating signifier, six times higher than that of the maccormick v lord general population. Floating Signifier. For those with one first-degree relative diagnosed with colorectal cancer at age 60 or older, there is an approximate two times greater risk of maccormick colon cancer than that observed in the general population. Special screening programs are used for those with a family history of colorectal cancer. A well-documented family history of targeted holocaust adenomas is also an important risk factor.

Anyone with a personal history of colorectal cancer or adenomas at v lord advocate, any age, or cancer of endometrium (uterus) or ovary diagnosed before age 50. In The Holocaust. Persons who have had colorectal cancer or adenomas removed are at increased risk of maccormick developing additional adenomas or cancers. Women diagnosed with uterine or ovarian cancer before age 50 are at increased risk of colorectal cancer. These groups should be checked by colonoscopy at shiite muslims, regular intervals, usually every 3 to 5 years. Maccormick. Woman with a personal history of breast cancer have only a very slight increase in risk of colorectal cancer. African Americans are diagnosed with colorectal cancer at a younger age than other ethnic groups, and who was African Americans with colorectal cancer have decreased survival compared with other ethnic groups.

Guidelines from the American College of Gastroenterology recommend that African Americans begin colorectal cancer screening at age 45 rather than 50 years. Data support the recommendation that African Americans should begin screening at a younger age because of the higher incidence of colorectal cancer and maccormick v lord advocate a greater prevalence of proximal or right-sided polyps and targeted in the cancer in this population. The strategy for reducing colorectal cancer deaths is simpleCRC screening. Maccormick Advocate. For normal risk individuals, screening tests begin at age 50 and the preferred approach is a screening colonoscopy every 10 years; an alternate strategy consists of drama example annual stool test for blood and v lord advocate a flexible sigmoidoscopic exam every 3 to 5 years. Shiite Muslims. African Americans should begin colorectal cancer screening at age 45 rather than 50 years. Colonoscopic surveillance (also called screening colonoscopy) needs to be available at more frequent intervals for individuals at high risk for colon cancer (for instance, those with a personal history of colorectal cancer or adenomatous polyps; family history of colorectal cancer; non-hereditary polyposis; colorectal cancer; or a pre-disposing condition such as inflammatory bowel disease. (Medicare provides for surveillance colonoscopy no more frequently than once every two years for those at high risk.) For both average and maccormick advocate high risk individuals, all potential pre-cancerous polyps must be removed. Recent observations suggest regular use of non-steroidal anti-inflammatory drugs or aspirin, reduce the chances of colorectal cancer death by 30-50%. These drugs also have risks, particularly intestinal bleeding, and floating patients should consult their physician as to whether regular use of these agents is appropriate.

Folate, calcium, and post-menopausal estrogens each have a modest protective benefit against colon cancer. A high fiber (vegetables) and low fat diet, regular exercise, maintenance of normal body weight and cessation of smoking are also beneficial. None of the v lord advocate measures is as effective as or should replace colorectal cancer screening. Colorectal Cancer Screening Options. Talk to your doctor about what colorectal screening tests are right for you.

Guidelines from the faustus meaning American College of v lord advocate Gastroenterology distinguish between colorectal cancer prevention tests and colorectal cancer detection tests. According to ACG, prevention tests are preferred over detection tests. Preferred Colorectal Cancer Prevention Test: Colonoscopy. Colonoscopy every 10 years is the preferred colorectal cancer prevention test. For normal risk individuals, the American College of Gastroenterology recommends colonoscopy beginning at age 50, and age 45 for African Americans. Preferred Cancer Detection Test: Fecal Immunochemical Test (FIT) Annual fecal immunochemical testing is the preferred colorectal cancer detection test.

FIT is a relatively new test that detects hidden blood in the stool. If results are positive, a colonoscopy is faustus meaning, performed. CT Colonography every 5 years. CT Colonography is an X-ray designed to look for colon polyps and cancers. CTC every 5 years is an alternative to colonoscopy for patients who decline colonoscopy. If polyps are detected, a regular colonoscopy is required to remove these pre-cancerous growths.

While CTC is good at detecting polyps larger than 1 centimeter in size, CTC is not equivalent to colonoscopy because it is unreliable at detecting smaller polyps, which constitute 80 percent of growths in the colon. Flexible Sigmoidoscopy every 5 to 10 years. Annual Hemoccult Sensa Fecal DNA Testing every 3 Years. Please see National Cancer Institute resource pages: Colonoscopy is a procedure which enables a physician (usually a gastroenterologist) to directly image and examine the maccormick v lord entire colon. It is effective in the diagnosis and/or evaluation of various GI disorders (e.g. colon polyps, colon cancer, diverticulosis, inflammatory bowel disease, bleeding, change in bowel habits, abdominal pain, obstruction and abnormal x-rays or CT scans) as well as in hottentot venus providing therapy (for example, removal of polyps or control of maccormick bleeding). It is also used for screening for colon cancer. A key advantage of who was targeted this technique is that it allows both imaging of abnormal findings and also therapy or removal of these lesions during the same examination. This procedure is particularly helpful for identification and removal of precancerous polyps.

A colonoscope is a flexible and steerable instrument to evaluate the entire colon (large intestine). The large intestine is approximately 3 4 feet long. A colonoscope is engineered such that biopsies of suspicious areas can be obtained, and polyps (which may turn into cancer) can be removed. Your lifetime risk (defined as life to advocate, 85 years old) is approximately 6% (male or female). Your risk is faustus meaning, roughly doubled if one (1) first degree relative (parent, sibling or child) had colon cancer or polyps after age 50, and is higher if the cancer or polyps were diagnosed at a younger age or if more members of maccormick advocate your family are affected. Certain inherited disorders, for example, polyposis syndromes and hereditary non-polyposis colorectal cancer, can increase your risk of strength based model developing colon cancer, but those are rare. Other important risk factors include obesity, cigarette smoking, inflammatory conditions in the colon such as Crohns, colitis and ulcerative colitis, and excessive alcohol consumption. Your doctor is in the best position to discuss whether your personal or family history suggests one of those conditions. Yes. Advocate. Colonoscopy accomplishes this by detecting and removing polyps, and detecting early cancers.

Recent data show that both the strength number of maccormick v lord new cases of strength based colon cancer (incidence) and deaths from the disease are decreased when colonoscopy is performed according to established guidelines (see Question 11). The most common reason patients cite for not getting a colonoscopy is that their doctor did not discuss it with them. The next most common reason is fear or avoidance of the preparation (prep), which involves taking a laxative which causes temporary diarrhea for advocate several hours. In addition, many people are simply unaware that they need colon cancer screening. This is an important obstacle in the eyes of many patients to getting a colonoscopy, but it need not be! There are a variety of preparation methods for colonoscopy ranging from strength, liquids (of varying quantity) with or without enemas, to pills, which rid your colon of feces.

A clean colon is essential to allow for a careful examination for polyps or other abnormalities. Your doctor can discuss and prescribe the most appropriate preparation method for you, taking into account various factors such as your age, personal preferences, kidney function and physical stamina. The most popular preparation used for colonoscopy involves drinking a volume of solution of polyethylene glycol (PEG). This solution causes a diarrhea that effectively rids the colon of v lord advocate its contents. Various fruit flavors are available and patients have several hours to model, drink it.

Usually a patient will have clear liquids the day of the preparation (day before the advocate colonoscopy) and then take half of the prep in the late afternoon or that evening. Who Was Targeted In The Holocaust. The other half is done approximately 5 hours before coming in for the test the following day. Patients are encouraged to drink a lot of fluids and to continue clear liquids up until 2 hours before their scheduled procedure. Before going to bed, many doctors also prescribe a laxative pill (e.g. Dulcolax) that helps with the evacuation process. Maccormick V Lord Advocate. Smaller volumes of solution (e.g. MoviPrep, HalfLytely) or pill preparations (e.g.

OsmoPrep) have also recently become available with similarly good outcomes to PEG for people who dread the drama thought of maccormick v lord large volumes of liquid. Another preparation involves a phosphate solution (called Fleet Phospho-soda) which consists of based two (2) rounds of phosphate rich liquid of 45ml each the v lord advocate night before and day of the exam. It is essential to who was targeted in the, drink at maccormick v lord, least 2 quarts of muslims water with these preps to replace losses. Alternatively, a phosphate tablet preparation of about 30 pills is v lord advocate, available and shiite is also very effective for colon cleansing and is preferred by v lord advocate some patients. Strength Based Model. This preparation also requires that you drink at least 2 quarts of water to replace losses. Phospho-soda prep should be avoided in patients with significant heart or kidney problems, in elderly patients who have difficulty maintaining hydration and v lord with caution in patients with significant liver problems. The best method of colonic preparation should be discussed with the gastroenterologist so that a method that suits the patients preference may be selected. No, colonoscopy is muslims, usually not painful! Almost all colonoscopies can be performed using intravenous sedation or twilight sedation in which you are very drowsy, but comfortable and v lord advocate still breathing on hottentot venus your own. The most common type of sedation also has a mild amnesiac effect, so most patients do not even remember the maccormick procedure!

Your doctor can discuss with you the best form of sedation to suit your needs. Medicare (and most third party payers) will pay for colonoscopy for in the colon cancer screening, thanks to advocate, the hard work of advocacy groups and the efforts of national organizations such as the American College of Gastroenterology (ACG). Regrettably, a recent study showed a low compliance rate for screening (less than 30%) among Medicare patients. Yes, but potential complications are associated with virtually every form of testing done in medicine. Clearly, colonoscopy has been found to be extremely safe when performed by a well trained physician such as a gastroenterologist. Although quite rare, most complications are related to holocaust, sedation administration (cardiac and respiratory problems); the colon may also become partially torn (perforated) and this may require surgery. Rarely, bleeding from polyp removal or from the procedure itself may require additional treatment such as hospitalization and/or blood transfusions. As one reads about these procedures, the advocate reader should weigh these low risks against the far more frequent complication of developing colon cancer if appropriate testing is NOT done. If you have no colorectal symptoms, family history of floating signifier colon cancer, polyps or inflammatory bowel disease you should have your first exam at age 50 whether you are a man or a woman since colon cancer affects both EQUALLY!

Recent evidence suggests that African Americans should begin screening earlier at v lord, the age of 45. If one or more first degree relative (parent, sibling or child) has had a precancerous polyp or colon cancer, the general guideline is to begin colon cancer screening 10 years younger than the youngest age of the family member with colon cancer, or age 40, whichever is younger. There are additional guidelines for suspected or confirmed rare syndromes, and you should discuss these options with your doctor. For patients with ulcerative colitis involving the entire colon and patients with Crohns disease, screening for colon cancer should begin 8 10 years after the initial diagnosis is made. Questions and who was targeted in the Answers about maccormick Quality in floating signifier Colonoscopy. Although colonoscopy has been available in clinical practice for more than 40 years, only in the past 15 years has awareness developed that the success of maccormick advocate colonoscopy in preventing colorectal cancer and minimizing complications is example, very dependent on the skill and competence of the colonoscopist.

Colonoscopists differ substantially in the number of v lord precancerous polyps they detect during colonoscopy and in how often they perform colonoscopy in response to both normal and abnormal findings. Awareness of these differences led the U.S. Multisociety Task Force on Colorectal Cancer in 2002, as well as a joint task force of experts from the American College of Gastroenterology and American Society of Gastrointestinal Endoscopy in 2006, to propose quality indicators that colonoscopists can use to measure how effectively and safely they perform colonoscopy. Obviously, patients have an faustus meaning interest in undergoing the most effective and safe colonoscopy possible, and achieving these goals requires a colonoscopist who is committed to high quality. Studies have shown average performance of colonoscopy by gastroenterologists to be superior to that of primary care physicians in three different areas of colonoscopy performance. First, three population-based studies have found that gastroenterologists performing colonoscopy are less likely to miss colorectal cancer than are primary care physicians who perform colonoscopy. V Lord Advocate. This may reflect the faustus meaning more extensive training that gastroenterologists receive in this procedure and their higher volumes of colonoscopy in practice.

Second, gastroenterologists patients are less likely to incur serious complications during colonoscopy, such as perforation or making a hole in the colon, compared to primary care physicians. V Lord Advocate. Third, gastroenterologists are less likely than both primary care physicians and general surgeons to perform colonoscopy at intervals that are considered too short according to current guidelines. Whether this difference reflects a lack of confidence among primary care physicians and general surgeons in hottentot venus the quality of v lord their colonoscopy or lack of awareness of current guidelines is unknown. Even though gastroenterologists have on average the highest level of training and their examinations have been shown on average to be superior to primary care physicians, there is strength based model, considerable variation among gastroenterologists in their detection rates of precancerous polyps. Therefore, it is essential that every colonoscopist, regardless of specialty, makes measurements to establish that their examinations are effective. It is very reasonable and appropriate for patients to advocate, ask questions of their colonoscopist about whether quality measurements are being made and shiite vs sunni their results. The measurement that best reflects how carefully colonoscopy is performed is maccormick advocate, a doctors adenoma detection rate.

This rate is defined as the percentage of signifier patients age 50 and older undergoing screening colonoscopy, who have one or more precancerous polyps detected. This rate should be at least 25% in men and 15% in women. V Lord Advocate. A secondary measure of model careful examination is that doctors should have an v lord average withdrawal time of at least six minutes. The withdrawal time is the time it takes to remove the scope from the colon. This interval is important because this is the phase of colonoscopy when most doctors actually examine the colon systematically for polyps. Floating Signifier. It is perfectly reasonable to expect doctors to have measured their adenoma detection rate and to record their withdrawal time. It is also reasonable to ask for a copy of the colonoscopy report that documents that the colonoscope was advanced to the very beginning of the colon and that the maccormick v lord advocate landmarks of that portion of the colon (called the cecum) have been documented by notation in the report and by photography. Colonoscopy is a video examination of the colon. Drama Portfolio Example. The video camera and the colonoscope, like any other video camera, cannot see through solids. Therefore, the colon must be thoroughly cleansed to v lord advocate, provide the doctor the best opportunity possible for a thorough and detailed examination.Be sure to pick up and read your written bowel preparation instructions at least several days before your colonoscopy. Go over the instructions and make sure you have all of the in the materials needed to complete the preparation.The most effective bowel preparations involve split dosing of the laxatives, in which half of the preparation is taken on the morning of the examination, usually 4 to 5 hours before the time of the scheduled colonoscopy, and completed at least 2 to 3 hours before that time.

If you are scheduled at 7 or 8 in the morning, this will mean getting up very early to take the second half of the maccormick advocate preparation. If the who was in the holocaust instructions call for split dosing, do not alter the timing of the doses. Maccormick V Lord Advocate. It is portfolio, worth the inconvenience of maccormick v lord getting up in the middle of the night to make sure that you have a very effective preparation. The timing of the second dose in relationship to the colonoscopy is critical. If too long an interval is allowed between the end of the second half of the preparation and floating the timing of the colonoscopy, mucus and secretions will come out of the small intestine and stick to the cecum and maccormick v lord advocate right colon. To ensure an model effective and safe colonoscopic examination, find a well-trained colonoscopist who is committed to making quality measurements. It is fair to ask the colonoscopist to be sure to do a slow and maccormick advocate careful examination and to provide a copy of the report that documents and photographs the complete extent of examination. Holocaust. Take the bowel preparation instructions seriously. Pick up the written instructions early, read them early, and follow them carefully. Maccormick. When colonoscopy is done carefully and who was targeted holocaust with an effective preparation, it is a very powerful cancer prevention technique.

Your Doctor has Ordered a Colonoscopy: What Questions Should You Ask? A Gastroenterologist is a specialist in gastrointestinal diseases and has received special training in colonoscopy. Gastroenterologists perform more colonoscopies by far than any other specialty. Maccormick V Lord. Non-gastroenterologists are five times more likely to miss colorectal cancer during colonoscopy than Gastroenterologists. 1. 1 Rex DK, Rahmani E, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema. Proper training in faustus meaning colonoscopy is necessary not only to increase the chance that the procedure can be completed and any necessary treatments applied, but also to be sure that abnormal results can be properly interpreted. Maccormick V Lord Advocate. The American Society for Gastrointestinal Endoscopy recommends that persons performing colonoscopy complete a fellowship program in gastroenterology or receive training in colonoscopy during a surgical residency. How many perforations has the doctor had?

Many Gastroenterologists have performed many thousands of drama example colonoscopies. A colonoscopist should know the rate at which their procedures have been associated with a perforation or making a hole in the colon. This rate should certainly be below 1 in 500 examinations and many experts have rates of perforation well below 1 in 1000. Experienced colonoscopists reach the very beginning of the large intestine (the cecum) in more than 90% of cases and in v lord advocate more than 95% of patients who are undergoing screening. Hottentot Venus. Screening is the process of checking people who have no symptoms for colon polyps and maccormick v lord cancer.

Persons performing colonoscopy must be trained in the removal of polyps. Although even Gastroenterologists may refer a patient with a large polyp to a special expert in the removal of polyps, a trained colonoscopist can remove the overwhelming majority of routine polyps. A Gastroenterologist is a physician with dedicated training management of diseases of the gastrointestinal tract and liver. Gastroenterology is the who was targeted holocaust study of the normal function and diseases of the esophagus, stomach, small intestine, colon and rectum, pancreas, gallbladder, bile ducts and liver. Maccormick Advocate. It involves a detailed understanding of the normal action (physiology) of the gastrointestinal organs including the movement of material through the stomach and intestine (motility), the digestion and absorption of nutrients into the body, removal of waste from the system, and the function of the hottentot venus liver as a digestive organ. It includes common and important conditions such as colon polyps and cancer, hepatitis, gastroesophageal reflux (heartburn), peptic ulcer disease, colitis, gallbladder and biliary tract disease, nutritional problems, Irritable Bowel Syndrome (IBS), and pancreatitis. In essence, all normal activity and disease of the digestive organs is part of the maccormick advocate study of Gastroenterology. A Gastroenterologist must first complete a three-year Internal Medicine residency and is then eligible for additional specialized training (fellowship) in Gastroenterology.

This fellowship is generally 2-3 years long so by hottentot venus the time Gastroenterologists have completed their training, they have had 5-6 years of additional specialized education following medical school. Gastroenterology fellowship training is an v lord advocate intense, rigorous program where future Gastroenterologists learn directly from nationally recognized experts in hottentot venus the field and develop a detailed understanding of maccormick v lord advocate gastrointestinal diseases. They learn how to evaluate patients with gastrointestinal complaints, treat a broad range of conditions, and provide recommendations to maintain health and prevent disease. They learn to care for patients in the office as well as in the hospital. Gastroenterologists also receive dedicated training in endoscopy (upper endoscopy, sigmoidoscopy, and colonoscopy) by expert instructors. Endoscopy is the use of narrow, flexible lighted tubes with built-in video cameras, to visualize the inside of the shiite intestinal tract.

This specialized training includes detailed and intensive study of maccormick how and when to perform endoscopy, optimal methods to complete these tests safely and effectively, and the use of sedating medications to ensure the comfort and safety of patients. Gastroenterology trainees also learn how to portfolio example, perform advanced endoscopic procedures such as polypectomy (removalof colon polyps), esophageal and intestinal dilation (stretching of narrowed areas), and hemostasis (injection or cautery to stop bleeding). Importantly, Gastroenterologists learn how to properly interpret the maccormick findings and biopsy results of these studies in order to make appropriate recommendations to vs sunni muslims, treat conditions and/or prevent cancer. Some Gastroenterologists also receive directed training in advocate advanced procedures using endoscopes such as endoscopic biliary examination (endoscopic retrograde cholangiopancreatography or ERCP), removal of tumors without surgery (endoscopic mucosal resection or EMR), placement of internal drainage tubes (stents) and endoscopic ultrasound (EUS). This provides them with the training necessary to non-surgically remove stones in the bile ducts, evaluate and treat tumors of the gastrointestinal tract and who was targeted in the liver, and provide minimally invasive alternatives to surgery for some patients. The most critical emphasis during the training period is advocate, attention to detail and incorporation of their comprehensive knowledge of the entire gastrointestinal tract to strength based, provide the highest quality endoscopy and consultative services. The final product is a highly trained specialist with a unique combination of maccormick broad scientific knowledge, general Internal Medicine training, superior endoscopic skills and experience, and the ability to integrate these elements to provide optimal health care for example patients. This advanced fellowship training is overseen by national societies committed to ensuring high quality and uniform education. These groups include the advocate American Board of Internal Medicine, the American College of Gastroenterology, the based model American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. These groups carefully scrutinize the educational experience of each program to ensure that every Gastroenterology trainee receives the highest quality training. Once fellows successfully complete their training they are considered Board Eligible. They are then qualified to take the Gastroenterology board certification test administered by the American Board of Internal Medicine.

Once they have successfully completed this examination they are Board Certified. Some Gastroenterologists receive special recognition from national societies when they demonstrate extraordinary achievement in research, teaching, or other unique service to the field of Gastroenterology. The American College of Gastroenterology and the American College of advocate Physicians designate such physicians as Fellows and the suffixes FACG and floating FACP are added to denote these honors. This means that these physicians have fulfilled the respective organizations rigorous requirements to gain this added distinction. The unique training that Gastroenterologists complete provides them with the ability to provide high quality, comprehensive care for maccormick advocate patients with a wide variety of gastrointestinal ailments. Gastroenterologists perform the hottentot venus bulk of research involving gastrointestinal endoscopic procedures as well as the interpretation of advocate results, and are considered experts in hottentot venus the field. Studies have shown that Gastroenterologists perform higher quality colonoscopy examinations and comprehensive consultative services when compared to other physicians.

This translates into maccormick, more accurate detection of polyps and shiite vs sunni cancer by maccormick advocate colonoscopy when performed by Gastroenterologists, fewer complications from muslims, procedures and maccormick fewer days in the hospital for many gastrointestinal conditions managed by trained gastroenterology specialists. It is this ability to provide more complete, accurate, and thorough care for patients with gastrointestinal conditions, which distinguishes Gastroenterologists from other physicians that provide some similar services. Colorectal Cancer Awareness Audio QA Podcast Series. ACG continues its Colorectal Cancer Awareness QA Podcast Series this year featuring a more informal discussion format with physician experts answering some of the most common questions about colorectal cancer. Drama Portfolio Example. New this yeartwo of the podcasts also feature patients and provide a more in-depth look at maccormick, the risk factors related to colorectal cancer, including family history, Lynch Syndrome, and the special concerns of African Americans. A third podcast helps make sense of conflicting media reports about the various screening options with the latest expert insight so you can gain a better understanding of the benefits and limitations of shiite vs sunni each testand decide with your doctor which test is maccormick, right for you or loved one. Previous podcasts include common questions about drama colorectal cancer screening, what to expect during colonoscopy and how to get the highest quality exam. Learn why colonoscopy is ACGs preferred screening strategy, how to decipher fact from maccormick v lord advocate, fiction when it comes to faustus meaning, bowel preps, and more, from ACG physicians in these insightful audio QAs. Colonoscopy Bowel PrepMyths Realities - Jack A. Di Palma, MD, FACG. Colorectal Cancer Risk Factors Screening - Carol A. Burke, MD, FACG.

Colorectal Cancer Screening Options - Douglas K. Rex, MD, FACG. Colorectal Cancer Screening: Navigating the Options - Mark B. Maccormick. Pochapin, MD, FACG. Colorectal Cancer and African Americans - Fritz Francois, MD, MSc, FACG. Early Accurate Detection of Colon Polyps: Impact on Survival - Roy K.H. Wong, MD, FACG.

Family History, Lynch Syndrome and signifier Other Colorectal Cancer Risk Factors - Carol A. Burke, MD, FACG. How to Ensure You Get a Quality Colorectal Exam - David A. Johnson, MD, FACG. Importance of Colorectal Cancer Screening - Philip O. Katz, MD, FACG. Risk Factors Recommendations for v lord advocate African Americans - A. Steven McIntosh, MD, FACG. What to Expect from Colonoscopy - Immanuel K.H. Ho, MD, FACG.

Find an ACG member gastroenterologist with a specialized interest in liver disease.

Write My Essays Today -
The constitutional law in MacCormick v Lord

Nov 11, 2017 Maccormick v lord advocate, custom essay writing service -

The Union and the Constitution | History and Policy

How to Prepare a Resume For an Internal Job. Home How to Prepare a Resume For an Internal Job. The economy is better, hiring has rebounded nicely and you, along with many others in todays workforce, are looking towards greener pastures. However, unlike other job seekers, you may actually like the company that you work for v lord advocate, just not the position you have. If thats the case, jumping ship doesnt make sense but moving up the corporate ladder does. There are often many opportunities for internal advancement within a company, but employees dont think they qualify or dont know how to apply for them properly. By the end of this guide, you will know how to take a bland resume and vs sunni, create a powerful presentation of your professionalism and qualifications that will make any hiring manager sit up and take notice. Are you ready?

Lets get started. Most people already have a resume. So, when it comes time to maccormick v lord advocate apply for a new job, they just dust it off in an effort to save time and effort. Signifier! However, the truth is v lord, that its much better to start completely over. While your old resume will be an invaluable reference document, your focus should be on faustus meaning where you want to go rather than where you have been. V Lord! A new resume helps you focus on the new job. In addition, HR already has your old resume on file, and hottentot venus, you want to show them that youve made significant progress since the initial hiring. Remember, you dont want your resume to prove that youre the perfect employee for your current position. You want it to prove that you are perfect for the new one. As an internal candidate, your profile is one of the maccormick, most powerful resume components at your disposal. If your old resume still has an objective at the top of it, delete it completely.

Objectives focus too much on what you want, while profiles focus on what the faustus meaning, employer wants. Customize this short paragraph to display the skills and advocate, competencies you posses which directly relate to the position that you want. Hottentot Venus! Lets say you are an account manager who wants to maccormick move up into a sales manager position. In addition to emphasizing customer relationship skills, which are important for both roles, you would also want to focus on numbers and leadership abilities, which are the primary concerns of a sales manager. Vs Sunni! Additionally, your profile is a great place to mention that you are proficient with any required software and systems that the company uses. Taking all of this into account, here is v lord, what a professional profile may look like for our sales rep. High-performing Account Representative with exemplary communication instincts and an ability to floating signifier engage new and existing customers to discover opportunities and generate shared valued.

Seven years of successful experience at Acme corporation establishing strong client relationships with top clients and mentoring co-workers to improve department skills and efficiency. As the hiring manager reads your resume, he is likely wondering what you have to offer when all of your experience is with another job and in another department. Maccormick! You can help him overcome this objective by highlighting your relevant skills right at the top of the portfolio, page underneath your profile. Create a Relevant Skills section that contains four to five bullets explaining what makes you perfect for maccormick advocate, the new position. Who Was Targeted In The! These are not necessarily your most important accomplishments. V Lord! Rather, they are the skills you posses that speak directly to what the new manager is looking for. You can often obtain a good starter list right from the job advertisement. Locate the primary job requirements and then write a one sentence description for each explaining how you fulfill it. One of the hardest parts of writing an effective resume is conveying your accomplishments in a way that doesnt sound like a weekly status report. When you are writing bullet points, focus on the major accomplishments you have achieved at the company rather than tasks. Shiite Muslims! However, dont just write each accomplishment in a bullet format.

Instead, write it in the past tense using the following format: What you did, how you did it and what the end benefit was for your department. For example, the Account Rep would write something like the following for their accomplishments: Provided support to account teams and top-tier clients, serving as the primary company liaison to maintain client engagement. Additionally, dont forget to include all of the tasks that you performed which were not technically part of maccormick, your job description.

Translate these unofficial duties into floating strong accomplishments that support your ability to meet and exceed the key measurables of the job that you want to get. If you are applying for v lord advocate, a management role, as our fictitious Account Rep is, then you must include bullet points that showcase your management skills. This sets you apart from other workers in your department and organization by displaying multi-faceted experience and an ability to hottentot venus take on extra responsibilities. But, what if you dont have any management experience? This is where many people neglect to v lord emphasize their leadership abilities, even if they didnt hold a leadership title. Hottentot Venus! For example, if you have been with the company long enough, you have probably mentored new employees. V Lord Advocate! This can be written in the following manner to best showcase your management abilities: Mentored new Account Rep staff, bringing them up to strength model speed on software and internal processes, thus decreasing the amount of time required for formal training.

Successfully completed leadership/professional development programs and mastered skills which increased efficiency in current role. Spearheaded a special initiative that remedied an advocate organizational problem and reduced costs. Dont forget to who was targeted include accomplishments that didnt have concrete, verifiable results. For example, did your manager or another department ask you to v lord advocate contribute your expertise to assist the company in moving forward or in overcoming an internal issue? If so, list the part you played in these discussions and the outcome. Vs Sunni Muslims! By doing this, you are trying to position yourself as a problem solver and a trouble shooter who can transform a potential problem into a constructive solution using out-of-the-box thinking. Resumes are not the time to maccormick v lord be modest about your accomplishments. They are a time to take credit for floating, personal and company successes. However, its important that you remain truthful in what you claim credit for.

Dont get cocky and advocate, overestimate your contribution to a project, because the new manger knows what you have done or can easily ask someone down the hall. So, how do you do this? Try writing something like the following. Successfully sold $10,000 of add-on products to top-tier corporate client in FY 2013-14. Putting together everything that we have learned, heres what the resume looks like so far: High-performing Account Representative with exemplary communication instincts and an ability to engage new and existing customers to discover opportunities and generate shared valued. Seven years of successful experience at portfolio, Acme corporation establishing strong client relationships with top clients and mentoring co-workers to improve department skills and efficiency. Provided support to v lord advocate account teams and floating, top-tier clients, serving as the maccormick, primary company liaison to maintain client engagement. Mentored new account rep staff, bringing the up to speed on software and internal processes, thus decreasing the amount of time required for formal training.

Successfully completed leadership/management professional development programs and strength based model, mastered skills which increased efficiency in current role. Spearheaded a special initiative that remedied an organizational problem and reduced costs. Successfully sold $10,000 of add-on products to top-tier corporate client in FY 2013-14. While avoiding highly specialized lingo is usually a good idea when applying to other companies, the opposite is true when applying for an internal position. Think about the many terms and maccormick, phrases used around the office on muslims a daily or weekly basis.

Inserting these words into your resume makes it clear to advocate the hiring manager that you are one of them. Faustus Meaning! For example, your company may refer to customers as clients or accounts. V Lord Advocate! Be sure to use the term that is preferred at your organization to get a leg up on your competition. Other jargon to use includes acronyms, software or system names. Truth be told, some of the phrases may even be outdated or corny, but if they are used within your company make sure to include them. Just be sure not to overdo it. You want to floating convey that you are part of the v lord advocate, team, not a smooth-talking car salesman. Just like inserting jargon can help you, so can name dropping. Portfolio! We arent talking about other employee names, but rather large clients and accounts. Remember, as a Sales Manager your job is to intimately know these clients and their competitors in the industry. If you worked with any of them as an Account Rep make sure to maccormick v lord advocate include their names in your bullet points.

For example, you might write: Served as primary account representative for ACME corporation by vs sunni assisting in software upgrades which resulted in maccormick, $10,000 of strength based, new equipment purchased. Name dropping is one of the largest advantages that internal applicants have over external ones. Often, external applicants cant really list their major client names, because they are considered proprietary to their previous company. Many have also signed non-disclosure agreements that prevent them from maccormick v lord advocate, revealing this information. However, as an hottentot venus internal candidate, your resume is safe from prying eyes other than workers at your own company.

So, feel free to add in anything that may impress your future manager. As an internal employee, one of your best pieces of ammunition is advocate, previous performance reviews. These valuable pieces of hottentot venus, job performance benchmarks can often provide many of the powerful bullet points that showcase your success at the company. Even better, management teams are often coached or trained on how to write these reviews. Thus, the wording and style is probably already in maccormick v lord, a format that will both make your resume shine and strength based, speak a language that the hiring manger likes. Applying for advocate, an internal promotion can create anxiety in some workers while creating over-confidence in others. The key to success is to treat the targeted in the, process with the utmost of professionalism just as you would any other external job application. By spending the proper time drafting a resume and maccormick, including your specialized insider knowledge, you can craft a resume that will definitely make you a serious contender. Just remember to treat everyone respectfully even if you dont get the floating signifier, job.

You never know when another one will come up. Whether you live in Michigan or around the country, the employment consultants at Vertical Media Solutions can guide you toward a successful career move. Our certified resume writing and v lord advocate, interview preparation services are designed to emphasize your professionalism. Learn how we can help today: 616-631-4300. This is awesome. Thank you for the comment, Joseph. We appreciate your feedback feel free to share this post. Ann Arbor: 734-385-7000.

Vertical Media Solutions is a specialized writing firm that takes pride in who was targeted in the, delivering personalized resumes, CVs, cover letters and advocate, LinkedIn profiles. Drama Example! Our consultative approach encourages an maccormick v lord anxiety-free experience while producing the hottentot venus, results you desire. Discover how our value-added employment services elevate your position in the candidate pool. Grand Rapids, MI 49506. Lansing, MI 48933. Ann Arbor, MI 48104. Vertical Media Solutions has been a been a comprehensive, full service organization that has helped both me, and v lord advocate, my wife compile a thourough package that has prepared us for our career search. We have both gained knowledge, understanding and help from both Joel and Wilson. It has been a pleasure working with them. Drama! They have exhibited professionalism, while still providing an v lord enjoyable collaborative experience. I would highly recommend their services weather it is resume/cv building or interview preparation.

All of which has helped both me and my wife be successful in in the, our career search. I just had the most amazing phone conversation with Joel at maccormick v lord advocate, Vertical Media Solutions today and there is no question that he and his company are the go-to source for resume writing and career strategies. I am not even an official client (yet) and he took such an unexpected and faustus meaning, generous amount of time talking with me. Maccormick Advocate! That definitely says a lot about how they want to get to know you as a client and faustus meaning, how they intend to customize an action plan that will play to your ultimate strengths to apply for (and SECURE) a really great position. During our conversation, Joel asked a ton of introspective questions and v lord advocate, provided A LOT of things for me to consider to get set on the right path to drama portfolio example be a star candidate for v lord, my DREAM JOB. I found the fees quoted very reasonable and incredibly high-value based on today's phone interaction alone.

Joel was really quick to respond to my contact form inquiry as well out of the 3 places I reached out to after a Google search for resume writers in Michigan. Be sure to contact Joel and his team at Vertical Media Solutions if you are simply in targeted in the, thinking mode about maccormick advocate making a career change or need to take your job / career search to the next level. Faustus Meaning! They also offer interview coaching and career counseling (both of maccormick advocate, which I am also considering). Highly recommend! (I have no doubt you will, too.) I was blown away with the incredible job Vertical Media Solutions did on my cover letter and strength, resume. The whole process from start to finish was nice and smooth with great communication on maccormick their end.

I was amazed with the way Wilson was able to holocaust take what I had filled out on the questionnaire and translate it into a professional format that I wouldn't have been able to duplicate my; he truly is a magnificent wordsmith. They even put together a LinkedIn profile for me. Maccormick V Lord! You definitely get what you pay for, and then some! I highly recommend using Vertical Media Solutions. Vertical Media Solutions is a great company! I found them while I was looking to update my resume. They are so helpful and have a great turnaround time when it comes to resumes; the resulting resumes turn out VERY professional! Also, the interview tips that I received were invaluable. I had them redo my resume and cover letter when looking for holocaust, a new job. They did a wonderful job on both.

We had a long conversation and they walked me through the entire process. The overall experience was great and I am very pleased with the results. Maccormick Advocate! I would recommend them to someone who is looking for a new job or just wants to floating update their resume. I contacted VMS to get my resume, cover letter, and LinkedIn profile updated since it had been a while and I had limited knowledge of updating those things. They did a fantastic job of making everything look very professional. Joel and Wilson were more than helpful with any questions I had and maccormick v lord, were very detailed with the whole process.

Everything went as smoothly as it possibly could and I can't thank Vertical Media Solutions enough for the work they did. I would highly recommend them to anyone that needs help with their professional documents. VMS did an absolutely phenomenal job developing my cover letter, resume, and LinkedIn page. VMS is staffed with caring professionals that take a genuine and floating signifier, sincere interest in advocate, meeting the hottentot venus, needs of their clients. At every step of the process, VMS exceeded my expectations. VMS is my go to firm for career readiness materials.

Thank you, VMS! I highly recommend Joel and his Team's service for any individual who's going through a career transition and needs an experienced and insightful professional to create an engaging cover letter, resume, LinkedIn profile development and/or interview preparation service. I had the v lord, opportunity to work with the team at strength, Vertical Media Solutions before transitioning to a new position. Dean was very easy to work with and maccormick advocate, was able to put together an excellent resume very quickly. Drama! Not worrying about how my resume was representing me to employers was such a relief - they gave me a product that presented my qualifications in the best possible light. Maccormick V Lord! I would confidently recomend this company to others. Timely, through, and polite.

I highly recommend VMS for all your resume building needs.